WO2007075629A2 - Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists - Google Patents

Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists Download PDF

Info

Publication number
WO2007075629A2
WO2007075629A2 PCT/US2006/048349 US2006048349W WO2007075629A2 WO 2007075629 A2 WO2007075629 A2 WO 2007075629A2 US 2006048349 W US2006048349 W US 2006048349W WO 2007075629 A2 WO2007075629 A2 WO 2007075629A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
group
obesity
heteroaryl
Prior art date
Application number
PCT/US2006/048349
Other languages
French (fr)
Other versions
WO2007075629A3 (en
Inventor
Mwangi W. Mutahi
Robert G. Aslanian
Michael Y. Berlin
Christopher W. Boyce
Manuel De Lera Ruiz
Kevin D. Mccormick
Daniel M. Solomon
Henry A. Vaccaro
Junying Zheng
Biju J. Purakkattle
Younong Yu
Wei Zhou
Xiaohong Zhu
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to AU2006331882A priority Critical patent/AU2006331882A1/en
Priority to JP2008547422A priority patent/JP2009521448A/en
Priority to MX2008008337A priority patent/MX2008008337A/en
Priority to EP06839411A priority patent/EP1976848A2/en
Priority to CA002634250A priority patent/CA2634250A1/en
Publication of WO2007075629A2 publication Critical patent/WO2007075629A2/en
Publication of WO2007075629A3 publication Critical patent/WO2007075629A3/en
Priority to IL192309A priority patent/IL192309A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Definitions

  • the present invention relates to phenoxypiperidines and analogs thereof useful as histamine H 3 antagonists.
  • the invention also relates to pharmaceutical compositions comprising said compounds and their use in treating inflammatory diseases, allergic conditions, diabetes, obesity, an obesity-related disorder, metabolic syndrome, a cognition deficit disorder, cardiovascular and central nervous system disorders.
  • the invention also relates to the use of a combination of histamine H3 antagonists of this invention with histamine Hi compounds for the treatment of inflammatory diseases and allergic conditions, as well to the use of a combination of an histamine H 3 antagonist of this invention with other actives useful for treating diabetes, obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder.
  • compositions comprising a combination of at least one novel histamine H 3 antagonist compound of the invention with at least one histamine Hi compound or gt least one compound useful for treating diabetes, obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder are also contemplated.
  • the histamine receptors, H 1 , H 2 , H 3 and H 4 have been characterized by their pharmacological behavior.
  • the H 1 receptors are those that mediate the response antagonized by conventional antihistamines.
  • H 1 receptors are present, for example, in the ileum, the skin, and the bronchial smooth muscle of humans and other mammals.
  • the most prominent H2 receptor-mediated responses are the secretion of gastric acid in mammals and the chronotropic effect in isolated mammalian atria.
  • H 4 receptors are expressed primarily on eosinophils and mast cells and have been shown to be involved in the chemotaxis of both cell types.
  • H3 receptor sites are found on sympathetic nerves, where they modulate sympathetic neurotransmission and attenuate a variety of end organ responses under control of the sympathetic nervous system. Specifically, H3 receptor activation by histamine attenuates norepinephrine outflow to resistance and capacitance vessels, causing vasodilation. In addition, in rodents, peripheral H 3 receptors are expressed in brown adipose tissue, suggesting that they may be involved in thermogenesis regulation. H 3 receptors are also present in the CNS. H 3 receptor expression is observed in cerebral cortex, hippocampal formation, hypothalamus and other parts of the human and animal brain.
  • H3 receptors are expressed on histaminergic neurons and, as heteroreceptors, on neurons involved in other neurotransmitter systems, where H 3 receptor activation results in presynaptic inhibition of neurotransmitter release.
  • H 3 receptors have been implicated in the regulation of histamine hypothalamic tone, which in turn has been associated with the modulation of sleeping, feeding and cognitive processes in the human brain (see, for example, Leurs et al., Nature Reviews, Drug Discovery, 4, (2005), 107). It is also known and has been described in the literature that histamine is involved in regulation of cognitive and memory processes in the human brain (see, for example, Life Sciences, 72, (2002), 409-414).
  • H 3 receptor antagonists may be useful for treating various neuropsychiatric conditions, where cognitive deficits are an integral part of the disease, specifically ADHD, schizophrenia and Alzheimer's disease (see, for example, Hancock, A.; Fox, G. in Drug Therapy (e ⁇ . Buccafusco, J.J.). (Birkhauser, Basel, 2003).
  • Imidazole H3 receptor antagonists are well known in the art. More recently, non-imidazole H3 receptor antagonists have been disclosed in US Patents 6,720,328 and 6,849,621 , and in US Published Applications 2004/0097483, 2004/0048843 and 2004/0019099. US 5,869,479 discloses compositions for the treatment of the symptoms of allergic rhinitis using a combination of at least one histamine H 1 receptor antagonist and at least one histamine H 3 receptor antagonist.
  • a is O, 1, 2, 3 or 4;
  • b is O, 1, 2 or 3;
  • M is CH, n is 1 or 2, and p is 0, 1 or 2; or M is N 1 n is 2, and p is 1 or 2; U and W are each CH, or one of U and W is CH and the other is N;
  • X is a bond, alkylene, -C(Q)-, -C(N-OR 5 )-, -C(N-OR 5 )-CH(R 6 )-, -CH(R 6 J-C(N-OR 5 )-, -O-, -OCH 2 -, -CH 2 O-, -CH(OH)-, -S-, -S(O)- Or-S(O) 2 -;
  • R 1 is R 11 -alkyl, R 11 -cycloalkyl, R 11 -aryl, R 11 -ary1alkyl, R 11 -(6-membered heteroaryl), R 11 -(6-membered heteroaryl)alkyl, R 11 -(5-membered heteroaryl), R 11 -(5- membered heteroaryl )alkyl, R 11 -heterocycloalkyl,
  • unfused ring carbon atoms and ⁇ i ⁇ represents two nitrogen atoms in the place of any two of the four unfused ring carbon atoms, provided that when R 1 is attached to X by a nitrogen atom, X is a bond or alkylene; k is 0, 1 , 2, 3 or 4; k1 is O, 1 , 2 or 3; k2 is 0, 1 or 2;
  • Q is O or S
  • FT is R ,13 -alkyl, R >13 -alkenyl, R ,13 -aryl, R 13 -arylalkyl, R »13 -heteroaryl, R ,13- heteroarylalkyl, R 13 -cycloalkyl or R 13 -heterocycloalkyl; each R 3 is independently selected from the group consisting of H 1 alkyl, halo, -OH, alkoxy, -CF 3 , -OCF 3 , -OCHF 2 , -NO 2 , -CO 2 R 14 , -N(R 14 ) 2 , -CON(R 14 ) 2 , - NHC(O)R 14 , -NHSO 2 R 14 , -SO 2 N(R 14 J 2 and -CN; each R 4 is independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OH, alkoxy, -CF 3 and -CN
  • R° is H, alkyl, haloalkyl, R i1 1 5 D -aryl t R 1 1 5 -heteroaryl, R ,1 1 5 o -cycloalkyl, R ,15- heterocycloalkyl, R 15 -arylalkyl, -CF 3 Or-CH 2 CF 3 ;
  • R 6 is H or alkyl;
  • R 7 is H, alkyl, haloalkyl, R 15 -aryl or R 15 -heteroaryl
  • R 8 is 1 , 2 or 3 substituents independently selected from the group consisting of H, R »1 1 5 -cycloalkyl, R ,15 -heterocycloalkyl, R 1 1 5 -aryl, R ,1 1 5 -heteroaryl and haloalkyl, provided that when the R 8 substituent is on the carbon joined to the nitrogen atom of the M-containing ring, R 8 is joined through a ring carbon atom;
  • R 9 is independently selected from the group consisting of H, alkyl and haloalkyl;
  • R 9a is independently selected from the group consisting of H, fluoro, alkyl and haloalkyl;
  • R 10 is 1 , 2 or 3 substituents independently selected from the group consisting of H 1 R 15 -cycloalkyl, R 15 -heterocycloalkyl, R 15 -aryl, R 15 -heteroaryl, halo, haloalkyl, - CN, -OH, alkoxy, -OCF 3 , -NO 2 , and -N(R 6 ) 2 ;
  • R 11 is 1 , 2, 3 or 4 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OH, alkoxy, alkylthio, R 15 -cycloalkyl, R 15 - heterocycloalkyl, R 15 -aryl, R 15 -arylalkyl, R 15 -heteroaryl, R 15 -heteroarylalkyl, aryloxy, - OCF 3 , -OCHF 2 , -NO 2 , -CO 2 R 12 , -N(R 12 ) 2 , -CON(R 12 J 2 , -NHC(O)R 12 , -NHSO 2 R 12 , - SO 2 N(R 12 ) 2 and -CN;
  • R 11a is H, alkyl, haloalkyl, alkoxy, alkylthio, R 15 -cycloalkyl, R 15 -heterocycloalkyl, R 15 -aryl, R 15 -arylalkyl, R 15 -cycloalkyl, R 15 -heterocycloalkyl, R 15 -heteroaryl, R 15 - heteroarylalkyl, R 15 -aryloxy, -OCF 3 , -OCHF 2 , -N(R 12 J 2 Or -SCF 3 ;
  • R 12 is independently selected from the group consisting of H, alkyl, haloalkyl, R 15 -aryl, R 15 -heteroaryl, R 15 -arylalkyl, R 15 -cycloalkyl and R 15 -heterocycloalkyl;
  • R 13 is 1 , 2 or 3 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OH, aikoxy, R 15 -aryl, R 15 -aryloxy, -OCF 3 , -OCHF 2 , -NO 2 , - CO 2 R 14 , -N(R 14 J 2 , -CON(R 14 ) 2> -NHC(O)R 14 , -NHSO 2 R 14 , -SO 2 N(R 14 J 2 and -CN;
  • R 14 is independently selected from the group consisting of H, alkyl, haloalkyl, R 15 -aryl, R 15 -heteroaryl, R 15 -cycloalkyl and R 15 -heterocycloalkyl;
  • R 15 is 1 , 2 or 3 substituents independently selected from the group consisting of H, alkyl, halo, haloalkyl, alkoxy, -N(R 18 J 2 , -alkylene-N(R 18 ) 2> -CN, -OCF 3 and - OCHF 2 ;
  • R 16 is independently selected from the group consisting of alkyl, halogen, haloalkyl, alkenyl, OH, alkoxy, -SOo- 2 -alkyl and -OCF 3 ;
  • R 17 is H, alkyl, hydroxy (C 2 C 6 )alkyl-, haloalkyl-, haloalkoxyalkyl-, alkoxyalkyl-, R 15 -aryl, R 15 -arylalkyl-, R 15 -heteroaryl, R 15 -heteroarylalkyl-, R 15 -cycloalkyl or R 15 - cycloalkylalkyl; and
  • R 18 is independently selected from the group consisting of H and alkyl.
  • This invention further provides methods for treating: allergy; an allergy- induced airway (e.g., upper airway) response, including but not limited to, pruritis, sneezing, rhinorrhea and mucosal inflammation (see, for example, McLeod, JPET.
  • an allergy- induced airway e.g., upper airway
  • pruritis e.g., sneezing
  • rhinorrhea e.g., mucosal inflammation
  • congestion such as nasal congestion; hypotension; a cardiovascular disease; a disease of the gastrointestinal tract; hyper- and hypo- motility and acidic secretion of the gastrointestinal tract, such as GERD; metabolic syndrome; obesity; an obesity-relat:ed disorder; a sleeping disorder such as hypersomnia, somnolence, insomnia or narcolepsy; hypo- and hyperactivity of the central nervous system, such as agitation and depression of the CNS; diabetes, including Type I and Type Il diabetes mellitus; a CNS disorder, such as migraine, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or a cognition deficit disorder (e.g., attention deficit hyperactivity disorder (ADHD), Alzheimer's Disease (AD) or schizophrenia); (each of the above described diseases/disorders being a "Condition”) comprising administering to a patient in need of such treatment an effective amount of at least one compound of formula (I).
  • a cardiovascular disease a disease of the gastrointestinal tract
  • the invention also provides pharmaceutical compositions comprising an effective amount of at least one compound of formula (I) and a pharmaceutically acceptable carrier.
  • the compositions further comprise one or more additional agents useful for treating obesity, diabetes, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder.
  • the compositions further comprise one or more Hh receptor antagonists.
  • the compositions are useful for treating a Condition.
  • the invention further provides methods for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder comprising administering to a patient in need of such treatment an effective amount of a combination of at least one compound of formula (I) and at least one other compound useful for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder.
  • the invention also provides methods for treating obesity or an obesity-related disorder in a patient, comprising administering to the patient an effective amount of at least one compound of formula (I) and an anti-diabetic agent.
  • the present invention also provides methods for treating allergy, an allergy- induced airway response or congestion comprising administering to a patient in need of such treatment an effective amount of at least one compound of claim 1 and an effective amount of an Hi receptor antagonist.
  • the present invention further provides methods for treating diabetes in a patient, comprising administering to the patient an effective amount of at least one compound of claim 1.
  • kits comprising a single package which contains: (i) a container containing a pharmaceutical composition comprising an effective amount of a compound of formula (I), and (ii) another container containing a pharmaceutical composition comprising an Hi receptor antagonist. Also provided are kits comprising a single package which contains: (i) a container containing a pharmaceutical composition comprising an effective amount of a compound of formula (I), and (ii) another container containing a pharmaceutical composition comprising an effective amount of a separate compound useful for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder.
  • the present invention provides compounds of formula (I), pharmaceutical compositions comprising at least one compound of formula (I), and methods of using at least one compound of formula (I) to treat or prevent a Condition.
  • a "patient” is a human or non-human mammal.
  • a patient is a human.
  • a patient is a non-human mammal, including, but not limited to, a monkey, dog, baboon, rhesus, mouse, rat, horse, cat or rabbit.
  • a patient is a companion animal, including but not limited to a dog, cat, rabbit, horse or ferret.
  • a patient is a dog.
  • a patient is a cat.
  • Alkyl refers to straight and branched carbon chains and contains from one to six carbon atoms.
  • Alkylene refers to a divalent straight or branched alkyl chain, e.g., methylene (-CH2-) or propylene (-CH 2 CH 2 CH 2 -).
  • Haloalkyl or haloalkoxy refer to alkyl or alkoxy chains as defined above wherein one or more hydrogen atoms are replaced by halogen atoms, e.g., -CF 3 , CF 3 CH 2 CH 2 -, CF 3 CF 2 - or CF 3 O-.
  • Aryl refers a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g., aryl is a phenyl or naphthyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment.
  • Arylalkyl refers to an aryl group, as defined above, bound to an alkyl group, as defined above, wherein said alkyl group is the point of attachment.
  • Cycloalkyl refers to a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms. In one embodiment, a cycloalkyl contains from about 5 to about 10 carbon atoms. In one embodiment, cycloalkyl rings contain about 3 to about 7 ring atoms.
  • suitable monocyclic cycloalkyls include cycjopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
  • Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantly and the like.
  • Halogen or halo refers to -F, -Cl, -Br, or -I.
  • Heteroaryl refers to cyclic groups, having 1 to 4 heteroatoms selected from O, S or N, said heteroatom interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character.
  • the aromatic heterocyclic groups contain from 2 to 14 carbon atoms. The rings do not contain adjacent oxygen and/or sulfur atoms.
  • Examples include but are not limited to 5-membered rings such as isothiazolyl, isoxazolyl, oxazolyl, furazanyl, triazolyl, tetrazolyl, thiazolyl, thienyl, furanyl (furyl), pyrrolyl and pyrazolyl, and 6-membered rings such as pyranyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyridyl (e.g., 2-, 3-, or 4-pyridyl), pyridyl N-oxide (e.g., 2-, 3-, or4-pyridyl N-oxide) and triazinyl, and biciclic groups such as pteridinyl, indolyl (benzopyrrolyl), pyridopyrazinyl, isoquinolinyl, quinolinyl, naphthyridinyl. All available substitutable carbon and
  • Examples include but are not limited to 2- or 3-tetrahydrofuranyl, 2- or 3- tetrahydrothienyl, 2-, 3- or 4-piperidinyl, 2- or 3-pyrrolidinyl, 2- or 3-piperizinyl, 2- or 4-dioxanyl, 1 ,3-dioxolanyl, 1,3,5-trithianyl, pentamethylene sulfide, perhydroisoquinolinyl, decahydroq ⁇ inolinyl, trimethylene oxide, azetidinyl, 1- azacycloheptanyl, 1 ,3-dithianyl, 1 ,3,5-trioxanyl, morpholinyl, thiomorpholinyl, 1 ,4- thioxanyl, and 1 ,3,5-hexahydrotriazinyl, thiazolidinyl, tetrahydropyranyl.
  • Cycloalkylene refers to a divalent cycloal
  • Heterocycloalkylene refers to a divalent heterocycloalkyl ring, e.g.
  • heterocycloalkylene groups such ' as oorr are contemplated.
  • v — means thai: two nitrogens are located at any two of the 4 non-fused positions of the ring, e.g., the 4 and 6 positions, the 4 and 7 positions, or the 5 and 6 positions.
  • upper airway usually means the upper respiratory system, i.e., the nose, throat, and associated structures.
  • Effective amount or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.
  • a line drawn into a ring means that the indicated bond may be attached to any of the substitutable ring carbon atoms.
  • substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • stable compound' or “stable structure” is meant to describe a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • the R 4 substituent can replace the H on said carbon, e.g., the ring can be:
  • purified refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof.
  • purified refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atorn(s) to satisfy the valences.
  • protecting groups When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991 ), Wiley, New York.
  • variable e.g., aryl, heterocycle, R 2 , etc.
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • Prodrugs and solvates of the compounds of the invention are also contemplated herein.
  • a discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press.
  • the term "prodrug” means a compound (e.g. a drug precursor) that is transformed in vivo to yield a compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood.
  • a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci-C ⁇ )alkyl, (C 2 -C 12 )alkanoyl- oxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1- (alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N- (alkoxycarbon
  • a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (C-i-CeJalkanoyloxymethyl, 1-((C 1 - C6)alkanoyloxy)-ethyl, 1 -methyl-1 -((Ci-C 6 )alkanoyloxy)ethyl, (C 1 - C 6 )alkoxycarbonyloxymethyl, N-(Ci-C 6 )alkoxycarbonylaminomethyl, succinoyl, (C 1 - C ⁇ jalkanoyl, ⁇ -amino(C 1 -C 4 )alkanyl, arylacyl and ⁇ -aminoacyl, or ⁇ -aminoacyl- ⁇ - aminoacyl, where each ⁇ -amlnoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH
  • a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R"-carbonyl, R"O-carbonyl, NR"R'"-carbonyl where R" and R"' are each independently (Ci-Cio)alkyl, (C 3 -C 7 ) cycloalkyl, benzyl, or R"-carbonyl is a natural ⁇ -ami ⁇ oacyl or natural ⁇ -aminoacyl, — C(OH)C(O)OY 1 wherein Y 1 is H, (d-CeJalkyl or benzyl, — C(OY 2 )Y 3 wherein Y 2 is (C 1 -C 4 ) alkyl and
  • Y 3 is (Ci-Ce)alkyl, carboxy (C ⁇ C ⁇ )alkyl, amino(C 1 -C 4 )alkyl or mono-N — or di-N,N-(C ⁇ C 6 )alkylaminoalkyl, — C(Y 4 )Y 5 wherein Y 4 is H or methyl and Y 5 is mono-N — or di- N.N-CC-rC-eJalkylamino morpholino a piperidin-1-yl or pyrrolidin-1-yl, and the like.
  • Solvate means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • Solvate encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.
  • “Hydrate” is a solvate wherein the solvent molecule is H ⁇ O.
  • the compounds of formula (I) can form salts which are also within the scope of this invention.
  • Reference to a compound of formula (I) herein is understood to include reference to salts thereof, unless otherwise indicated.
  • the term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • zwitterions inner salts
  • a salt is a pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salt, although other salts are also useful.
  • Salts of the compounds of the formula (I) may be formed, for example, by reacting a compound of formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one ⁇ n which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salits, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
  • alkali metal salts such as sodium, lithium, and potassium salits
  • alkaline earth metal salts such as calcium and magnesium salts
  • salts with organic bases for example, organic amines
  • organic amines such as dicyclohexylamines, t-butyl amines
  • salts with amino acids such as arginine, lysine and the like.
  • Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others. All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
  • lower alkyl halides e.g., methyl, ethyl, and butyl chlorides, bromides and iodides
  • esters of the present compounds include the following groups: (1 ) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n- propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphonate esters and (5) mono-, di-, di
  • One or more compounds of the invention may also exist as, or optionally converted to, a solvate.
  • Preparation of solvates is generally known.
  • M. Caira et al, J. Pharmaceutical ScL, 93(3). 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water.
  • Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSciTech., 511 ⁇ , article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001).
  • Atypical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods.
  • Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
  • All stereoisomers for example, geometric isomers, optical isomers and the like
  • of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs
  • those which may exist due to asymmetric carbons on various substituents including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
  • Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
  • the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
  • the use of the terms "salt”, “solvate”, “ester”, “prodrug” and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
  • Polymorphic forms of the compounds of formula (I), and of the salts, solvates, esters and prodrugs of the compounds of formula (I) are intended to be included in the present invention.
  • At least one compound of formula (I) means that one to three different compounds of formula (I) may be used in a pharmaceutical composition or method of treatment. In one embodiment one compound of formula (I) is used.
  • at least one Hi receptor antagonist or “at least one other compound (or agent) for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder” means that one to three different Hi antagonists or other compounds may be used in a pharmaceutical composition or method of treatment. In one embodiment, one Hi antagonist or one other compound for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder is used in the combinations.
  • an obese patient refers to a patient being overweight and having a body mass index (BMI) of 25 or greater.
  • BMI body mass index
  • an obese patient has a BMI of 25 or greater.
  • an obese patient has a BMI from 25 to 30.
  • an obese patient has a BMI greater than 30.
  • an obese patient has a BMI greater than 40.
  • the term "obesity-related disorder” as used herein refers to any disorder which results from a patient having a BMI of 25 or greater. Non-limiting examples of an obesity-related disorder include edema, shortness of breath, sleep apnea, skin disorders and high blood pressure.
  • metabolic syndrome refers to a combination of risk factors for cardiovascular disease (CVD) identified in the National Cholesterol Education Program's Adult Treatment Panel III report. See for example the discussion by Grundy et al in Circulation. 109 (2004), 433-438.
  • CVD cardiovascular disease
  • the components of metabolic syndrome are: 1) abdominal obesity; 2) atherogenic dyslipidemia; 3) raised blood pressure; 4) insulin resistance; 5) proinflammatory state; and 6) prothrombotic state.
  • CVD cardiovascular disease
  • the invention provides compounds having the formula:
  • R 1 , R 2 , R 3 , R 4 , M, U, W, X, Y, Z, a, b, n and p are defined above for the compounds of formula (I).
  • R 1 is R 11 -aryl, R 11 -(6-membered heteroaryl),
  • R 1 is R 11 -aryl, aryl is phenyl and R 11 is 1 to 4 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl or -CN.
  • R 11 is one or two substituents independently selected from H and halo, or R 11 is one substituent selected from the group consisting Of-CF 3 , - CHF 2 and -CN.
  • R 1 is R 11 -(6-membered heteroaryl), the 6-membered heteroaryl is pyridyl and R 11 is 1-3 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl and -CN.
  • R 1 is R 11 -(6-membered heteroaryl), the 6-membered heteroaryl is pyridyl is one or two substituents independently selected from the group consisting of H and halo, or R 11 is one substituent selected from the group consisting of -CF3, -CHF 2 and -CN.
  • R 1 is R 11 -(6-membered heteroaryl), the 6-membered heteroaryl is pyridyl and R 11 is 1-3 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl and -CN.
  • R 1 is R 11 -(6-membered heteroaryl), the 6-membered heteroaryl is
  • R ,11a is C 1 -C 3 alkyl, halo(Ci-C 3 )alkyl, C 1 -C 3 alkoxy, Ci-C 3 alkylthio, R 15 -phenyl or R ,15- heteroaryl;
  • R 15 is 1-3 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OCF 3 , -CHF 2 or -CN;
  • R 16 is as defined abovd; and k, k1 and k2 are each 0, 1 or 2.
  • R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R i11a is (Ci-C 3 )alkyl, C 1 -C 3 alkoxy, C 1 -C 3 alkylthio, R 15 -phenyl or R -pyridyl;
  • R ,15 is 1 or 2 substituents independently selected from the group consisting of H, halo, alkyl and haloalkyl; R 16 is as defined above; and k1 is 0 or 1.
  • R J is
  • R ,1 1 1 i a a is -C 2 F 5 , -CF 3 , C 2 Hs-O-, CH 3 -O-, C 2 H 5 -S-, CH 3 -S-, R 1 -phenyl or R 15 -pyridyl;
  • R 15 is 1 or 2 substituents independently selected from the group consisting of H, F, Cl, -CH 3 , and -CF 3 ;
  • k1 is 0 or 1 ;
  • R 16 is F, Cl Or-CF 3 .
  • M is CH.
  • M is N.
  • R 3 and R 4 are independently selected from the group consisting of H, alkyl, fluoro and -OH.
  • M is CR 4 , wherein R 4 is H or fluoro.
  • n is 2 and p is 1.
  • a and b are each independently 0 or 1.
  • a and b are each 0.
  • both U and W are CH.
  • X is y a single bond or -C(N-OR 5 )-, wherein R 5 is H or alkyl.
  • X is a single bond.
  • Z is -CH 2 -.
  • R 2 is R 13 -heteroaryl or R 13 -heterocycloalkyl.
  • R 2 is a R 13 -(5 or 6 membered heteroaryl) or a R 13 -(4, 5 or 6-membered heterocycloalkyl).
  • R 2 is R 13 -pyridyl, R 13 -pyrimidyl, R 13 -pyradazinyl, R 13 -tetrahydropyranyl, R 13 -azetidinyl, R 13 -oxazolyl or R 13 -thiazolyl.
  • R 13 is 1 or 2 substituents independently selected from the group consisting of H, -CH 3 , -NH 2 and -NHCH 3 .
  • R 2 when R 2 is R 13 -tetrahydropyranyl or R 13 -azetidinyl, R 13 is 1 or 2 substituents independently selected from the group consisting of H and -CH 3 .
  • R 2 is 2-amino pyridyl, 2-amino oxazolyl, 2-amino thiazolyl, 1-methyl-azetidinyl or t € ⁇ trahydropyranyl.
  • R 2 is 2-amino pyridyl.
  • the compounds of formula (I) have the formula (IA):
  • W is CH or N
  • R 1 is -aryl, -heteroaryl, -heterocycloalkyl
  • an aryl group can be substituted with up to 2 groups chosen from alkyl, halo or -CN; a heterocycloalkyl can be substituted with up to groups chosen from alkyl and heteroaryl; and a heteroaryl group can be substituted with up to 2 groups chosen from -halo, alkyl and alkoxy;
  • R 2 is -heterocycloalkyl, heteroaryl, -CH(G)-aryl, -CH(G)-heteroaryl,
  • each occurrence of R is independently —halo
  • R11 a is -H, -S-alkyl, hetqroaryl, aryl, -CF 2 (CF 3 ) or -CF 3 ;
  • R 16 is -H, -halo, Ci-C 6 alkyli; or alkenyl;
  • R 19 is -H or alkyl;
  • R 20 is -H or-alkyl;
  • G is -H or -alkyl;
  • Q is O or S;
  • V is CH or N; a is 0, 1 or 2; and k is 0 or 1.
  • M is CH.
  • M is N.
  • W is CH.
  • W is N.
  • X is a bond. In another embodiment, X is -CH 2 -.
  • X is -C(O)-.
  • X is -CH(OH)-.
  • Y is — O-. In another embodiment, Y is -CH 2 -.
  • Y is -C(O)-.
  • Y is -S-.
  • Y is -SO 2 -.
  • M is CH and Y is -O-. In another embodiment, M is CH and Y is -CH2-.
  • M is CH and Y is -C(O)-.
  • M is CH and Y is -S-.
  • M is CH and Y is -SO 2 -.
  • M is N and Y is -O-. In another embodiment, M is N and Y is -CH 2 -.
  • M is N and Y is -C(O)-.
  • R 1 is aryl
  • R 1 is heteroaryl. In another embodiment, R 1 is heterocycloalkyl. In still another embodiment, R 1 is:
  • R 1 is phenyl
  • R 1 is pyridyl
  • R 1 is pyrimidinyl
  • R 1 is thiophenyl
  • R ' ' is /V-piperaz ⁇ nyl.
  • R 1 is ⁇ /-piperidinyl.
  • R 1 is A/-pyrrolidinyl.
  • R 1 is /V-morpholinyl.
  • R 1 is /V-azetidinyl.
  • R 1 is ⁇ /-[1 ,4]-diazapanyl.
  • R 1 is:
  • R 1 is:
  • R 1 is- :
  • R 2 is -heteroaryl.
  • R 2 is -heterocycloalkyl.
  • R 2 is -CH 2 -heteroaryl.
  • R 2 is -CHa-heterocycloalkyl.
  • R 2 is -CH(G)-aryl.
  • R 2 is ⁇ CH(G)-heteroaryl.
  • R 2 is: In one embodiment, R 2 i
  • R 2 is:
  • R is:
  • R 2 is tetrahydropyranyl.
  • R i2'" i.s thiazolyl.
  • R 2 is --CH 2 -aryl.
  • R 2 is — CH(CH 3 )-aryl.
  • R 2" is. -CH 2 -heteroaryl.
  • R 2 is. -CH(CH 3 )-heteroaryl In one embodiment, R 2 is -Chh-phenyl. In one embodiment, R 2 is:
  • R 2 is -CH(CH 3 )-pyridyl. In still another embodiment, R 2 is:
  • a is 1 and R is -F.
  • a is 2 and each occurrence of R 3 is -F.
  • M is N
  • Z is a bond
  • R 2 is:
  • R 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • M is CH
  • R 1 is
  • Illustrative compounds of formula (I) include, but are not limited to, the compounds of formulas 1A-16A, 16B, 17A-81A, 81B and 82A-116A as depicted below in the Examples section.
  • the compounds of formula (I) can be prepared via procedures known to those skilled in the art. Compounds of this invention are most typically prepared through the initial assembly of the central part of the molecule (BC fragment — see Scheme 1 ), followed by the attachment of the corresponding A and D fragments.
  • R', R" and R'" are as defined in the Scheme; Pr is a protecting group such as BOC; X' is, for example & halogen, aldehyde, amino or nitro group; and the remaining variables are as defined above for formula (I).
  • connection between the B and C rings in cases (1), where Y is -O- and M is CH is achieved through a Mitsunobu reaction of the B-ring-based phenol, or alternatively, through an aromatic nucleophilic substitution on a halogen-substituted B ring by the C-ring alcohol.
  • a Grignard or an organolithium reagent an organometallic nucleophile
  • connection between the B and C rings is most easily established through amide coupling of the corresponding B-ring benzoic acid and C-ring piperazine or diazepine.
  • the installation or formation of the A ring is most conveniently accomplished by taking advantage of a preinstalled functionality on the B-ring (X' - see Scheme 1 ), including, but not limited to an aldehyde, an amino group, a nitro group or a halogen.
  • halogen and aldehyde substituted compounds are used to provide compounds wherein R 1 is aryl or heteroaryl, and nitro and amino substituted compounds are used to prepare compounds wherein R 1 is benzimidazolyl.
  • Some general approaches are shown in Scheme 2.
  • Ar is a N ⁇ 2 -substituted aryl group or a synthetic precursor therefore, which can be later elaborated into a benzimidazole as described in specific procedures, below.
  • R 1 is chosen so as to provide R 1 upon the transformation shown in the scheme.
  • Pr is a protecting group
  • Hal and Met are as defined in the scheme
  • the remaining variables are as defined for formula (I).
  • the D-electrophile is a one-carbon aldehyde or alkyl halide attached to the R 2 group (Z' is a bond in D — Scheme 3), but can also be an epoxide or other longer-chain electrophile in cases where 21 is an optionally substituted Ci to C 5 alkyl or alkenyl group.
  • the compounds are synthesized through chain extension of one-carbon starting D-aldehydes (previously described or commercially available) by various methods known to those skilled in the art.
  • Those methods include, but are not limited to, the reactions of starting aldehydes with alkylmetal reagents, carbon-phosphorus reagents (known to those skilled in the art as Wittig reactions and Horner-Ernmons reactions), and also include reactions with other carbon nucleophiles, followed by appropriate functional elaboration, leading to compounds of the type D, where Z' is an appropriately substituted Ci to C 5 alkyl or alkenyl group.
  • the corresponding D fragment with the elongated Z 1 is prepared by coupling an aryl halide with an appropriate alkyl or alkenyl metal reagent (e.g., Li or MgX, wherein X is a halogen), optionally in the presence of an appropriate transition metal catalyst (e.g, Cu, Ni).
  • an appropriate alkyl or alkenyl metal reagent e.g., Li or MgX, wherein X is a halogen
  • an appropriate transition metal catalyst e.g, Cu, Ni
  • compounds described in this invention are prepared in a right- to-left stepwise fashion: C + D, followed by B + CD, followed by A + BCD, using the same synthetic approaches as described above, but in a different sequence. Also, when the process of bond formation between any of the two fragments is generally compatible with the rest of the molecule, the compounds are synthesized through a left-to-right stepwise approach: A + B, followed by AB + C, followed by ABC + D.
  • the compounds of formula (I) are useful for treating or preventing a Condition. Accordingly, the present invention provides methods for treating or preventing a Condition in a patient, comprising administering to the patient an effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
  • the compounds of formula (I) are useful for treating congestion, metabolic syndrome, obesity, an obesity-related disorder or a cognition deficit disorder.
  • the compounds of formula (I) are useful for treating obesity or an obesity-related disorder.
  • the compounds of formula (I) are useful for treating diabetes.
  • diabetes There are two major forms of diabetes: Type I diabetes (also referred to as insulin-dependent diabetes or NIDDM) and Type Il diabetes (also referred to as noninsulin dependent diabetes or NIDDM).
  • Type I diabetes also referred to as insulin-dependent diabetes or NIDDM
  • Type Il diabetes also referred to as noninsulin dependent diabetes or NIDDM
  • the compounds of formula (I) are useful for treating Type I diabetes.
  • the compounds of formula (I) are useful for treating Type Il diabetes.
  • the present methods for treating or preventing a Condition can further comprise administering one or more additional therapeutic agents in addition to the at least one compound of formula (I).
  • Additional therapeutic agents useful in the present methods include, but are not limited to, Hi receptor antagonists, weight-loss agents, HMG-CoA reductase inhibitors, sterol absorption inhibitors, anti-diabetic agents, any agent useful for treating obesity, an obesity-related disorder, any agent useful for treating metabolic syndrome, any agent useful for treating a cognition deficit disorder, or any combination of two or more of these additional therapeutic agents.
  • the compounds of formula (I) can be combined with an H 1 receptor antagonist (i.e., the compounds of formula (I) can be combined with an Hi receptor antagonist in a pharmaceutical composition, or the compounds of formula (I) can be administered with an Hi receptor antagonist).
  • an H 1 receptor antagonist i.e., the compounds of formula (I) can be combined with an Hi receptor antagonist in a pharmaceutical composition, or the compounds of formula (I) can be administered with an Hi receptor antagonist.
  • Hi receptor antagonists include, without limitation: astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, diphenhydramine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine,
  • the Hi receptor antagonist is used at its known therapeutically effective dose, or the Hi receptor antagonist is used at its normally prescribed dosage.
  • said H 1 receptor antagonist is selected from: azatadine, brompheniramine, cetirizine, chlorpheniramine, carebastine, descarboethoxyloratadine, diphenhydramine, ebastine, fexofenadine, loratadine, or norastemizole.
  • said Hi antagonist is selected from loratadine, descarboethoxyloratadine, fexofenadine or cetirizine.
  • nasal congestion is treated.
  • Weight-loss agents include appetite suppressants, metabolic rate enhancers and nutrient absorption inhibitors.
  • Appetite suppressant agents useful for treating obesity or metabolic syndrome include cannabinoid receptor 1 (CB 1 ) antagonists or inverse agonists (e.g., rimonabant); Neuropeptide Y (NPY1, IMPY2, NPY4 and NPY5) antagonists; metabotropic glutamate subtype 5 receptor (mGluR ⁇ ) antagonists (e.g., 2-methyl-6-(phenylethynyl)-pyridine and 3[(2-methyl-1 ,4-thiazol-4- yl)ethynyl]pyridine); melanin-concentrating hormone receptor (MCH 1 R and MCH2R) antagonists; melanocortin receptor agonists (e.g., Melanotan-ll and Mc4r agonists); serotonin uptake inhibitors (e.g., dexfenfluramine and fluoxetine); serotonin (5HT) transport
  • NE transporter inhibitors e.g., desipramine, talsupram and nomifensine
  • ghrelin antagonists e.g., leptin or derivatives thereof
  • opioid antagonists e.g., ⁇ almefene, 3-methoxynaltrexone, naloxone and nalterxone
  • orexin antagonists bombesin receptor subtype 3 (BRS3) agonists
  • CCK-A Cholecystokinin- A
  • CNTF ciliary neurotrophic factor
  • monoamine reuptake inhibitors e.g., sibutramine
  • GLP-1 glucagons-like peptide 1
  • Metabolic rate enhancers include acetyl-CoA carboxylase-2 (ACC2) inhibitors; beta adrenergic receptor 3 ( ⁇ 3) agonists; diacylglycerol acyltransferase inhibitors (DGAT1 and DGAT2); fatty acid synthase (FAS) inhibitors (e.g., Cerulenin); phosphodiesterase (PDE) inhibitors (e.g., theophylline, pentoxifylline, zaprinast, sildenafil, amrinone, milrinone, cilqstamide, rolipram and cilomilast); thyroid hormone ⁇ agonists; uncoupling protein activators (UCP-1 ,2 or 3) (e.g., phytanic acid, 4-[(E)- 2-(5,6,7,8-tetramethyl-2-naphthale.nyl)-1-propenyl]benzoic acid and retinoic acid); acyl-
  • Nutrient absorption inhibitors include lipase inhibitors (e.g., orlistat, lipstatin, tetrahydrolipstatin, teasaponin and diethylumbelliferyl phosphate); fatty acid transporter inhibitors; dicarboxylate transporter inhibitors; glucose transporter inhibitors; and phosphate transporter inhibitors.
  • lipase inhibitors e.g., orlistat, lipstatin, tetrahydrolipstatin, teasaponin and diethylumbelliferyl phosphate
  • fatty acid transporter inhibitors e.g., orlistat, lipstatin, tetrahydrolipstatin, teasaponin and diethylumbelliferyl phosphate
  • dicarboxylate transporter inhibitors e.g., dicarboxylate transporter inhibitors
  • glucose transporter inhibitors e.
  • Specific compounds for use in the combination for treating obesity and metabolic syndrome include rimonabant, 2-methyl-6-(phenylethynyl)-pyridine, 3[(2- methyl-1,4-thiazol-4-yl)ethynyl]pyridine, Melanotan-ll, dexfenfluramine, fluoxetine, paroxetine, fenfluramine, fluvoxamine, sertaline, imipramine, desipramine, talsupram, nomifensine, leptin, nalmefene, 3-methoxynaltrexone, naloxone, nalterxone, butabindide, axokine, sibutramine, topiramate, phytopharm compound 57, Cerulenin, theophylline, pentoxifylline, zaprinast, sildenafil, amrinone, milrinone, cilostamide, rolipram, cilomilast, phyt
  • compounds for use in the combination for treating obesity and metabolic syndrome include rimonabant, dexfenfluramine, fenfluramine, phentermine, leptin, nalmefene, axokine, sibutramine, topiramate, phytopharm compound 57, oleoyl-estrone and orlistat.
  • the invention provides combinations of at least one compound of formula (I) and one or more HMG-CoA reductase inhibitors and/or one or more substituted azetidinone or substituted ⁇ -lactam sterol absorption inhibitors for treating metaolic syndrome or obesity.
  • Typical HMG-CoA reductase inhibitors include statins such as lovastatin, simvastatin, pravastatin, atorvastatin, fluvastatin, resuvastatin, cerivastatin, rivastatin and pravastatin.
  • statins such as lovastatin, simvastatin, pravastatin, atorvastatin, fluvastatin, resuvastatin, cerivastatin, rivastatin and pravastatin.
  • the HMG-CoA reductase inhibitor is simvastatin.
  • sterol absorption inhibitor means a compound capable of inhibiting the absorption of one or more sterols, including but not limited to cholesterol, phytosterols (such as isitosterol, campesterol, stigmasterol and avenosterol), 5 ⁇ -stanols (such as cholestanol, 5 ⁇ -campestanol, 5 ⁇ -sitostanol), and/or mixtures thereof, when administered in a therapeutically effective (sterol and/or 5 ⁇ -stanol absorption inhibiting) amount to a mammal or human.
  • phytosterols such as isitosterol, campesterol, stigmasterol and avenosterol
  • 5 ⁇ -stanols such as cholestanol, 5 ⁇ -campestanol, 5 ⁇ -sitostanol
  • mixtures thereof when administered in a therapeutically effective (sterol and/or 5 ⁇ -stanol absorption inhibiting) amount to a mammal or human.
  • Non-limiting examples of suitable substituted azetidinones and methods of making the same include those disclosed in U.S. Patents Nos. RE 37,721, 5,306,817, 5,561,227, 5,618,707, 5,624,920, 5,631 ,365, 5,656,624, 5,627,176, 5,633,246, 5,661 ,145, 5,688,785, 5,688,787, 5,688,990, 5,698,548, 5,728,827, 5,739,321, 5,744,467, 5,756,470, 5,767,115, 5,846,966, 5,856,473, 5,886,171 , 5,919,672, 6,093,812, 6,096,883, 6,133,001, 6,207,822, 6,627,757, 6,632,933, U.S.
  • the compound of Formula (A) can be in anhydrous or hydrated form.
  • a product containing ezetimibe compound is commercially available as ZETIA® ezetimibe formulation from MSP Pharmaceuticals.
  • Typical compounds for use in combination with an H3 antagonist of this invention for the treatment of a cognition deficit disorder are atomoxetine and dexmethylphenidate for the treatment of ADHD, olanzapine, risperidone or aripiprazole for treatment of schizophrenia, and donepezil, heptylphysostigmine, tacrine, rivastigmine or galantamine for the treatment of Alzheimer's Disease.
  • the compounds of formula (I) can be co-administered with an anti-diabetic agent for treating diabetes.
  • insulin sensitizers such as PPAR agonists, DPPIV inhibitors, PTP-1B inhibitors and glucokinase activators
  • ⁇ -glucosidase inhibitors such as PPAR agonists, DPPIV inhibitors, PTP-1B inhibitors and glucokinase activators
  • ⁇ -glucosidase inhibitors such as PPAR agonists, DPPIV inhibitors, PTP-1B inhibitors and glucokinase activators
  • the anti-diabetic agent is an insulin sensitizer or a sulfonylurea.
  • sulfonylureas include glipizide, tolbutamide, glyburide, glimepiride, chlorpropamide, acetohexamide, gliamilide, gliclazide, glibenclamide and tolazamide.
  • Insulin sensitizers include PPAR- ⁇ agonists described in detail above.
  • useful PPAR- ⁇ agonists are troglitazone, rosiglitazone, pioglitazone and englitazone; biguanidines such as metformin and phenformin; DPPIV inhibitors such as sitagliptin, saxagliptin, denagliptin and vildagliptin; PTP-1E3 inhibitors; and glucokinase activators, ⁇ - Glucosidase inhibitors that can be useful in treating type Il diabetes include miglitol, acarbose, and voglibose.
  • Hepatic glucose output lowering drugs include
  • Insulin secretagogues include sulfonylurea and non-sulfonylurea drugs such as Gl 1 P-I , exendin, GIP, secretin, glipizide, chlorpropamide, nateglinide, megl ⁇ tinide, glibenclamide, repaglinide and glimepiride. Insulin includes all formualtions of insulin, including long acting and short acting forms of insulin.
  • Non-limiting examples of anti-obesity agents useful in the present methods for treating diabetes include CB1 antagonists or inverse agonists such as rimonabant, neuropeptide Y antagonists, MCR4 agonists, MCH receptor antagonists, histamnine H3 receptor antagonists or inverse agonists, leptin, appetite suppressants such as sibutramine, and lipase inhibitors such as xenical.
  • CB1 antagonists or inverse agonists such as rimonabant, neuropeptide Y antagonists, MCR4 agonists, MCH receptor antagonists, histamnine H3 receptor antagonists or inverse agonists, leptin, appetite suppressants such as sibutramine, and lipase inhibitors such as xenical.
  • Non-limiting examples of antihypertensive agents useful in the present methods for treating diabetes include ⁇ -blockers and calcium channel blockers (for example diltiazem, verapamil, nifedipine, amlopidine, and mybefradil), ACE inhibitors (for example captopril, lisinopril, enalapril, spirapril, ceranopril, zefenopril, fosinopril, cilazopril, and quinapril), AT-1 receptor antagonists (for example losartan, irbesartan, and valsartan), renin inhibitors and endothelin receptor antagonists (for example sitaxsentan).
  • ⁇ -blockers and calcium channel blockers for example diltiazem, verapamil, nifedipine, amlopidine, and mybefradil
  • ACE inhibitors for example captopril, lisinopril, enala
  • Non-limiting examples of meglitinides useful in the present methods for treating diabetes include repaglinide and nateglinide.
  • Non-limiting examples of insulin sensitizers include biguanides, such as metformin and thiazolidinediones.
  • the insulin sensitizer is a thiazolidinedione.
  • Alpha-glucosidase inhibitors help the body to lower blood sugar by delaying the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals.
  • Non-limiting examples of suitable alpha-glucosidase inhibitors include acarbose; miglitol; camiglibose; certain polyamines as disclosed in WO 01/47528 (incorporated herein by reference); voglibose.
  • suitable peptides for increasing insulin production including amlintide (CAS Reg. No. 122384-88-7 from Amylin; pramlintide, exendin, certain compounds having Glucagon-like peptide-1 (GLP-1) agonistic activity as disclosed in WO 00/07617 (incorporated herein by reference).
  • Non-limiting examples of orally administrable insulin and insulin containing compositions include AL-401 from Autoimmune, and the compositions disclosed in U.S. Patent Nos. 4,579,730; 4,849,405; 4,963,526; 5,642,868; 5,763,396; 5,824,638; 5,843,866; 6,153,632; 6,191 ,105; and International Publication No. WO 85/05029, each of which is incorporated herein by reference.
  • the compounds of formula (I) can be co-administered with an anti-diabetic agent for treating obesity or an obesity-related disorder.
  • Anti-diabetic agents useful in the present methods for treating obesity or an obesity-related disorder include, but are not limited to the anti-diabetic agents listed above herein.
  • the at least one compound of formula (I) and the one or more additional therapeutic agents can be administered simultaneously (at the same time, in a single dosage form or in separate dosage forms) or sequentially (first one and then another, etc. . . over a period of time) in any order.
  • inert, pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • the powders and tablets may be comprised of from about 5 to about 95 percent active ingredient.
  • Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, tatc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), The Science and Practice of Pharmacy, 20 th Edition, (2000), Lippincott Williams & Wilkins, Baltimore, MD.
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
  • a pharmaceutically acceptable carrier such as an inert compressed gas, e.g. nitrogen.
  • transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • the compound of formula (I) is administered orally.
  • the pharmaceutical preparation is in a unit dosage form.
  • the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 150 mg. In one embodiment, the quantity per unit dose is from about 1 mg to about 75 mg. In one embodiment, the quantity per unit dose is from about 1 mg to about 50 mg, according to the particular application.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divfded and administered in portions during the day as required. The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated.
  • a typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 300 mg/day. In one embodiment the daily dosage is from about 1 mg/day to about 75 mg/day, in two to four divided doses.
  • the two active components may be co-administered simultaneously or sequentially, or a single pharmaceutical composition comprising a H3 antagonist and an Ht antagonist in a pharmaceutically acceptable carrier can be administered.
  • the components of the combination can be administered individually or together in any conventional dosage form such as capsule, tablet, powder, cachet, suspension, solution, suppository, nasal spray, etc.
  • the dosage of the Hi antagonist can be determined from published material, and may range from about 1 to about 1000 mg per dose. In one embodiment, when used in combination, the dosage levels of the individual components are lower than the recommended individual dosages because of the advantageous effect of the combination.
  • kits comprising in a single package, one container comprising an H3 antagonist in a pharmaceutically acceptable carrier, and a separate container comprising an Hi antagonist in a pharmaceutically acceptable carrier, with the H3 and Hi antagonists being present in amounts such that the combination is therapeutically effective.
  • a kit is advantageous for administering a combination when, for example, the components must be administered at different time intervals or when they are in different dosage forms.
  • the two active components may be co- administered simultaneously or sequentially, or a single pharmaceutical composition comprising a H 3 antagonist and another compound in a pharmaceutically acceptable carrier can be administered.
  • the components of the combination can be administered individually or together in any conventional dosage form such as capsule, tablet, powder, cachet, suspension, solution, suppository, nasal spray, etc.
  • the dosage of the other compound for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder can be determined from published material, and may range from about 1 to about 1000 mg per dose.
  • kits comprising in a single package, one container comprising an H 3 antagonist in a pharmaceutically acceptable carrier, and a separate container comprising a compound for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder in a pharmaceutically acceptable carrier, with the H 3 antagonists and other compounds being present in amounts such that the combination is therapeutically effective.
  • a kit is advantageous for administering a combination when, for example, the components must be administered at different time intervals or when they are in different dosage forms.
  • LCMS analysis was performed using an Applied Biosystems API-100 mass spectrometer equipped with a Shimadzu SCL-10A LC column: Altech platinum C18, 3 ⁇ m, 33 mm X 7 mm ID; gradient flow: 0 minutes, 10% CH 3 CN; 5 minutes, 95% CH 3 CN; 7 minutes, 95% CH 3 CN; 7.5 minutes, 10% CH 3 CN; 9 minutes, stop.
  • Flash column chromatography was performed using Selecto Scientific flash silica gel, 32-63 mesh.
  • Analytical and preparative TLC was performed using Analtech Silica gel GF plates.
  • Chiral HPLC was performed using a Varian PrepStar system equipped with a Chiralpak OD column (Chiral Technologies).
  • Step 1
  • Step 1
  • Step 1
  • Compound 20 was converted into the title compound using the methods set forth in Example 5, steps 2-5, followed by procedures from Example 4, steps 6 and 7.
  • Step 1
  • Step i
  • Step 3 To a solution of nitro compound 23 (11.5 g, 25.5 mmol) in EtOH (250 mL) was added 20% palladium hydroxide-on-carbon catalyst (1.5 g), and the resultant mixture was hydrogenated for 16 h on a Parr shaker apparatus at an initial pressure of 40 psi. Catalyst was removed by filtration, and the filtrate was concentrated under vacuum to provide a dark gray solid, which was triturated with EtOH. Filtration yielded ⁇ 7.9 g of compound 24 as a gray solid deemed sufficiently pure for use in the next step. Step 3:
  • Step 1
  • Step 1
  • Step 1
  • Step i
  • Step 1
  • Compounds 49A and 49B were converted into Compounds 16A (MH + 436) and 16B (MH + 436), respectively, by using the procedures of Example 13, step 3, followed by Example 10, steps 5 and 6.
  • Step i
  • Compound 50 was prepared from 2-bromopyridine and methyl 4- formylbenzoate using the procedure of Example 16A, step 2, except that THF was used instead of toluene as the solvent.
  • LiAIH 4 (10.0 g, 0.264 mol, 1.24 eq) was portionwise added to a solution of methyl-2-chloro-6-methylpyridine-4-carboxylate 54 (39.62 g, 0.213 mol) in dry THF (800 mL) at room temperature, with stirring, over a period of 1.4 h. The resulting mixture was stirred for 1 h and quenched with water. Then 15% aqueous NaOH (100 mL) was added, followed by aqueous sodium-potassium tartrate (1 I).
  • Step 1
  • Step 1
  • Compound 75 was prepared from commercially available 2-aminothiazole-5- carbaldehyde by a standard procedure ((BOC) 2 O, DCM, room temperature).
  • Step 5 76 was prepared from 74 and 75.
  • Step 2 Compound 77 was converted into the title compound using the method set forth in Example 4, step 8. MH + 506.
  • Trifluoroacetic acid (1mL) was added to a solution of compound 88 (360mg, 0.755mmol) in DCM (4ml_), and the reaction was allowed to stir at room temperature for 16h.
  • the reaction mixture was then diluted with DCM (10 ml_), basified using 50% NH 4 OH (v/v, 6 ml_), then the aqueous was extracted once more with DCM (10 ml_).
  • the combined organics were dried over anhydrous MgSO 4 , and concentrated in vacuo to provide compound 89 as a light pink solid (0.265g).
  • Step 4 Compound 89 was converted to the title compound using the methods set forth in steps 6-7 of Example 4.
  • Compound 96 was prepared from compound 95 and 2-chloro-3-nitropyridine using the method set forth in Example 75, step 3.
  • Compound 110 was convert:ed to 111 by using the method described in
  • H 3 -Receptor Binding Assay The source of the H 3 receptors in this experiment was guinea pig brain. Alternatively, the source of H3 receptors was recombinant human receptor, expressed in HEK-293 (human embryonic kidney) cells.
  • the animals weighed 400-600 g.
  • the brain tissue was homogenized with a solution of 50 mM Tris, pH 7.5.
  • the final concentration of tissue in the homogenization buffer was 10% w/v.
  • the homogenates were centrifuged at 1 ,000 x g for 10 min. in order to remove clumps of tissue and debris.
  • the resulting supernatants were then centrifuged at 50,000 x g for 20 min. in order to sediment the membranes, which were next washed three times in homogenization buffer (50,000 x g for 20 min. each).
  • the membranes were frozen and stored at -70 0 C until needed.
  • Bound ligand was separated from unbound ligand by filtration, and the amount of radioactive ligand bound to the membranes was quantitated by liquid scintillation spectrometry. All incubations were performed in duplicate and the standard error was always less than 10%. Compounds that inhibited more than 70% of the specific binding of radioactive ligand to the receptor were serially diluted to determine a Kj (nM).
  • Compounds of formula (I) have a Ki within the range of about 0.6 to about 600 nM at the recombinant human H 3 receptor and from about 18 nM to about 400 nM at the guinea pig brain receptor.
  • Compound 69A has a Kj of 0.6 nM the recombinant human receptor assay and a K 1 of 18 nM in the guinea pig receptor assay.
  • mice Male, approx. 5 weeks of age, purchased from The Jackson Laboratory, Bar Harbor, ME
  • Table 1 shows the effects of illustrative compounds of the invention on diet- induced obesity in mice.
  • Compound numbers correspond to the compound numbering set forth in the specification.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: M is CH or N; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, -C(O)-, -C(N-OR5)-, -C(N-OR5)-CH(R6)-, -CH(R6)-C(N-OR5)-, -O-, -OCH2-, -CH2O- or -S(O)0-2-; Y is -O-, -(CH2)2-, -C(=O)-, -C(=NOR7)- or -SO0-2-; Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group; R1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof; R2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combination with other agents.

Description

PHENOXYPIPERIDINES AND ANALOGS THEREOF USEFUL AS HISTAMINE hh ANTAGONISTS
FIELD OF THE INVENTION
The present invention relates to phenoxypiperidines and analogs thereof useful as histamine H3 antagonists. The invention also relates to pharmaceutical compositions comprising said compounds and their use in treating inflammatory diseases, allergic conditions, diabetes, obesity, an obesity-related disorder, metabolic syndrome, a cognition deficit disorder, cardiovascular and central nervous system disorders. The invention also relates to the use of a combination of histamine H3 antagonists of this invention with histamine Hi compounds for the treatment of inflammatory diseases and allergic conditions, as well to the use of a combination of an histamine H3 antagonist of this invention with other actives useful for treating diabetes, obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder. Pharmaceutical compositions comprising a combination of at least one novel histamine H3 antagonist compound of the invention with at least one histamine Hi compound or gt least one compound useful for treating diabetes, obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder are also contemplated.
BACKGROUND OF THE INVENTION
The histamine receptors, H1, H2, H3 and H4 have been characterized by their pharmacological behavior. The H1 receptors are those that mediate the response antagonized by conventional antihistamines. H1 receptors are present, for example, in the ileum, the skin, and the bronchial smooth muscle of humans and other mammals. The most prominent H2 receptor-mediated responses are the secretion of gastric acid in mammals and the chronotropic effect in isolated mammalian atria. H4 receptors are expressed primarily on eosinophils and mast cells and have been shown to be involved in the chemotaxis of both cell types.
In the periphery, H3 receptor sites are found on sympathetic nerves, where they modulate sympathetic neurotransmission and attenuate a variety of end organ responses under control of the sympathetic nervous system. Specifically, H3 receptor activation by histamine attenuates norepinephrine outflow to resistance and capacitance vessels, causing vasodilation. In addition, in rodents, peripheral H3 receptors are expressed in brown adipose tissue, suggesting that they may be involved in thermogenesis regulation. H3 receptors are also present in the CNS. H3 receptor expression is observed in cerebral cortex, hippocampal formation, hypothalamus and other parts of the human and animal brain. H3 receptors are expressed on histaminergic neurons and, as heteroreceptors, on neurons involved in other neurotransmitter systems, where H3 receptor activation results in presynaptic inhibition of neurotransmitter release. In the particular case of histaminergic neurons, H3 receptors have been implicated in the regulation of histamine hypothalamic tone, which in turn has been associated with the modulation of sleeping, feeding and cognitive processes in the human brain (see, for example, Leurs et al., Nature Reviews, Drug Discovery, 4, (2005), 107). It is also known and has been described in the literature that histamine is involved in regulation of cognitive and memory processes in the human brain (see, for example, Life Sciences, 72, (2002), 409-414). Consequently, indirect modulation of histaminergic brain function through the central H3 receptors may be a means to modulate these processes. Different classes of H3 receptor ligands have been described and their use for neurological and psychiatric diseases has been suggested (see, e.g., US Patent Publication No. 20040224953, International Publication No. WO2004089373: and International Publication No. WO2004101546). H3 receptor antagonists may be useful for treating various neuropsychiatric conditions, where cognitive deficits are an integral part of the disease, specifically ADHD, schizophrenia and Alzheimer's disease (see, for example, Hancock, A.; Fox, G. in Drug Therapy (eά. Buccafusco, J.J.). (Birkhauser, Basel, 2003). Imidazole H3 receptor antagonists are well known in the art. More recently, non-imidazole H3 receptor antagonists have been disclosed in US Patents 6,720,328 and 6,849,621 , and in US Published Applications 2004/0097483, 2004/0048843 and 2004/0019099. US 5,869,479 discloses compositions for the treatment of the symptoms of allergic rhinitis using a combination of at least one histamine H1 receptor antagonist and at least one histamine H3 receptor antagonist.
SUMMARY OF THE INVENTION In one aspect, the present invention provides compounds of formula (I):
Figure imgf000004_0001
and pharmaceutically acceptable salts and solvates thereof, wherein: a is O, 1, 2, 3 or 4; b is O, 1, 2 or 3;
M is CH, n is 1 or 2, and p is 0, 1 or 2; or M is N1 n is 2, and p is 1 or 2; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, -C(Q)-, -C(N-OR5)-, -C(N-OR5)-CH(R6)-, -CH(R6J-C(N-OR5)-, -O-, -OCH2-, -CH2O-, -CH(OH)-, -S-, -S(O)- Or-S(O)2-; Y is -O-, -CH2-, -(CH2J2-, -C(=O)-, -C(=NOR7)-, -S-, -S(O)- or -SO2-, provided that when M is N, Y is -CH2-, -(CH2)*-, -C(=O)-, -S-, -S(O)- Or-SO2-; Z is a bond, -CH(R9)-(R10-C1-C5 alkylene), -CH(R9)-CH(R9)-O-, -CH(R9)-CH(R9)-N-, -CH(R9)-C(RS)a)=C(R9a)-, -CH(R9)-C(R9a)=C(R9a)-(R10-CrC3 alkylene) or R8-alkylene interrupted by a cycloalkylene or heterocycloalkylene group, provided that when Z is R8-alkylene interrupted by a heterocycloalkylene group bonded through a ring nitrogen, the alkylene portion of the Z group has 2-4 carbon atoms between the ring to which it is attached and said nitrogen;
R1 is R11-alkyl, R11-cycloalkyl, R11-aryl, R11-ary1alkyl, R11-(6-membered heteroaryl), R11-(6-membered heteroaryl)alkyl, R11-(5-membered heteroaryl), R11-(5- membered heteroaryl )alkyl, R11-heterocycloalkyl,
Figure imgf000005_0001
wherein represents one nitrogen atom in the place of any one of the four
unfused ring carbon atoms, and ^i^ represents two nitrogen atoms in the place of any two of the four unfused ring carbon atoms, provided that when R1 is attached to X by a nitrogen atom, X is a bond or alkylene; k is 0, 1 , 2, 3 or 4; k1 is O, 1 , 2 or 3; k2 is 0, 1 or 2;
Q is O or S;
FT is R ,13 -alkyl, R >13 -alkenyl, R ,13 -aryl, R 13 -arylalkyl, R »13 -heteroaryl, R ,13- heteroarylalkyl, R13-cycloalkyl or R13-heterocycloalkyl; each R3 is independently selected from the group consisting of H1 alkyl, halo, -OH, alkoxy, -CF3, -OCF3, -OCHF2, -NO2, -CO2R14, -N(R14)2, -CON(R14)2, - NHC(O)R14, -NHSO2R14, -SO2N(R14J2 and -CN; each R4 is independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OH, alkoxy, -CF3 and -CN;
R° is H, alkyl, haloalkyl, R i115D-arylt R 115 -heteroaryl, R ,115o-cycloalkyl, R ,15- heterocycloalkyl, R15-arylalkyl, -CF3 Or-CH2CF3; R6 is H or alkyl;
R7 is H, alkyl, haloalkyl, R15-aryl or R15-heteroaryl; R8 is 1 , 2 or 3 substituents independently selected from the group consisting of H, R »115 -cycloalkyl, R ,15 -heterocycloalkyl, R 115 -aryl, R ,115 -heteroaryl and haloalkyl, provided that when the R8 substituent is on the carbon joined to the nitrogen atom of the M-containing ring, R8 is joined through a ring carbon atom;
R9 is independently selected from the group consisting of H, alkyl and haloalkyl; R9a is independently selected from the group consisting of H, fluoro, alkyl and haloalkyl;
R10 is 1 , 2 or 3 substituents independently selected from the group consisting of H1 R15-cycloalkyl, R15-heterocycloalkyl, R15-aryl, R15-heteroaryl, halo, haloalkyl, - CN, -OH, alkoxy, -OCF3, -NO2, and -N(R6)2;
R11 is 1 , 2, 3 or 4 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OH, alkoxy, alkylthio, R15-cycloalkyl, R15- heterocycloalkyl, R15-aryl, R15-arylalkyl, R15-heteroaryl, R15-heteroarylalkyl, aryloxy, - OCF3, -OCHF2, -NO2, -CO2R12, -N(R12)2, -CON(R12J2, -NHC(O)R12, -NHSO2R12, - SO2N(R12)2 and -CN;
R11a is H, alkyl, haloalkyl, alkoxy, alkylthio, R15-cycloalkyl, R15-heterocycloalkyl, R15-aryl, R15-arylalkyl, R15-cycloalkyl, R15-heterocycloalkyl, R15-heteroaryl, R15- heteroarylalkyl, R15-aryloxy, -OCF3, -OCHF2, -N(R12J2 Or -SCF3;
R12 is independently selected from the group consisting of H, alkyl, haloalkyl, R15-aryl, R15-heteroaryl, R15-arylalkyl, R15-cycloalkyl and R15-heterocycloalkyl;
R13 is 1 , 2 or 3 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OH, aikoxy, R15-aryl, R15-aryloxy, -OCF3, -OCHF2, -NO2, - CO2R14, -N(R14J2, -CON(R14)2> -NHC(O)R14, -NHSO2R14, -SO2N(R14J2 and -CN;
R14 is independently selected from the group consisting of H, alkyl, haloalkyl, R15-aryl, R15-heteroaryl, R15-cycloalkyl and R15-heterocycloalkyl;
R15 is 1 , 2 or 3 substituents independently selected from the group consisting of H, alkyl, halo, haloalkyl, alkoxy, -N(R18J2, -alkylene-N(R18)2> -CN, -OCF3 and - OCHF2;
R16 is independently selected from the group consisting of alkyl, halogen, haloalkyl, alkenyl, OH, alkoxy, -SOo-2-alkyl and -OCF3;
R17 is H, alkyl, hydroxy (C2 C6)alkyl-, haloalkyl-, haloalkoxyalkyl-, alkoxyalkyl-, R15-aryl, R15-arylalkyl-, R15-heteroaryl, R15-heteroarylalkyl-, R15-cycloalkyl or R15- cycloalkylalkyl; and
R18 is independently selected from the group consisting of H and alkyl.
This invention further provides methods for treating: allergy; an allergy- induced airway (e.g., upper airway) response, including but not limited to, pruritis, sneezing, rhinorrhea and mucosal inflammation (see, for example, McLeod, JPET. 305 (2003) 1037); congestion, such as nasal congestion; hypotension; a cardiovascular disease; a disease of the gastrointestinal tract; hyper- and hypo- motility and acidic secretion of the gastrointestinal tract, such as GERD; metabolic syndrome; obesity; an obesity-relat:ed disorder; a sleeping disorder such as hypersomnia, somnolence, insomnia or narcolepsy; hypo- and hyperactivity of the central nervous system, such as agitation and depression of the CNS; diabetes, including Type I and Type Il diabetes mellitus; a CNS disorder, such as migraine, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or a cognition deficit disorder (e.g., attention deficit hyperactivity disorder (ADHD), Alzheimer's Disease (AD) or schizophrenia); (each of the above described diseases/disorders being a "Condition") comprising administering to a patient in need of such treatment an effective amount of at least one compound of formula (I).
The invention also provides pharmaceutical compositions comprising an effective amount of at least one compound of formula (I) and a pharmaceutically acceptable carrier. In one aspect, the compositions further comprise one or more additional agents useful for treating obesity, diabetes, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder. In one aspect, the compositions further comprise one or more Hh receptor antagonists. The compositions are useful for treating a Condition. The invention further provides methods for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder comprising administering to a patient in need of such treatment an effective amount of a combination of at least one compound of formula (I) and at least one other compound useful for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder.
The invention also provides methods for treating obesity or an obesity-related disorder in a patient, comprising administering to the patient an effective amount of at least one compound of formula (I) and an anti-diabetic agent.
The present invention also provides methods for treating allergy, an allergy- induced airway response or congestion comprising administering to a patient in need of such treatment an effective amount of at least one compound of claim 1 and an effective amount of an Hi receptor antagonist. The present invention further provides methods for treating diabetes in a patient, comprising administering to the patient an effective amount of at least one compound of claim 1.
The invention also provides, kits comprising a single package which contains: (i) a container containing a pharmaceutical composition comprising an effective amount of a compound of formula (I), and (ii) another container containing a pharmaceutical composition comprising an Hi receptor antagonist. Also provided are kits comprising a single package which contains: (i) a container containing a pharmaceutical composition comprising an effective amount of a compound of formula (I), and (ii) another container containing a pharmaceutical composition comprising an effective amount of a separate compound useful for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides compounds of formula (I), pharmaceutical compositions comprising at least one compound of formula (I), and methods of using at least one compound of formula (I) to treat or prevent a Condition.
Definitions and Abbreviations
As used herein, the following terms have the following meanings, unless indicated otherwise:
A "patient" is a human or non-human mammal. In one embodiment, a patient is a human. In another embodiment, a patient is a non-human mammal, including, but not limited to, a monkey, dog, baboon, rhesus, mouse, rat, horse, cat or rabbit. In another embodiment, a patient is a companion animal, including but not limited to a dog, cat, rabbit, horse or ferret. In one embodiment, a patient is a dog. In another embodiment, a patient is a cat.
"Alkyl" (including, for example, the alkyl portions of arylalkyl and alkoxy) refers to straight and branched carbon chains and contains from one to six carbon atoms.
"Alkylene" refers to a divalent straight or branched alkyl chain, e.g., methylene (-CH2-) or propylene (-CH2CH2CH2-). "Haloalkyl" or "haloalkoxy" refer to alkyl or alkoxy chains as defined above wherein one or more hydrogen atoms are replaced by halogen atoms, e.g., -CF3, CF3CH2CH2-, CF3CF2- or CF3O-.
"Aryl" (including the aryl portion of arylalkyl) refers a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g., aryl is a phenyl or naphthyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment.
"Arylalkyl" refers to an aryl group, as defined above, bound to an alkyl group, as defined above, wherein said alkyl group is the point of attachment. "Cycloalkyl" refers to a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms. In one embodiment, a cycloalkyl contains from about 5 to about 10 carbon atoms. In one embodiment, cycloalkyl rings contain about 3 to about 7 ring atoms. Non-limiting examples of suitable monocyclic cycloalkyls include cycjopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantly and the like.
"Halogen" or "halo" refers to -F, -Cl, -Br, or -I.
"Heteroaryl" refers to cyclic groups, having 1 to 4 heteroatoms selected from O, S or N, said heteroatom interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character. In one embodiment, the aromatic heterocyclic groups contain from 2 to 14 carbon atoms. The rings do not contain adjacent oxygen and/or sulfur atoms. Examples include but are not limited to 5-membered rings such as isothiazolyl, isoxazolyl, oxazolyl, furazanyl, triazolyl, tetrazolyl, thiazolyl, thienyl, furanyl (furyl), pyrrolyl and pyrazolyl, and 6-membered rings such as pyranyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyridyl (e.g., 2-, 3-, or 4-pyridyl), pyridyl N-oxide (e.g., 2-, 3-, or4-pyridyl N-oxide) and triazinyl, and biciclic groups such as pteridinyl, indolyl (benzopyrrolyl), pyridopyrazinyl, isoquinolinyl, quinolinyl, naphthyridinyl. All available substitutable carbon and nitrogen atoms can be substituted as defined. "Heterocycloalkyl" refers to a saturated carbocylic ring containing from 3 to
15 carbon atoms. In one embodiment, from 4 to 6 carbon atoms, which carbocyclic ring is interrupted by 1 to 3 hetero atoms selected from -O-, -S-, -SO-, -SO2 or - NR40- wherein R40 represents H, Ci to C6 alkyl, arylalkyl, -C(O)R30, -C(O)OR30, or - C(O)N(R30)2 (wherein each R30 is independently selected from the group consisting of H, alkyl, phenyl and benzyl). The rings do not contain adjacent oxygen and/or sulfur atoms. Examples include but are not limited to 2- or 3-tetrahydrofuranyl, 2- or 3- tetrahydrothienyl, 2-, 3- or 4-piperidinyl, 2- or 3-pyrrolidinyl, 2- or 3-piperizinyl, 2- or 4-dioxanyl, 1 ,3-dioxolanyl, 1,3,5-trithianyl, pentamethylene sulfide, perhydroisoquinolinyl, decahydroqμinolinyl, trimethylene oxide, azetidinyl, 1- azacycloheptanyl, 1 ,3-dithianyl, 1 ,3,5-trioxanyl, morpholinyl, thiomorpholinyl, 1 ,4- thioxanyl, and 1 ,3,5-hexahydrotriazinyl, thiazolidinyl, tetrahydropyranyl. "Cycloalkylene" refers to a divalent cycloalkyl ring, e.g.
Figure imgf000010_0001
"Heterocycloalkylene" refers to a divalent heterocycloalkyl ring, e.g.
Figure imgf000010_0002
therefore, when R >8- a, lkylene is said to be interrupted by cycloalkylene or
heterocycloalkylene, groups such' as
Figure imgf000010_0003
oorr are contemplated.
(N) , for example in the structure
Figure imgf000010_0004
represents a nitrogen atom that is located at one of the 4 non-fused positions of the ring, i.e., positions 4, 5, 6 or 7 indicated below:
Figure imgf000010_0005
5 6 Similarly, v — means thai: two nitrogens are located at any two of the 4 non-fused positions of the ring, e.g., the 4 and 6 positions, the 4 and 7 positions, or the 5 and 6 positions.
Also, as used herein, "upper airway" usually means the upper respiratory system, i.e., the nose, throat, and associated structures.
"Effective amount" or "therapeutically effective amount" is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect. A line drawn into a ring means that the indicated bond may be attached to any of the substitutable ring carbon atoms.
The term "substituted" means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. The term "stable compound' or "stable structure" is meant to describe a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
When M is CH and an R4 substituent is present on the ring (i.e., b is 1 , 2 or 3), the R4 substituent can replace the H on said carbon, e.g., the ring can be:
Figure imgf000011_0001
The term "optionally substi uted" means opti .onal substitution with the specified groups, radicals or moieties.
The term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof. Thus, the term "purified", "in purified form" or "in isolated and purified form" for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atorn(s) to satisfy the valences.
When a functional group in a compound is termed "protected", this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991 ), Wiley, New York.
When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in formula (I), its definition on each occurrence is independent of its definition at every other occurrence.
As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
Prodrugs and solvates of the compounds of the invention are also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g. a drug precursor) that is transformed in vivo to yield a compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Prodrugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987. For example, if a compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (Ci-Cβ)alkyl, (C2-C12)alkanoyl- oxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1- (alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N- (alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4- crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(Ci-C-2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di (Ci- C2)alkylcarbamoyl-(Ci-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2- C3>alkyl, and the like. Similarly, if a compound of formula (I) contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (C-i-CeJalkanoyloxymethyl, 1-((C1- C6)alkanoyloxy)-ethyl, 1 -methyl-1 -((Ci-C6)alkanoyloxy)ethyl, (C1- C6)alkoxycarbonyloxymethyl, N-(Ci-C6)alkoxycarbonylaminomethyl, succinoyl, (C1- Cβjalkanoyl, α-amino(C1-C4)alkanyl, arylacyl and α-aminoacyl, or α-aminoacyl-α- aminoacyl, where each α-amlnoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(Ci-C6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate), and the like. If a compound of formula (I) incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R"-carbonyl, R"O-carbonyl, NR"R'"-carbonyl where R" and R"' are each independently (Ci-Cio)alkyl, (C3-C7) cycloalkyl, benzyl, or R"-carbonyl is a natural α-amiπoacyl or natural α-aminoacyl, — C(OH)C(O)OY1 wherein Y1 is H, (d-CeJalkyl or benzyl, — C(OY2)Y3 wherein Y2 is (C1-C4) alkyl and
Y3 is (Ci-Ce)alkyl, carboxy (CτCβ)alkyl, amino(C1-C4)alkyl or mono-N — or di-N,N-(Cτ C6)alkylaminoalkyl, — C(Y4)Y5 wherein Y4 is H or methyl and Y5 is mono-N — or di- N.N-CC-rC-eJalkylamino morpholinoa piperidin-1-yl or pyrrolidin-1-yl, and the like.
"Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H^O.
The compounds of formula (I) can form salts which are also within the scope of this invention. Reference to a compound of formula (I) herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of formula (I) contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. In one embodiment, a salt is a pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salt, although other salts are also useful. Salts of the compounds of the formula (I) may be formed, for example, by reacting a compound of formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one ϊn which the salt precipitates or in an aqueous medium followed by lyophilization. Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl ef a/, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.
Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salits, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others. All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.
Pharmaceutically acceptable esters of the present compounds include the following groups: (1 ) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n- propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen,
Figure imgf000015_0001
or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C1-20 alcohol or reactive derivative thereof, or by a 2,3-di (C<3-24)acyl glycerol.
One or more compounds of the invention may also exist as, or optionally converted to, a solvate. Preparation of solvates is generally known. Thus, for example, M. Caira et al, J. Pharmaceutical ScL, 93(3). 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water. Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSciTech., 511}, article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001). Atypical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
Compounds of formula (I), and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention. All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds. Polymorphic forms of the compounds of formula (I), and of the salts, solvates, esters and prodrugs of the compounds of formula (I), are intended to be included in the present invention.
The phrase "at least one compound of formula (I)" means that one to three different compounds of formula (I) may be used in a pharmaceutical composition or method of treatment. In one embodiment one compound of formula (I) is used. Similarly, "at least one Hi receptor antagonist" or "at least one other compound (or agent) for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder" means that one to three different Hi antagonists or other compounds may be used in a pharmaceutical composition or method of treatment. In one embodiment, one Hi antagonist or one other compound for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder is used in the combinations.
The term "obesity" as used herein, refers to a patient being overweight and having a body mass index (BMI) of 25 or greater. In one embodiment, an obese patient has a BMI of 25 or greater. In another embodiment, an obese patient has a BMI from 25 to 30. In another embodiment, an obese patient has a BMI greater than 30. In still another embodiment, an obese patient has a BMI greater than 40. The term "obesity-related disorder" as used herein refers to any disorder which results from a patient having a BMI of 25 or greater. Non-limiting examples of an obesity-related disorder include edema, shortness of breath, sleep apnea, skin disorders and high blood pressure.
The term "metabolic syndrome" refers to a combination of risk factors for cardiovascular disease (CVD) identified in the National Cholesterol Education Program's Adult Treatment Panel III report. See for example the discussion by Grundy et al in Circulation. 109 (2004), 433-438. The components of metabolic syndrome are: 1) abdominal obesity; 2) atherogenic dyslipidemia; 3) raised blood pressure; 4) insulin resistance; 5) proinflammatory state; and 6) prothrombotic state. Unless otherwise stated, the following abbreviations, as used herein, have the following meanings:
Me=methyl; Et=ethyl; Bn=benzyl; Bu=butyl; Pr=propyl; Ph=phenyl; t- BOC=tert-butoxycarbonyl; Ac=acetyl; BINAP=2,2>-bis(diphenylphosphino)- 1 ,1'binaphthyl; DCE= 1,2-dichloroethane; DCM= dichloro-methane; DEAD= diethyl azodicarboxylate; DIPEA= Λ/,Λ/-diisopropylethylamine (Hunig's base); DMF=dimethylformamide; EDC= 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; HOBT= 1-hydroxybenzotriazole; NaBH(OaC)3= sodium triacetoxyboro-hydride; PyBOP=benzotriazol-1-yloxytri-pyrrolidinophosphonium hexafluorophosphate; RT=room temperature; TFA=trifluoroacetic acid; THF=tetrahydrofuran; TEMPO=2,2,6,6-tetramethyl-1-piperidinyloxy, free radical; TLC=thin layer chromatography; MS=Mass Spectrometry; nM= nanomolar; Ki= Dissociation Constant for substrate/receptor complex.
The Compounds of Formula (I)
The invention provides compounds having the formula:
Figure imgf000018_0001
and pharmaceutically acceptable salts and solvates thereof, wherein R1 , R2, R3, R4, M, U, W, X, Y, Z, a, b, n and p are defined above for the compounds of formula (I).
In one embodiment, R1 is R11-aryl, R11-(6-membered heteroaryl),
Figure imgf000018_0002
In one embodiment, R1 is R11-aryl, aryl is phenyl and R11 is 1 to 4 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl or -CN. In another embodiment, R11 is one or two substituents independently selected from H and halo, or R11 is one substituent selected from the group consisting Of-CF3, - CHF2 and -CN.
In another embodiment, R1 is R11-(6-membered heteroaryl), the 6-membered heteroaryl is pyridyl and R11 is 1-3 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl and -CN. In another embodiment, R1 is R11-(6-membered heteroaryl), the 6-membered heteroaryl is pyridyl is one or two substituents independently selected from the group consisting of H and halo, or R11 is one substituent selected from the group consisting of -CF3, -CHF2 and -CN. In one embodiment, R1 is
Figure imgf000019_0001
R ,11a is C1-C3 alkyl, halo(Ci-C3)alkyl, C1-C3 alkoxy, Ci-C3 alkylthio, R 15 -phenyl or R ,15- heteroaryl; R15 is 1-3 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OCF3, -CHF2 or -CN; R16 is as defined abovd; and k, k1 and k2 are each 0, 1 or 2.
In another embodiment, R1 is
Figure imgf000019_0002
wherein R i11a is (Ci-C3)alkyl, C1-C3 alkoxy, C1-C3 alkylthio, R 15 -phenyl or R -pyridyl;
R ,15 is 1 or 2 substituents independently selected from the group consisting of H, halo, alkyl and haloalkyl; R16 is as defined above; and k1 is 0 or 1. In another embodiment, RJ is
Figure imgf000019_0003
wherein R ,111iaa is -C2F5, -CF3, C2Hs-O-, CH3-O-, C2H5-S-, CH3-S-, R1 -phenyl or R15-pyridyl; R15 is 1 or 2 substituents independently selected from the group consisting of H, F, Cl, -CH3, and -CF3; k1 is 0 or 1 ; and R16 is F, Cl Or-CF3.
In one embodiment, M is CH.
In another embodiment, M is N.
In still another embodiment, R3 and R4 are independently selected from the group consisting of H, alkyl, fluoro and -OH.
In a further embodiment, M is CR4, wherein R4 is H or fluoro.
In one embodiment, n is 2 and p is 1. In another embodiment, a and b are each independently 0 or 1. In another embodiment, a and b are each 0. In still another embodiment, both U and W are CH.
In a further embodiment, X is y a single bond or -C(N-OR5)-, wherein R5 is H or alkyl.
In one embodiment, X is a single bond. In another embodiment, Y is— O- or -C(=O)-, In another embodiment, Y is -O-.
In still another embodiment, Z is Ci-C3 alkylene, -CH(R9)-(R10-C1-C5 alkylene)-, -CH(R9)-C(R9a)=C(R9a)-, -(CH2)2-O- or Ci-C3 alkylene interrupted by a cycloalkylene group, wherein R9 and R9a are each H and R10 is halo.
In another embodment, Z is -CH2-, -(CH2J3-, -CH2-CH=CH-, -(CH2J2-CH(F)-, -
H
CH2-CH(F)-CH2-, -(CH2)2-O- or V H
In one embodiment, Z is -CH2-. In one embodiment, R2 is R13-heteroaryl or R13-heterocycloalkyl.
In another embodiment, R2 is a R13-(5 or 6 membered heteroaryl) or a R13-(4, 5 or 6-membered heterocycloalkyl).
In still another embodiment, R2 is R13-pyridyl, R13-pyrimidyl, R13-pyradazinyl, R13-tetrahydropyranyl, R13-azetidinyl, R13-oxazolyl or R13-thiazolyl. In a further embodiment, when R2 is R13-pyridyl, R13-pyrimϊdyl, R13- pyradazinyl, R13-oxazolyl or R13-thiazolyl, R13 is 1 or 2 substituents independently selected from the group consisting of H, -CH3, -NH2 and -NHCH3.
In one embodiment, when R2 is R13-tetrahydropyranyl or R13-azetidinyl, R13 is 1 or 2 substituents independently selected from the group consisting of H and -CH3. In another embodiment, R2 is 2-amino pyridyl, 2-amino oxazolyl, 2-amino thiazolyl, 1-methyl-azetidinyl or t€ϊtrahydropyranyl.
In one embodiment, R2 is 2-amino pyridyl.
In one embodiment, the compounds of formula (I) have the formula (IA):
Figure imgf000021_0001
(IA) and pharmaceutically acceptable salts or solvates thereof, wherein M is CH or N;
W is CH or N;
X is a single bond, -CH2-, -C(O)-, -C(=NOR)-( -CH(OH)-; Y is -O-, -S-, -SO2-, -C(O)- or -CH2-, such that when M is N, Y is -S-, -SO2-, -C(O)- Or -CH2-; Z is a single bond;
R1 is -aryl, -heteroaryl, -heterocycloalkyl,
Figure imgf000021_0002
wherein an aryl group can be substituted with up to 2 groups chosen from alkyl, halo or -CN; a heterocycloalkyl can be substituted with up to groups chosen from alkyl and heteroaryl; and a heteroaryl group can be substituted with up to 2 groups chosen from -halo, alkyl and alkoxy;
R2 is -heterocycloalkyl, heteroaryl, -CH(G)-aryl, -CH(G)-heteroaryl,
Figure imgf000021_0003
each occurrence of R is independently —halo;
R11a is -H, -S-alkyl, hetqroaryl, aryl, -CF2(CF3) or -CF3; R16 is -H, -halo, Ci-C6 alkyli; or alkenyl; R19 is -H or alkyl; R20 is -H or-alkyl; G is -H or -alkyl; Q is O or S;
V is CH or N; a is 0, 1 or 2; and k is 0 or 1.
In one embodiment, M is CH.
In another embodiment, M is N.
In one embodiment, W is CH.
In another embodiment, W is N.
In one embodiment, X is a bond. In another embodiment, X is -CH2-.
In another embodiment, X is -C(O)-.
In still another embodiment, X is -C(=NOR)-.
In a further embodiment, X is -CH(OH)-.
In one embodiment, Y is — O-. In another embodiment, Y is -CH2-.
In another embodiment, Y is -C(O)-.
In still another embodiment, Y is -S-.
In a further embodiment, Y is -SO2-.
In one embodiment, M is CH and Y is -O-. In another embodiment, M is CH and Y is -CH2-.
In still another embodiment, M is CH and Y is -C(O)-.
In another embodiment, M is CH and Y is -S-.
In still another embodiment, M is CH and Y is -SO2-.
In one embodiment, M is N and Y is -O-. In another embodiment, M is N and Y is -CH2-.
In still another embodiment, M is N and Y is -C(O)-.
In one embodiment, R1 is aryl.
In another embodiment, R1 is heteroaryl. In another embodiment, R1 is heterocycloalkyl. In still another embodiment, R1 is:
Figure imgf000023_0001
In one embodiment, R1 is phenyl.
In another embodiment, R1 is pyridyl.
In another embodiment, R1 is pyrimidinyl.
In still another embodiment, R1 is thiophenyl.
In a further embodiment, R'' is /V-piperazϊnyl.
In one embodiment, R1 is Λ/-piperidinyl.
In another embodiment, R1 is A/-pyrrolidinyl.
In yet another embodiment, R1 is /V-morpholinyl.
In another embodiment, R1 is /V-azetidinyl.
In a further embodiment, R1 is Λ/-[1 ,4]-diazapanyl.
In one embodiment, R1 is:
Figure imgf000023_0002
In another embodiment, R1 is:
Figure imgf000023_0003
In another embodiment, R1 is:
Figure imgf000024_0001
wherein k is 0 or 1 and R is -Cl, -F, -Br, n-propyl Or-CH=CHCH3.
In still another embodiment, R 1 : is- :
Figure imgf000024_0002
wherein k is 0 or 1 and R16, when present, is -Cl, -F, -Br, n-propyl Or -CH=CHCH3. In one embodiment, R2 is -heteroaryl. In another embodiment, R2 is -heterocycloalkyl. In another embodiment, R2 is -CH2-heteroaryl. In still another embodiment, R2 is -CHa-heterocycloalkyl. In another embodiment, R2 is -CH(G)-aryl. In still another embodiment, R2 is ~CH(G)-heteroaryl. In yet another embodiment, R2 is: In one embodiment, R 2 i
Figure imgf000025_0001
In another embodiment, R 2 is:
Figure imgf000025_0002
In another embodiment, R is:
Figure imgf000025_0003
In a further embodiment, R2 is tetrahydropyranyl.
In another embodiment, R i2'" : i.s thiazolyl.
In one embodiment, R2 is --CH2-aryl.
In another embodiment, R2 is — CH(CH3)-aryl.
In another embodiment, R 2" : is. -CH2-heteroaryl.
In still another embodiment, R 2 : is. -CH(CH3)-heteroaryl In one embodiment, R2 is -Chh-phenyl. In one embodiment, R2 is:
Figure imgf000025_0004
In another embodiment, R2 is -CH(CH3)-pyridyl. In still another embodiment, R2 is:
Figure imgf000026_0001
In one embodiment, a is 1 and R is -F.
In another embodiment, a is 2 and each occurrence of R3 is -F.
In one embodiment, M is N, Z is a bond and R2 is:
Figure imgf000026_0002
In another embodiment, R1 is
Figure imgf000026_0003
and R is:
Figure imgf000026_0004
In another embodiment, M is CH, R1 is
Figure imgf000026_0005
and R is:
Figure imgf000027_0001
Illustrative compounds of formula (I) include, but are not limited to, the compounds of formulas 1A-16A, 16B, 17A-81A, 81B and 82A-116A as depicted below in the Examples section.
Methods For Making the Compounds of Formula (I) The compounds of formula (I) can be prepared via procedures known to those skilled in the art. Compounds of this invention are most typically prepared through the initial assembly of the central part of the molecule (BC fragment — see Scheme 1 ), followed by the attachment of the corresponding A and D fragments. In Scheme 1 , R', R" and R'" are as defined in the Scheme; Pr is a protecting group such as BOC; X' is, for example & halogen, aldehyde, amino or nitro group; and the remaining variables are as defined above for formula (I).
Scheme 1
Figure imgf000028_0001
Figure imgf000028_0002
The connection between the B and C rings in cases (1), where Y is -O- and M is CH, is achieved through a Mitsunobu reaction of the B-ring-based phenol, or alternatively, through an aromatic nucleophilic substitution on a halogen-substituted B ring by the C-ring alcohol. In cases (2), where Y is C=O and M is CH, connection between the B and C rings is established through addition of an organometallic nucleophile (a Grignard or an organolithium reagent), derived from one of the fragments, to a carbonyl-based el'ectrophile derived from the other fragment, followed by the adjustment of the oxidation state of the linker, if necessary. In cases (3), where Y is C=O and M is N, connection between the B and C rings is most easily established through amide coupling of the corresponding B-ring benzoic acid and C-ring piperazine or diazepine.
The installation or formation of the A ring is most conveniently accomplished by taking advantage of a preinstalled functionality on the B-ring (X' - see Scheme 1 ), including, but not limited to an aldehyde, an amino group, a nitro group or a halogen. For example, halogen and aldehyde substituted compounds are used to provide compounds wherein R1 is aryl or heteroaryl, and nitro and amino substituted compounds are used to prepare compounds wherein R1 is benzimidazolyl. Some general approaches are shown in Scheme 2. In Scheme 2, Ar is a Nθ2-substituted aryl group or a synthetic precursor therefore, which can be later elaborated into a benzimidazole as described in specific procedures, below. R1 is chosen so as to provide R1 upon the transformation shown in the scheme. Pr is a protecting group, Hal and Met are as defined in the scheme, and the remaining variables are as defined for formula (I).
Scheme 2
Figure imgf000029_0001
A BC
While the preinstalled functional groups play the key role in establishing the connectivity between the A and EJ rings, final elaboration of the A ring may require several additional steps known to those skilled in the art.
Examples of D fragments,, as well as practical methods employed in the addition of D fragments onto the ABC portion of the molecule have been previously described for different structural series (e.g., US 6,720,378 and US 2004/0097483). In Scheme 3, Z' is as described below and the remaining variables are as defined for formula (I).
Scheme_3
Figure imgf000030_0001
In the most simple case the D-electrophile is a one-carbon aldehyde or alkyl halide attached to the R2 group (Z' is a bond in D — Scheme 3), but can also be an epoxide or other longer-chain electrophile in cases where 21 is an optionally substituted Ci to C5 alkyl or alkenyl group. The compounds are synthesized through chain extension of one-carbon starting D-aldehydes (previously described or commercially available) by various methods known to those skilled in the art. Those methods include, but are not limited to, the reactions of starting aldehydes with alkylmetal reagents, carbon-phosphorus reagents (known to those skilled in the art as Wittig reactions and Horner-Ernmons reactions), and also include reactions with other carbon nucleophiles, followed by appropriate functional elaboration, leading to compounds of the type D, where Z' is an appropriately substituted Ci to C5 alkyl or alkenyl group. Alternatively, in the particular case when R2 is an aryl or heteroaryl, the corresponding D fragment with the elongated Z1 is prepared by coupling an aryl halide with an appropriate alkyl or alkenyl metal reagent (e.g., Li or MgX, wherein X is a halogen), optionally in the presence of an appropriate transition metal catalyst (e.g, Cu, Ni).
Alternatively, compounds described in this invention are prepared in a right- to-left stepwise fashion: C + D, followed by B + CD, followed by A + BCD, using the same synthetic approaches as described above, but in a different sequence. Also, when the process of bond formation between any of the two fragments is generally compatible with the rest of the molecule, the compounds are synthesized through a left-to-right stepwise approach: A + B, followed by AB + C, followed by ABC + D.
Uses of the Compounds of Formula (I) The compounds of formula (I) are useful for treating or preventing a Condition. Accordingly, the present invention provides methods for treating or preventing a Condition in a patient, comprising administering to the patient an effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.
In one embodiment, the compounds of formula (I) are useful for treating congestion, metabolic syndrome, obesity, an obesity-related disorder or a cognition deficit disorder.
In another embodiment, the compounds of formula (I) are useful for treating obesity or an obesity-related disorder.
In another embodiment, the compounds of formula (I) are useful for treating diabetes. There are two major forms of diabetes: Type I diabetes (also referred to as insulin-dependent diabetes or NIDDM) and Type Il diabetes (also referred to as noninsulin dependent diabetes or NIDDM). In one embodiment, the compounds of formula (I) are useful for treating Type I diabetes. In another embodiment, the compounds of formula (I) are useful for treating Type Il diabetes.
Combination Therapy
The present methods for treating or preventing a Condition can further comprise administering one or more additional therapeutic agents in addition to the at least one compound of formula (I). Additional therapeutic agents useful in the present methods include, but are not limited to, Hi receptor antagonists, weight-loss agents, HMG-CoA reductase inhibitors, sterol absorption inhibitors, anti-diabetic agents, any agent useful for treating obesity, an obesity-related disorder, any agent useful for treating metabolic syndrome, any agent useful for treating a cognition deficit disorder, or any combination of two or more of these additional therapeutic agents.
In one embodiment, the compounds of formula (I) can be combined with an H1 receptor antagonist (i.e., the compounds of formula (I) can be combined with an Hi receptor antagonist in a pharmaceutical composition, or the compounds of formula (I) can be administered with an Hi receptor antagonist).
Numerous chemical substances are known to have histamine Hi receptor antagonist activity and can therefore be used in the methods of this invention. Representative Hi receptor antagonists include, without limitation: astemizole, azatadine, azelastine, acrivastine, brompheniramine, cetirizine, chlorpheniramine, clemastine, cyclizine, carebastine, cyproheptadine, carbinoxamine, descarboethoxyloratadine, diphenhydramine, doxylamine, dimethindene, ebastine, epinastine, efletirizine, fexofenadine, hydroxyzine, ketotifen, loratadine, levocabastine, meclizine, mizolastine, mequitazine, mianserin, noberastine, norastemizole, picumast, pyrilamine, promethazine, terfenadine, tripelennamine, temelastine, trimeprazine and triprolidine. Other compounds can readily be evaluated to determine activity at Hi receptors by known methods, including specific blockade of the contractile response to histamine of isolated guinea pig ileum. See for example, WO98/06394 published February 19, 1998.
Those skilled in the art will appreciate that the Hi receptor antagonist is used at its known therapeutically effective dose, or the Hi receptor antagonist is used at its normally prescribed dosage. In one embodiment, said H1 receptor antagonist is selected from: azatadine, brompheniramine, cetirizine, chlorpheniramine, carebastine, descarboethoxyloratadine, diphenhydramine, ebastine, fexofenadine, loratadine, or norastemizole. In another embodiment, said Hi antagonist is selected from loratadine, descarboethoxyloratadine, fexofenadine or cetirizine. In one embodiment, in the above combinations of H3 and H1 antagonists, nasal congestion is treated.
Weight-loss agents include appetite suppressants, metabolic rate enhancers and nutrient absorption inhibitors. Appetite suppressant agents useful for treating obesity or metabolic syndrome include cannabinoid receptor 1 (CB1) antagonists or inverse agonists (e.g., rimonabant); Neuropeptide Y (NPY1, IMPY2, NPY4 and NPY5) antagonists; metabotropic glutamate subtype 5 receptor (mGluRδ) antagonists (e.g., 2-methyl-6-(phenylethynyl)-pyridine and 3[(2-methyl-1 ,4-thiazol-4- yl)ethynyl]pyridine); melanin-concentrating hormone receptor (MCH 1 R and MCH2R) antagonists; melanocortin receptor agonists (e.g., Melanotan-ll and Mc4r agonists); serotonin uptake inhibitors (e.g., dexfenfluramine and fluoxetine); serotonin (5HT) transport inhibitors (e.g., paroxetine, fluoxetine, fenfluramine, fluvoxamine, sertaline and imipramine); norepinephrine. (NE) transporter inhibitors (e.g., desipramine, talsupram and nomifensine); ghrelin antagonists; leptin or derivatives thereof; opioid antagonists (e.g., πalmefene, 3-methoxynaltrexone, naloxone and nalterxone); orexin antagonists; bombesin receptor subtype 3 (BRS3) agonists; Cholecystokinin- A (CCK-A) agonists; ciliary neurotrophic factor (CNTF) or derivatives thereof (e.g., butabindide and axokine); monoamine reuptake inhibitors (e.g., sibutramine); glucagons-like peptide 1 (GLP-1) agonists; topiramate; and phytopharm compound 57. Metabolic rate enhancers include acetyl-CoA carboxylase-2 (ACC2) inhibitors; beta adrenergic receptor 3 (β3) agonists; diacylglycerol acyltransferase inhibitors (DGAT1 and DGAT2); fatty acid synthase (FAS) inhibitors (e.g., Cerulenin); phosphodiesterase (PDE) inhibitors (e.g., theophylline, pentoxifylline, zaprinast, sildenafil, amrinone, milrinone, cilqstamide, rolipram and cilomilast); thyroid hormone β agonists; uncoupling protein activators (UCP-1 ,2 or 3) (e.g., phytanic acid, 4-[(E)- 2-(5,6,7,8-tetramethyl-2-naphthale.nyl)-1-propenyl]benzoic acid and retinoic acid); acyl-estrogens (e.g., oleoyl-estrone); glucocorticoid antagonists; 11-beta hydroxyl steroid dehydrogenase type 1 (11β HSD-1) inhibitors; melanocortin-3 receptor (Mc3r) agonists; and stearoyl-CoA desaturase-1 (SCD-1) compounds. Nutrient absorption inhibitors include lipase inhibitors (e.g., orlistat, lipstatin, tetrahydrolipstatin, teasaponin and diethylumbelliferyl phosphate); fatty acid transporter inhibitors; dicarboxylate transporter inhibitors; glucose transporter inhibitors; and phosphate transporter inhibitors. Specific compounds for use in the combination for treating obesity and metabolic syndrome include rimonabant, 2-methyl-6-(phenylethynyl)-pyridine, 3[(2- methyl-1,4-thiazol-4-yl)ethynyl]pyridine, Melanotan-ll, dexfenfluramine, fluoxetine, paroxetine, fenfluramine, fluvoxamine, sertaline, imipramine, desipramine, talsupram, nomifensine, leptin, nalmefene, 3-methoxynaltrexone, naloxone, nalterxone, butabindide, axokine, sibutramine, topiramate, phytopharm compound 57, Cerulenin, theophylline, pentoxifylline, zaprinast, sildenafil, amrinone, milrinone, cilostamide, rolipram, cilomilast, phytanic acid, 4-[(E)-2-(5,6,7,8-tetramethyl-2- naphthalenyl)-1-propenyl]benzoic acid, retinoic acid, oleoyl-estrone, orlistat, lipstatin, tetrahydrolipstatin, teasaponin and diethylumbelliferyl phosphate. In one embodiment, compounds for use in the combination for treating obesity and metabolic syndrome include rimonabant, dexfenfluramine, fenfluramine, phentermine, leptin, nalmefene, axokine, sibutramine, topiramate, phytopharm compound 57, oleoyl-estrone and orlistat.
In another embodiment, the invention provides combinations of at least one compound of formula (I) and one or more HMG-CoA reductase inhibitors and/or one or more substituted azetidinone or substituted β-lactam sterol absorption inhibitors for treating metaolic syndrome or obesity.
Typical HMG-CoA reductase inhibitors include statins such as lovastatin, simvastatin, pravastatin, atorvastatin, fluvastatin, resuvastatin, cerivastatin, rivastatin and pravastatin. In one embodiment, the HMG-CoA reductase inhibitor is simvastatin.
As used herein, "sterol absorption inhibitor" means a compound capable of inhibiting the absorption of one or more sterols, including but not limited to cholesterol, phytosterols (such as isitosterol, campesterol, stigmasterol and avenosterol), 5α-stanols (such as cholestanol, 5α-campestanol, 5α-sitostanol), and/or mixtures thereof, when administered in a therapeutically effective (sterol and/or 5α-stanol absorption inhibiting) amount to a mammal or human.
Non-limiting examples of suitable substituted azetidinones and methods of making the same include those disclosed in U.S. Patents Nos. RE 37,721, 5,306,817, 5,561,227, 5,618,707, 5,624,920, 5,631 ,365, 5,656,624, 5,627,176, 5,633,246, 5,661 ,145, 5,688,785, 5,688,787, 5,688,990, 5,698,548, 5,728,827, 5,739,321, 5,744,467, 5,756,470, 5,767,115, 5,846,966, 5,856,473, 5,886,171 , 5,919,672, 6,093,812, 6,096,883, 6,133,001, 6,207,822, 6,627,757, 6,632,933, U.S. Patent Publication Nos. 2003/0105028, 2004/0180860, 2004/0180861, and 2004/0198700, N-suIfonyl-2-azetiqlinones such as are disclosed in U.S. Patent No. 4,983,597, ethyl 4-(2-oxoazetidin-4-yl)phenoxy-alkanoates such as are disclosed in Ram et al., Indian J. Chem. Sect. B. 29B, 12 (1990), p. 1134-7, and diphenyl azetidinones and derivatives disclosed in U.S. Patent Publication Nos. 2002/0039774, 2002/0128252, 2002/0128253 and 2002/0137689, and PCT Published Application Nos. WO 2002/066464, WO 04/000805, WO 04/005247, WO 04/000804, WO 04/000803, WO 04/014947, WO 04/087655, WO 05/009955, WO 05/023305, WO 05/021495, WO 05/021497, WO 05/044256, WO 05/042692, WO 05/033100, WO 05/030225, WO 05/047248, WO 05/046662, WO 05/061451 , WO 05/061452, WO 05/062824, WO 05/02897, WO 05/000353, each of which is incorporated by reference herein.
An example of a suitable substituted azetidinone compound is represented by Formula (A) (ezetimibe) below:
Figure imgf000035_0001
or pharmaceutically acceptable salts or solvates of the compound of Formula (A). The compound of Formula (A) can be in anhydrous or hydrated form. A product containing ezetimibe compound is commercially available as ZETIA® ezetimibe formulation from MSP Pharmaceuticals. Typical compounds for use in combination with an H3 antagonist of this invention for the treatment of a cognition deficit disorder are atomoxetine and dexmethylphenidate for the treatment of ADHD, olanzapine, risperidone or aripiprazole for treatment of schizophrenia, and donepezil, heptylphysostigmine, tacrine, rivastigmine or galantamine for the treatment of Alzheimer's Disease. In one embodiment, the compounds of formula (I) can be co-administered with an anti-diabetic agent for treating diabetes.
Examples of anti-diabetic agents useful in the present methods for treating diabetes include sulfonylureas, insulin sensitizers (such as PPAR agonists, DPPIV inhibitors, PTP-1B inhibitors and glucokinase activators), α-glucosidase inhibitors, insulin secretagogues, hepatic glucose output lowering compounds, anti-obesity agents, antihypertensive agents, meglitinides, insulin and insulin-containing compositions.
In one embodiment, the anti-diabetic agent is an insulin sensitizer or a sulfonylurea. Non-limiting examples of sulfonylureas include glipizide, tolbutamide, glyburide, glimepiride, chlorpropamide, acetohexamide, gliamilide, gliclazide, glibenclamide and tolazamide. Insulin sensitizers include PPAR-γ agonists described in detail above. In one embodiment, useful PPAR-γ agonists are troglitazone, rosiglitazone, pioglitazone and englitazone; biguanidines such as metformin and phenformin; DPPIV inhibitors such as sitagliptin, saxagliptin, denagliptin and vildagliptin; PTP-1E3 inhibitors; and glucokinase activators, α- Glucosidase inhibitors that can be useful in treating type Il diabetes include miglitol, acarbose, and voglibose. Hepatic glucose output lowering drugs include
Glucophage and Glucophage XR. Insulin secretagogues include sulfonylurea and non-sulfonylurea drugs such as Gl1P-I , exendin, GIP, secretin, glipizide, chlorpropamide, nateglinide, meglϊtinide, glibenclamide, repaglinide and glimepiride. Insulin includes all formualtions of insulin, including long acting and short acting forms of insulin.
Non-limiting examples of anti-obesity agents useful in the present methods for treating diabetes include CB1 antagonists or inverse agonists such as rimonabant, neuropeptide Y antagonists, MCR4 agonists, MCH receptor antagonists, histamnine H3 receptor antagonists or inverse agonists, leptin, appetite suppressants such as sibutramine, and lipase inhibitors such as xenical.
Non-limiting examples of antihypertensive agents useful in the present methods for treating diabetes include β-blockers and calcium channel blockers (for example diltiazem, verapamil, nifedipine, amlopidine, and mybefradil), ACE inhibitors (for example captopril, lisinopril, enalapril, spirapril, ceranopril, zefenopril, fosinopril, cilazopril, and quinapril), AT-1 receptor antagonists (for example losartan, irbesartan, and valsartan), renin inhibitors and endothelin receptor antagonists (for example sitaxsentan).
Non-limiting examples of meglitinides useful in the present methods for treating diabetes include repaglinide and nateglinide. Non-limiting examples of insulin sensitizers include biguanides, such as metformin and thiazolidinediones.
In one embodiment, the insulin sensitizer is a thiazolidinedione. Non-limiting examples of antidiabetic agents that slow or block the breakdown of starches and certain sugars and are suitable for use in the compositions and methods of the present invention include alpha-glucosidase inhibitors and certain peptides for increasing insulin production. Alpha-glucosidase inhibitors help the body to lower blood sugar by delaying the digestion of ingested carbohydrates, thereby resulting in a smaller rise in blood glucose concentration following meals. Non-limiting examples of suitable alpha-glucosidase inhibitors include acarbose; miglitol; camiglibose; certain polyamines as disclosed in WO 01/47528 (incorporated herein by reference); voglibose. Non-limiting examples of suitable peptides for increasing insulin production including amlintide (CAS Reg. No. 122384-88-7 from Amylin; pramlintide, exendin, certain compounds having Glucagon-like peptide-1 (GLP-1) agonistic activity as disclosed in WO 00/07617 (incorporated herein by reference).
Non-limiting examples of orally administrable insulin and insulin containing compositions include AL-401 from Autoimmune, and the compositions disclosed in U.S. Patent Nos. 4,579,730; 4,849,405; 4,963,526; 5,642,868; 5,763,396; 5,824,638; 5,843,866; 6,153,632; 6,191 ,105; and International Publication No. WO 85/05029, each of which is incorporated herein by reference.
In one embodiment, the compounds of formula (I) can be co-administered with an anti-diabetic agent for treating obesity or an obesity-related disorder.
Anti-diabetic agents useful in the present methods for treating obesity or an obesity-related disorder include, but are not limited to the anti-diabetic agents listed above herein.
In the combination therapies of the present invention, the at least one compound of formula (I) and the one or more additional therapeutic agents can be administered simultaneously (at the same time, in a single dosage form or in separate dosage forms) or sequentially (first one and then another, etc. . . over a period of time) in any order.
Pharmaceutical Compositions and Administration
For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, tatc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), The Science and Practice of Pharmacy, 20th Edition, (2000), Lippincott Williams & Wilkins, Baltimore, MD.
Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions. The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
In one embodiment, the compound of formula (I) is administered orally. In one embodiment, the pharmaceutical preparation is in a unit dosage form.
In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 150 mg. In one embodiment, the quantity per unit dose is from about 1 mg to about 75 mg. In one embodiment, the quantity per unit dose is from about 1 mg to about 50 mg, according to the particular application.
The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divfded and administered in portions during the day as required. The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 300 mg/day. In one embodiment the daily dosage is from about 1 mg/day to about 75 mg/day, in two to four divided doses.
When the invention comprises a combination of H3 antagonist and H1 antagonist compounds, the two active components may be co-administered simultaneously or sequentially, or a single pharmaceutical composition comprising a H3 antagonist and an Ht antagonist in a pharmaceutically acceptable carrier can be administered. The components of the combination can be administered individually or together in any conventional dosage form such as capsule, tablet, powder, cachet, suspension, solution, suppository, nasal spray, etc. The dosage of the Hi antagonist can be determined from published material, and may range from about 1 to about 1000 mg per dose. In one embodiment, when used in combination, the dosage levels of the individual components are lower than the recommended individual dosages because of the advantageous effect of the combination.
When separate H3 and Hi antagonist pharmaceutical compositions are to be administered, they can be provided in a kit comprising in a single package, one container comprising an H3 antagonist in a pharmaceutically acceptable carrier, and a separate container comprising an Hi antagonist in a pharmaceutically acceptable carrier, with the H3 and Hi antagonists being present in amounts such that the combination is therapeutically effective. A kit is advantageous for administering a combination when, for example, the components must be administered at different time intervals or when they are in different dosage forms.
Similarly, when the invention comprises a combination of H3 antagonist and another compound for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder , the two active components may be co- administered simultaneously or sequentially, or a single pharmaceutical composition comprising a H3 antagonist and another compound in a pharmaceutically acceptable carrier can be administered. The components of the combination can be administered individually or together in any conventional dosage form such as capsule, tablet, powder, cachet, suspension, solution, suppository, nasal spray, etc. The dosage of the other compound for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder can be determined from published material, and may range from about 1 to about 1000 mg per dose.
Kits
When separate pharmaceutical compositions comprising an H3 antagonist and another compound for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder are to be administered, they can be provided in a kit comprising in a single package, one container comprising an H3 antagonist in a pharmaceutically acceptable carrier, and a separate container comprising a compound for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder in a pharmaceutically acceptable carrier, with the H3 antagonists and other compounds being present in amounts such that the combination is therapeutically effective. A kit is advantageous for administering a combination when, for example, the components must be administered at different time intervals or when they are in different dosage forms.
Compounds of formula (I) can be prepared by the general methods outlined above. Specifically exemplified compounds were prepared as described in the examples below, from starting materials known in the art or prepared as described below. These examples are being provided to further illustrate the present invention. They are for illustrative purposes only; the scope of the invention is not to be considered limited in any way thereby.
EXAMPLES General Methods
The starting materials and reagents used in preparing compounds described are either available from commercial suppliers such as Aldrich Chemical Co. (Wisconsin, USA) and Acros Organics Co. (New Jersey, USA) or were prepared using methods well-known to those skilled in the art of organic synthesis. All commercially purchased solvents and reagents were used as received. LCMS analysis was performed using an Applied Biosystems API-100 mass spectrometer equipped with a Shimadzu SCL-10A LC column: Altech platinum C18, 3 μm, 33 mm X 7 mm ID; gradient flow: 0 minutes, 10% CH3CN; 5 minutes, 95% CH3CN; 7 minutes, 95% CH3CN; 7.5 minutes, 10% CH3CN; 9 minutes, stop. Flash column chromatography was performed using Selecto Scientific flash silica gel, 32-63 mesh. Analytical and preparative TLC was performed using Analtech Silica gel GF plates. Chiral HPLC was performed using a Varian PrepStar system equipped with a Chiralpak OD column (Chiral Technologies).
Example 1 Preparation of Compound 1A
Figure imgf000041_0001
To a stirred suspension of compound 2 (20.1 g, 0.100 mol) in terf-butanol
(120 mL) was added portionwise potassium te/f-butoxide (9.5 g, 0.084 mo!). The mixture was heated under reflux for 30 min, yielding a homogeneous solution, which was cooled to 350C, and to which was added compound 1 (12.7 g, 0.09 mol) in a single portion. An exothermic reaction raised the internal temperature to 680C. When the exotherm had subsided, the mixture was heated to reflux for 30 min. Solvent was removed under vacuum, and the residue was treated with ice water, which resulted in formation of an insoluble fraction. Crude product 3 was isolated by filtration of the insoluble solid. Crude 3 (21 g, 0.0672 mol) was treated with a mixture of 2N HCI and EtOAc, and the resultant mixture was stirred at room temperature for 10 min. The insoluble material was filtered and washed thoroughly with water and EtOAc to provide 18.1 g of the HCI salt of compound 3, mp 287-289 0C. The HCI salt was stirred in a mixture of 1N NaOH (150 mL) and DCM (250 mL) until all solids dissolved. The organic phase was separated, washed with water and dried (anhydrous MgSO4). The drying agent was filtered, and the filtrate was stripped of solvent under vacuum to provide 15.7 g of the free base form of compound 3 as a beige solid. Step 2:
3 - H2N-^ ryp ^^Bn 4
A solution of compound 3 (9.0 g, 28.8 mmol) in warm DMF (40 mt_) was diluted with EtOH (120 rriL). The solution was cooled to room temperature , and to it was added half a teaspoon of Raney nickel paste (50% water). The resultant mixture was hydrogenated at 35 psi until hydrogen uptake leveled off. The spent catalyst was filtered through a pad of celite, and the filtrate was concentrated under vacuum. The residue was partitioned between water and Et2θ: EtOAc (1 :1). The organic extract was washed with water, dried over anhydrous MgSO4 and filtered. The filtrate was concentrated under vacuum to provide 7.8 g of compound 4 as syrup, which was used without purification in next step. Step 3:
Figure imgf000042_0001
A stirred mixture of compound 4 (3.5 g, 12.4 mmol), anhydrous K2CO3 (1.87 g, 13.5 mmol) and 2-chloro-3-nitropyridine (1.97 g, 12.4 mmol) in anhydrous toluene (50 ml_) was heated under reflux for 18 h. TLC revealed a mixture of starting material and product. Therefore, additional quantities of 2-chloro-3-nitropyridine (0.5 g) and anhydrous K2CO3 (0.5 g) were introduced, and heating under reflux was continued for another 18 h. After cooling to room temperature, the mixture was treated with ice-water and extracted with toluene. Combined toluene extracts were washed successively with 0.5N aqueous NaOH and water, and were then treated with 0.5N HCI (200 ml_). The red precipitate which formed was filtered to provide 3.3 g of the crude HCI salt of compound 5. The acidic aqueous phase was separated, washed with EtOAc and basified with 10% aqueous NaOH. The resultant red precipitate was filtered and washed with water to provide 1.3 g of the free base form of compound 5. A mixture of HCIi salt (3.2 g) and free base (1.3 g) were partitioned between 0.5N NaOH and DCM. The organic phase was washed with water and dried (anhydrous MgSθ4). The drying agent was filtered, and the filtrate was concentrated under vacuum to provide 4.5 g of the free base form of compound 5, which was used in the next step without purification. Step 4:
Figure imgf000043_0001
A solution of compound 5 (2.2 g, 5.5 mmol) in warm DMF (30 ml_) was diluted with EtOH (60 ml_). The solution was cooled to room temperature, and to it was added half a teaspoon of Raney nickel paste (50% water). The resultant mixture was hydrogenated at 44 psi until hydrogen uptake leveled off. The spent catalyst was filtered through a pad of celite, and the filtrate was concentrated under vacuum. The residual oil was partitioned between water and EtOAc. The organic extract was washed with water, dried over anhydrous MgSO4 and filtered. The filtrate was concentrated under vacuum to produce a solid that was triturated with hexane. Filtration yielded 1.58 g of compound 6. MH+ 375 Step 5:
To a stirred solution of compound 6 (0.59 g, 1.58 mmol) in 90% EtOH (35 mL) was added carbon disulfide (0.5 mL). The resultant solution was heated under reflux for 18h, and was then concentrated under vacuum to a solid residue, which was triturated with water and filtered. The crude product was crystallized from EtOH to provide 0.139 g of title compound. MH+ 417
Example 2 Preparation of Compound 2A
Figure imgf000043_0002
2A To a stirred solution of compound 1 A (0.1 g, 0.24 mmol) and powdered NaOH (24 mg, 0.6 mmol) in MeOH (10 ml) was added dimethylsulfate (38 mg, 0.3 mmol). After stirring at room temperature for 18 h, the reaction mixture was diluted with water and the insoluble pink solid filtered. The solid was crystallized from EtOAc- hexane (including treatment with decolorizing carbon) to provide 38 mg of title compound as a cream-colored solid. M H+ 431
Example 3 Preparation of Compound 3A
Figure imgf000044_0001
3A
Step 1 :
Figure imgf000044_0002
To a stirred, ice-cooled solution of compound 6 (0.73 g, 1.95 mmol) and Et3N (2.0 mL) in dry DCM (30 mL) was added picolinoyl chloride hydrochloride (0.38 g, 2.15 mmol) in a few portions. Stirring at ~50C was maintained for 5 min, then continued at room temperature for 18 h. The reaction mixture was treated with ice water, and the organic phase was separated and washed with water, dried over anhydrous MgSO4, filtered and concentrated, to a viscous residue, which contained significant unchanged starting material, according to TLC. Therefore, this residue (0.85 g) was dissolved in dry DCM (30 mL), and to this solution were added picolinoyl chloride hydrochloride (0.38 g, 2.15 mmol) and Et3N (1 mL). The reaction solution was stirred at room temperature for 18 h. The reaction mixture was treated with water, and the organic phase was separated and washed with water, dried over anhydrous MgSθ4, filtered and concentrated to a viscous residue, which was purified using flash column chromatography on silica gel, eluting with DCM-MeOH (95:5) to provide compound 7 as a glass (810 mg). MH+ 480 Step 2:
To a stirred solution of compound 7 (0.55 g, 1.15 mmol) in EtOH (20 mL) was added dropwise concentrated H2SO4 (2.5 mL). The solution was heated under reflux for 18 h, and was then poured into ice-water, basified with 25% aqueous NaOH and extracted with DCM. Combined organic extracts were washed with water, dried (anhydrous MgSO4) and filtered. The filtrate was concentrated under vacuum to provide a viscous residue, which was purified using flash column chromatography on silica gel, eluting with EtOAc-MeOH (97:3) to provide title compound as a beige solid (140 mg). MH+ 462
Example 4 Preparation of Compound 4A
Figure imgf000045_0001
4A
Step i:
To a stirred mixture of potassium te/f-butoxide (19 g, 0.169 mol) and compound 8 (32.7 g, 0.162 mol) in terf-butanol (200 mL) at 500C was added compound 1 (25.2 g, 0.178 mol) in one portion. After being heated under reflux for 0.5 h, the mixture was cooled to room temperature, diluted with ether and treated with water. The organic phase was separated, washed with water, dried over anhydrous MgSO4, and filtered. The filtrate was concentrated to a solid which was triturated with hexane and filtered to give 42 g of compound 9. Step 2
Figure imgf000046_0001
A suspension of compound 9 (20 g, 0.062 mol) in DMF (40 ml_) and EtOH (130 ml_) was mixed with a half-teaspoonful of 50% Raney Nickel (aqueous slurry) and hydrogenated at 38 psi for 0.5 h. The spent catalyst was filtered off, and the filtrate was concentrated to a solid which was triturated with ether-hexane (1 :2) and filtered to produce 17 g of compound 10. Step 3:
Figure imgf000046_0002
A stirred mixture of compound 10 (HCI salt) (4.28 g, 13 mmol), anhydrous potassium carbonate (3.87 g, 28 mmol), 2-chloro-3-nitropyridine (2.06 g, 13 mmol) and NaI (0.1 g) in toluene (80 ml_) was heated under reflux for 48 h. After being cooled to room temperature, the mixture was treated with water and extracted with ether. Ether extracts were washed with water, dried over anhydrous MgSO4, and filtered. The filtrate was concentrated to a solid which was triturated with ether- hexane (1 :2) and filtered to give 5 g of compound 11. Step 4:
Figure imgf000046_0003
A solution of compound 11 (5 g, 12 mmol) in THF (60 mL) and fert-butanol (40 mL) was hydrogenated in the presence of 3 g of 50% Raney Nickel at 25 psi for 18 h. The spent catalyst was filtered off, and the filtrate was concentrated to a solid which was purified using chromatography on silica gel with EtOAc-CH2CI2 (1.5:8.5) to produce 3 g of compound 12. Step 5
12
Figure imgf000046_0004
To a stirred solution of compound 12 (11.87 g, 4.87 mmol) and Et3N (1.5 ml_) in DCM (30 mL) was added picolinoyl chloride hydrochloride (0.87 g, 4.87 mmol) in a few portions. After being stirred at room temperature for 18 h, the mixture was treated with water and the organic phase was separated. The organic solution was washed with water, dried over anhydrous MgSO-j, filtered and concentrated to a glass residue (2.4 g, ESI-MS: MH+ 490). This residue (1 g, 2.05 mmol) in EtOH- conc H2SO4 (5:1, 24 mL) was heated under reflux for 18 h, diluted with ice water, basified with 50% aqueous NaOH and extracted with DCM. Organic extracts were concentrated to a glass, which was purified using column chromatography on silica gel, eluting with 7N methanolic ammonia-DCM (3:47) to produce 0.47 g of compound 23 (as a glass). Step 6:
Figure imgf000047_0001
A mixture of compound 13 (0.43 g, 1.16 mmol), N-BOC-2-aminopyridine-4- carbaldehydealdehyde (for preparation, see WO2002032893) (0.284 g, 1.28 mmol) and NaBH(OAc)3 (0.81 g, 3.84 mmol) in anhydrous DCM (40 mL) was stirred at room temperature for 48 h. The mixture was treated with water, and the organic phase was separated and concentrated to dryness in vacuo. The solid residue was triturated with a mixture of EtOAc and a 1% aqueous solution of maleic acid (40 mL). Insoluble solids were filtered and washed with EtOAc and water to provide 0.31 g of the maleate salt of compound 14. Step 7:
A solution of the maleate salt of 14 (300 mg, 0.432 mmol) in a mixture of DCM (2 mL) and TFA (2 mL) was stirred for 2 h at room temperature, and was then concentrated under vacuum. The viscous residue was basified with 0.1 N NaOH, and the resultant insoluble solid was crystallized from 5% MeOH-DCM and ether to provide 0.138 g of title compound. MH+ 478
Example 5
Preparation of Compound 5A
Figure imgf000048_0001
5A
Step 1 :
Figure imgf000048_0002
A stirred mixture of compound 10 (HGI salt) (12.0 g, 41 mmol), anhydrous potassium carbonate (6.80 g, 49 mmol) and 2,5-difluoronitrobenzene (7.17 g, 45 mmol) in molecular sieve-dried toluene (120 ml_)was heated under reflux for 48 h. After cooling to room temperature;, the mixture was treated with ice-water and extracted with EtOAc. Combined extracts were washed with water, dried over anhydrous MgSO4, filtered and concentrated under vacuum to a syrup, which was flash chromatographed on silica gel. Elution with DCM, followed by DCM-MeOH (98:2) yielded 4.5 g of compound 15 as a red syrup. Step 2:
Figure imgf000048_0003
A solution of compound 15 (4.4 g, 12 mmol) in warm DMF (20 mL) was diluted with EtOH (80 mL). The solution was cooled in an ice-water bath, and to it was added half a teaspoon of Raney nickel paste (50% water). The resultant mixture was hydrogenated at 33 psi for 18 h. The spent catalyst was filtered off and the filtrate was concentrated under vacuum. The residue was diluted with water and extracted with ether. Combined extracts were washed with water, dried over anhydrous MgSO4 and filtered. The filtrate was concentrated under vacuum to a solid residue, which was triturated with hexane. Filtration yielded 3.4 g of compound 16. Step 3:
Figure imgf000049_0001
A solution of compound 16 (1.85 g, 4.6 mmol) and thiocarbonyldϋmidazole (90%; 1.0 g, 5 mmol) in anhydrous THF (30 ml.) was heated under reflux for 18 h. Solvent was removed under vacuum. The residue was triturated with 5% HCI in an ice-water bath. Insoluble solid was filtered, dissolved in EtOH (300 ml_), washed with water and dried (anhydrous MgSO4). The drying agent was filtered, and the filtrate was stripped of solvent under vacuum. The solid residue was triturated with hexane and filtered to provide 1.98 g of compound 17. Step 4:
Figure imgf000049_0002
To a stirred mixture of compound 17 (1g, 2.25 mmol) and powdered NaOH
(0.185 g, 4.6 mmol) in MeOH (20 ml_) was added dimethylsulfate (0.29 g, 2.3 mmol).
After stirring at room temperature for 1 h, the reaction mixture was partitioned between water and diethyl ether. Combined extracts were washed successively with 5% aqueous NaOH and water, dried over anhydrous MgSO4 and filtered. The filtrate was stripped of solvent in vacuo to provide 1 g of compound 28 as a glass.
Step 5:
Figure imgf000049_0003
A solution of compound 18 (1 g, 2.19 mmol) and TFA (10 mL) in DCM (15 mL) was stirred at room temperature for 18 h. The reaction mixture was concentrated under vacuum. The residue was partitioned between 0.5N aqueous NaOH and diethyl ether. Combined extracts were washed with water and dried over anhydrous MgSC^. Drying agent was filtered, and the filtrate was stripped of solvent under vacuum to provide 0.88 g of compound 19 as a syrup. Step 6:
To a stirred solution of compound 19 (0.15 g, 0.42 mmol) in anhydrous DCM (20 mL) was added 2-aminopyrimidine-5-carbaldehyde (see WO2002032893) (0.062 g, 0.5 mmol), followed by NaBH(OaC)3 (0.32 g, 1.5 mmol). The reaction mixture was stirred at room temperature for -5 days and was then partitioned between 0.5 N aqueous NaOH and DCM. The organic extract was concentrated in vacuo to a solid residue, which was purified using flash column chromatography on silica gel, eluting with DCM-MeOH (96:4) to provide the title compound as a glass (102 mg). A solution of this free base form of the title compound (0.215 mmol) in EtOAc was mixed with a solution of maleic acid (25 mg, 0.215 mmol) in EtOAc. The mixture was cooled in an ice-water bath. The resultant precipitate was filtered to provide the maleate salt form of title compound. MH+ 465 Example 6
Preparation of Compound 6A
Figure imgf000050_0001
6A The title compound was prepared using the procedure of Example 5, step 6, except that pyridazine-4-carbaldehyde (see WO2002032893) was used in place of 2-aminopyrimidine-5-carbaldehyde. MH+ 450
Example 7 Preparation of Compound 7A
Figure imgf000051_0001
7A
Step 1 :
Figure imgf000051_0002
Compound 20 was prepared from compound 10 and 2,5-dichloro-3- nitropyridine using the method set forth in Example 6, step 1. Step 2:
Compound 20 was converted into the title compound using the methods set forth in Example 5, steps 2-5, followed by procedures from Example 4, steps 6 and 7.
MH+ 481
Example 8 Preparation of Compound 8A
Figure imgf000051_0003
8A
Step 1 :
Figure imgf000052_0001
A solution of triphenylphosphine oxide (2.8 g, 10 mmol) in dry DCE (15 mL) was cooled to 0 0C in an ice-water bath, and to it was added, dropwise with stirring, a solution of triflic anhydride (0.85 ml, 5 mmol) in dry DCE (15 mL). A precipitate formed, and the resultant mixture was stirred at 0 0C for 15 min before adding a solution of picolinic acid (0.3 g, 2.5 mmol) and compound 16 (0.8 g, 2 mmol) in dry DCE (10 mL), along with a few drops of Et3N. The mixture was stirred at 00C for 30 min, then at room temperature for 18 h. before pouring into water and basifying with 5% aqueous NaHC(>3. The aqueous mixture was extracted with DCM. The organic extract was washed with water and dried over anhydrous MgSO4. Drying agent was removed by filtration, and the filtrate was concentrated under vacuum to a dark green syrup, which was subjected to flash column chromatography on silica gel, eluting first with EtOAc-hexane (1 :1ι) (to remove triphenylphosphine oxide), then with DCM-7N methanolic ammonia (97:7) to provide a partially purified product. This material was re-subjected to flash chromatography, eluting with DCM-7N methanolic ammonia (95:5) to provide 230 mg of compound 21 as a glass. Step 2:
Compound 21 was converted into title compound using the procedure from Example 5, step 6. MH+ 496 Example 9
Preparation of Compound 9A
Figure imgf000052_0002
9A
Figure imgf000053_0001
To a stirred suspension of polymer-supported triphenylphosphine (8.0 g, 24 mmol) in anhydrous DCM (80 ml_) at 0 0C was added DEAD (3.2 g, 18 mmol) dropwise over ~3 min. This was followed by dropwise addition over 30 min of a solution of 4-cyano-4'-hydroxybiphenyl (3.2g, 15 mmol) and 8 (3.15 g, 15 mmol) in anhydrous DCM (100 ml_). The cooling bath was removed, and the reaction mixture was stirred at room temperature for 18 h. Insoluble material was removed by filtration through a pad of celite. The filtrate was concentrated under vacuum. The residue was treated with 0.5N aqueous NaOH and DCM, and the resultant emulsion was filtered to provide two separable phases. The organic layer was separated and washed with water, dried (anhydrous MgSO4) and filtered. The filtrate was concentrated under vacuum to provide a viscous residue which was flash chromatographed on silica gel. Elution with DCM yielded 2.81 g of compound 22. Step 2: Compound 22 was converted into the title compound using the procedures from Example 5, steps 5 and 6. MH+ 386
Example 10 Preparation of Compound 10A
Figure imgf000053_0002
10A
Step i :
Figure imgf000053_0003
To a stirred, ice-cooled mixture of 4,6-dichloro-5-nitropyrimidine (5.30 g, 27.4 mmol) and K2CO3 (7.56 g, 54.8 mmol) in THF (60 ml_) was added slowly a solution of compound 10 in THF (60 m!_) over 20 min. The resultant mixture was stirred at 0 0C for 1 h. The reaction mixture was then treated with DCM (60 ml_) and water (20 ml_). Insoluble material was filtered, and the layers of the filtrate were separated. The aqueous layer was extracted with a second portion of DCM (40 mL). Combined extracts were washed with brine (30 mL), dried over anhydrous MgSO4, filtered and concentrated under vacuum. The residue was purified using flash chromatography, eluting with DCM-EtOAc (8:1 ) to provide 9.82 g of compound 23 as a bright orange solid. Step 2:
Figure imgf000054_0001
To a solution of nitro compound 23 (11.5 g, 25.5 mmol) in EtOH (250 mL) was added 20% palladium hydroxide-on-carbon catalyst (1.5 g), and the resultant mixture was hydrogenated for 16 h on a Parr shaker apparatus at an initial pressure of 40 psi. Catalyst was removed by filtration, and the filtrate was concentrated under vacuum to provide a dark gray solid, which was triturated with EtOH. Filtration yielded ~7.9 g of compound 24 as a gray solid deemed sufficiently pure for use in the next step. Step 3:
Figure imgf000054_0002
To a stirred solution of compound 24 (5.0 g, 13.0 mmol) and Et3N (3.6 ml, 26.0 mmol) in DCM (50 mL), maintained at 0 0C in an ice-water bath, was added slowly via dropping funnel pentafluoropropionic anhydride (2.66 ml, 13.6 mmol). The resultant mixture was stirred at 00C for 1 h, then at room temperature for 16 h. The reaction mixture was concentrated' under vacuum, and the residue was flash chromatographed on silica gel, eluting with DCM-2N methanolic ammonia (12:1), to provide 6.53 g of compound 25 as a dark brown solid, containing some EtaN, but sufficiently pure for use in the next step. Step 4:
Figure imgf000055_0001
A stirred mixture of compound 25 (6.00 g, 11.3 mmol) and Eaton's reagent
(7.7% wt. P2O5 in methanesulfonic acid) (50 ml_) was heated at 800C for 16 h. The reaction mixture was poured onto ice (-30 g) and was basified to pH 10 by slow addition of 50% aqueous NaOH. The alkaline mixture was extracted with DCM (2 x 200 mL). Combined extracts were washed with brine (100 mL) and dried over anhydrous MgSO4. Drying agent was filtered, and the filtrate was stripped of solvent under vacuum. The residue was flash chromatographed on silica gel, eluting with DCM-2N methanolic ammonia (12:1), to provide 2.84 g of compound 26 as a yellow solid. Step 5:
Figure imgf000055_0002
A solution of compound 26 (200 nπg, 0.484 mmol) and N-BOC-2- aminopyridine-4-carbaldehydealdehyde (see WO2002032893) (129 mg, 0.581 mmol) in DCM (10 mL) was stirred at room temperature for 1 h before adding NaBH(Oac)3 (205 mg, 0.968 mmol). The resultant mixture was stirred at room temperature for 16 h, and was then washed successively with 1 N aqueous NaOH (10 mL) and brine (10 mL). Combined extracts were dried over anhydrous MgSO4. Drying agent was filtered, and the filtrate was stripped of solvent under vacuum . The residue was flash chromatographed on silica gel, eluting with DCM-2N methanolic ammonia (20:1), to provide 315 mg of compound 27 as a yellow solid. Step 6:
To a stirred solution of compound 27 (300 mg, 0.484 mmol) in anhydrous DCM (8 mL) was added TFA (2.0 rnL), and stirring was continued at room temperature for 2 h. The reaction mixture was diluted with DCM (10 ml_) and treated with a 1:1 (v/v) mixture of concentrated NH4OH and water (6 ml_). Layers were separated, and the aqueous phase was extracted with DCM (8 mL). Combined organic extracts were dried over anhydrous MgSO4, filtered and concentrated under vacuum. The residue was purified using flash chromatography, eluting with DCM-2N methanolic ammonia (16:1), to provide 175 mg of the free base form of the title compound as a cream-colored solid. This free base was dissolved in EtOH (0.5 mL), to which solution was added maleic acid (75 mg, 2 eq). The resultant solution was concentrated in vacuo, and the residue was crystallized from EtOH to provide the bis-maleate salt form of title compound as an off-white solid. MH+ 520
Example 11 Preparation of Compound 11 A
Figure imgf000056_0001
HA
Step 1 :
Figure imgf000056_0002
To a stirred mixture of potassium terf-butoxide (11.8 g, 105 mol) and compound 8 (22.5 g, 110 mol) in te/f-butanol (150 mL) at 50 0C was added 3,4,5- trifluoronitrobenzene (18.Og, 102 rnmol) in one portion. The resultant mixture was stirred at 500C for 16 h. The reaction mixture was cooled to room temperature, diluted with ether (400 mL) and treated with water (250 mL). Layers were separated, and the aqueous phase was extracted with a second volume (200 mL) of ether. The combined extracts were washed with brine (200 mL), dried over anhydrous MgSO4, filtered and concentrated to a residue which was purified using flash chromatography, eluting with EtOAc-hexanes (1:4), to provide 33.2 g of compound 28 as a light yellow solid. Step 2
Figure imgf000057_0001
To a solution of nitro compound 28 (30.0 g, 83.8 mmol) in EtOH (100 nriL)- THF (300 ml_) was added Raney nickel (2800; slurry in water; 10 g), and the resultant mixture was hydrogenated for 16 h on a Parr shaker apparatus at an initial pressure of 35 psi. Catalyst was removed by filtration and washed with EtOH. The filtrate and washings were combined and concentrated under vacuum, and the residue was purified using flash chromatography, eluting with EtOAc-hexanes (1 :1) to provide 26.8 g of compound 29 as a white solid. Step 3:
Figure imgf000057_0002
A mixture of 2-chloro-3-nitropyridine (3.95 g, 25 mmol), compound 29 (8.2Og, 25 mmol], K2CO3 (6.90 g, 50 mmol), palladium acetate (224 mg, 1 mmol) and BINAP (622 mg, 1mmol) in toluene (80 ml.) was heated at reflux for 16 h. The mixture was cooled to room temperature and partitioned with EtOAc (300 ml_) and water (150 ml_). Layers were separated, and the aqueous phase was extracted with a second portion of EtOAc (100 mL). Combined extracts were washed with brine (150 ml_), dried over anhydrous MgSO4, filtered and concentrated under vacuum. The residue was purified using flash chromatography, eluting with EtOAc-hexanes (1:4) to provide 9.23 g of πitro compound 30 as a bright orange solid. Step 4
Figure imgf000057_0003
To a solution of nitro compound 30 (9.20 g, 20.4 mmol) in EtOH (50 mL)-THF (200 mL) was added Raney nickel (2800; slurry in water; 3.0 g), and the resultant mixture was hydrogenated for 16 h on a Parr shaker apparatus at an initial pressure of 40 psi. Catalyst was removed by filtration, and washed with EtOH. The filtrate and washings were combined and concentrated under vacuum, and the residue was purified using flash chromatography, eluting with EtOAc-hexanes (1 :1) to provide 6.02 g of compound 31 as a red solid sufficiently pure for use in the next step. Step 5:
33
Figure imgf000058_0001
To a stirred mixture of compound 31 (2.50 g, 5.95 mmol) and Et3N (1.66 ml, 7.15 mmol) in DCM (30 ml_), maintained at 0 0C in an ice-water bath, was added in small portions 2-picolinoyl chloride hydrochloride (1.28 g, 7.15 mmol). The reaction mixture was diluted with DCM (20 ml_), washed successively with 1N aqueous NaOH (20 mL) and brine (20 mL), dried over anhydrous MgSO4, filtered and concentrated under vacuum. The residue was flash chromatographed on silica gel, eluting with EtOAc-hexanes (3:4), to provide 2.70 g of compound 32 as a light tan solid. Step 6
Figure imgf000058_0002
Concentrated H2SO4 (1 mL) was added to a solution of compound 32 in EtOH
(5 mL). The reaction mixture was stirred in an oil bath maintained at 85 0C for 20.5 h, at which time a second portion of concentrated H2SO4 (1 mL) was added. Stirring at 85 0C was maintained for an additional 19.5 h. The mixture was then cooled to room temperature, treated with 50% aqueous NaOH (25 mL) and extracted with DCM (2 x 20 mL). Combined organic extracts were washed with brine, dried over anhydrous MgSO4, filtered and concentrated under vacuum to provide crude compound 33, which was purified using flash chromatography, eluting with DCM-2N methanolic ammonia (12:1) to provide 150 mg of compound 33 as a cream-colored solid sufficiently pure for use in the next step. Step 7: Compound 33 was converted into the title compound using procedures of Example 10, steps 5 and 6. MH+ 514
Example 12 Preparation of Compound 12A
Figure imgf000059_0001
12A
Step 1 :
Figure imgf000059_0002
To a stirred solution of compound 31 and Et3N (2.0 ml, 14.3 mmol) in DCM
(40 ml_), maintained at 0 0C in an ice-water bath, was added trifluoroacetic anhydride (1.15 g, 8.58 mmol). The reaction mixture was concentrated under vacuum, and the residue was flash chromatographed on silica gel, eluting with EtOAc-hexanes (3:2), to provide 3.56 g of compound 34 as a red foamy solid. Step 2
Figure imgf000059_0003
Compound 35 was converted into the title compound using the procedures of Example 10, steps 4 - 6. MH+ 505
Example 13 Preparation of Compound 13A NH2
Figure imgf000060_0001
13A
Step 1 :
Figure imgf000060_0002
A solution of diamine 12, 3,5-difluoropicolinic acid (1.14 g, 7.16 mmol), HOBT (1.32 g, 9.75 mmol), EDC (1.86 g, 9.75 mmol) and DIPEA (5.0 ml, 28.7 mmol) in DCM (50 ml_) was stirred at room temperature for 16 h. The reaction mixture was then washed successively with 1N aqueous NaOH (30 ml_) and brine (30 ml_) and dried (anhydrous MgSO4). Drying agent was removed by filtration, and the filtrate was concentrated under vacuum. The residue was flash chromatographed on silica gel, eluting with EtOAc-hexanes (3:4), to provide 3.30 g of compound 35 as a brownish solid. Step 2:
Figure imgf000060_0003
A stirred mixture of compound 35 (800 mg, 1.52 mmol) and ethylene glycol (8 ml_) in a sealed glass pressure vessel (Chemglass) was heated at 1200C for 16 h. The reaction mixture was allowed to cool to room temperature and was then partitioned between EtOAc (50 ml.) and water (40 mL). The aqueous layer was extracted with a second volume of EtOAc (30 mL). Combined extracts were dried over anhydrous MgSO4. Drying agent was filtered, and the filtrate was stripped of solvent under vacuum. The residue was flash chromatographed on silica gel, eluting with a stepped gradient of DCM-acetone (20:1 -> 6:1), to provide 210 mg of compound 36 as a light yellow foamy solid.
Step 3
Figure imgf000061_0001
To a stirred solution of compound 36 (210 mg, 0.414 mmol) in anhydrous
DCM (4 mL) was added TFA (1.0 mL), and stirring was continued at room temperature for 16 h. The reaction mixture was diluted with DCM (10 mL) and treated with a 1 :1 (v/v) mixture of concentrated NH4OH and water (6 mL). Layers were separated, and the aqueous phase was extracted with DCM (6 mL). Combined organic extracts were dried over anhydrous MgSO4, filtered and the filtrate concentrated under vacuum to provide 167 mg of compound 37 as a white foamy solid. Step 4:
Compound 37 was converted into the title compound using the procedures of Example 10, steps 5 and 6. MH+ 514
Example 14 Preparation of Compound 14A
Figure imgf000061_0002
14A
Step i :
Figure imgf000061_0003
39 To a stirred solution of te/f-butyl nitrite (55.2 ml, 466 mmol) and anhydrous Cu(II)CI2 (50.0 g, 372 mmol) in CHjCN (500 ml_), maintained at 70 0C, was added 2- amino-5-chloro-3-nitro benzene 38 (J53.6 g, 310 mmol) portionwise over 30 min. The mixture turned from greenish to brown, and gas evolution was observed. Stirring at 70 0C was continued for 16 h. The reaction mixture was cooled and partitioned between 20% aqueous HCI (400 mL) and diethyl ether (1 I). Layers were separated, and the aqueous phase was extracted with EtOAc (500 mL). Combined extracts were washed successively with 20% aqueous HCI (200 mL) and brine (300 mL), dried over anhydrous MgSCU, filtered and concentrated under vacuum. The residue was flash chromatographed on silica gel, eluting with EtOAc-hexanes (1 A), to provide 17.3 g of compound 39 as a yellow oil, which spontaneously crystallized upon standing at room temperature. Step 2:
Figure imgf000062_0001
A mixture of pyridine derivative 39 (15.0 g, 78.1 mmol), compound 10, K2CO3
(21.5 g, 156 mmol) and Kl (1 g) in toluene (200 mL) was heated at 110 0C for 8 h. The mixture was cooled to room temperature and partitioned with DCM (500 mL) and water (400 mL). Layers were separated, and the aqueous phase was extracted with a second portion of DCM (300 mL). Combined extracts were washed with brine (250 mL), dried over anhydrous Mg1SO4, filtered and concentrated under vacuum to provide 35.3 g of compound 40 as a dark red solid. Step 3:
Compound 40 was converted into the title compound using the following sequence of procedures: Example 11 , steps 4 and 5, followed by Example 13, steps 2 and 3, followed by Example 10, steps 5 and 6. MH+ 512
Example 15
Preparation of Compound 15A
Figure imgf000062_0002
15A StθP i
Figure imgf000063_0001
To a solution of N-BOC-piperaziπe 41 (3.8 g, 20.6 mmol) and 4-acetylpyridine 42 (2.0 g, 16.5 mmol) in CICH2CH2CI (15 m!_) were added Ti(OPr)4 (5.9 g, 20.6 mmol) and 3 molecular sieves. After stirring at room temperature under N2 for 2h and at 600C for another 2h, the mixture was cooled to room temperature, Na(OAc)3BH (4.9 g, 21.4 mmol) and CICH2CH2CI (85 mL) were added. The mixture was stirred at room temperature under N2 for 72h. Saturated NaHCO3 aqueous solution was added to the mixture to form the solid. The mixture was then filtered through celite, the filtrate was extracted with DCM, dried over Na2SO4, concentrated in vacuum, and purified using flash chromatography to give 3.0 g of 43. Step 2:
Figure imgf000063_0002
To a solution of 43 (3.0 g, 10.3 mmol) in DCM (60 mL) was added 4N HCI in
1 ,4-diαxane (15.4 ml, 61.8 mmol). The mixture was stirred at room temperature for 2Oh. The solvent was removed in vacuum to give 3.6 g of crude 44. Step 3:
To a solution of 44 (0.66 g, 2.2 mmol) in DCM (20 ml_)were added biphenyl- 4-carboxylic acid (0.42 g, 2.0 mmol), DIPEA (1.75 ml, 10.0 mmol), and PyBOP (1.04 g, 2.0 mmol). After stirring at room temperature under N2 for 2Oh, the mixture was extracted with DCM and saturated aqueous NaHCO3. The combined organic layers were dried over Na2SO4, concentrated in vacuum, and purified using flash chromatography to give 0.7 g of the title compound. MH+ 372 Example 16
Preparation of Compounds 16A and 16B
Figure imgf000064_0001
Step 1 :
Figure imgf000064_0002
45
A mixture of phenol 45 (0.61 g, 5.0 mmol), piperidinol 8 (1.00 g, 5.0 mmol), 1 ,1'-(azodicarbonyl)dipiperidine (1.77 g, 7.0 mmol) and tributylphosphine (1.74 ml, 7.0 mmol) was stirred for 12 h at room temperature. The reaction mixture was subjected to aqueous work-up — EtOAc extraction, followed by flash chromatography (DCM) to produce 0.36 g of compound 46 as a colorless oil. Step 2:
Figure imgf000064_0003
A solution of 2-bromo-5-fluoropyridine (0.29 g, 1.63 mmol) in toluene (6 mL) was added slowly to a solution of n-BuLi (2.5M in hexanes; 0.7 ml, 1.75 mmol) in toluene (10 mL) cooled to -78 0C and the mixture was stirred at -78 0C for 30 min. A solution of aldehyde 46 (0.36 g, 1.16 mmol) in toluene (5 mL) was added and the reaction mixture was stirred at -78 0C for 2 h. It was quenched with AcOH at -78 0C and diluted with water. The product was extracted with DCM and the organic layer was dried over Na2SO4. Purification by flash chromatography (0-1% MeOH/DCM) provided 0.30 g of alcohol 47 as a yellow oil. Step 3:
Figure imgf000064_0004
To a solution of alcohol 47 (0.30 g, 0.74 mmol) in DCM (6 mL) was added saturated aqueous solution of NaHCO3 (0.75 g, 0.89 mmol) and NaBr (0.004 g, 0.037 mmol). The mixture was cooled to 0 0C and TEMPO (0.001 g, 0.007 mmol) was added followed by 0.7 M (2.5 ml, 1.48 mmol) commercial bleach (NaOCI) in portions over 15 min. The reaction mixture was stirred at 0 0C for 30 min and it was quenched with saturated aqueous Na2S2O3 solution. The product was extracted with DCM and the organic layer was dried over Na2SO4. Purification by flash chromatography (0-0.5% MeOH/DCM) provided 0.20 g of 48 as a white solid. Step 4:
Figure imgf000065_0001
To a solution of 48 (0.19 g, 0.47 mmol) in pyridine (1 ml_) was added methoxylamine hydrochloride (0.072g; 0.095 mmol), and the reaction mixture was stirred at 80 0C overnight. Pyridine, was removed and saturated aqueous NaHCO3 solution was added. The product was extracted with DCM. The organic layer was dried over Na2SO4 and concentrated to provide 0.2038 g (100%) of the crude product (mixture of oximes 49A and 49B) as a yellowish solid. Separation of two isomers was performed by HPLC (OD chiralpak; 5 % IPA/hexanes with 0.1 DEA; 15 ml/min) to produce 0.044 g of E-oxime 49A as a clear oil and 0.056 g of Z-oxime 49B as a white solid. Step 5:
Compounds 49A and 49B were converted into Compounds 16A (MH+ 436) and 16B (MH+ 436), respectively, by using the procedures of Example 13, step 3, followed by Example 10, steps 5 and 6.
Example 17 Preparation of Compound 17A
Figure imgf000065_0002
17A
Step i :
Figure imgf000065_0003
Compound 50 was prepared from 2-bromopyridine and methyl 4- formylbenzoate using the procedure of Example 16A, step 2, except that THF was used instead of toluene as the solvent.
To a solution of 50 (1.3 g; 5.33 mmol) in dioxane (50 mL) was added MnO2 (2.32 g, 26.6 mmol) and cone. H2SO4 (0.2 mL). The reaction mixture was stirred at 750C overnight, cooled down, diluted with MeOH and filtered. The precipitate was washed repeatedly with MeOH and DCM, and the filtrate was combined and concentrated to produce 0.50 g of ketone 51. Step 2:
Figure imgf000066_0001
A mixture of 51 (0.50 g, 2.1 mmol) and LiOH monohydrate (0.12 g, 2.9 mmol) in dioxane - water was stirred overnight at 700C. The reaction mixture was concentrated to dryness to produce crude 52, which was used without purification in the next step. Step 3
52 + L N JL A *^ 17A
53
Compound 53 was prepared as described in WO2002032893. Compounds 52 and 53 were reacted following the procedure of Example 13, step 1 , to provide the title compound. MH+ 402 Example 18
Preparation of Compound 18A
Figure imgf000066_0002
18A
The title compound was prepared from the compound 17A using the procedure of Example 16A, step 4. MH+ 431 Example 19 Preparation of Compound 19A
Figure imgf000067_0001
19A
The title compound was prepared from 4-benzoyl benzoic acid and compound 53 using the procedure of Example 13, step 1. MH+ 401
Example 20
Preparation of Compound 2OA
Figure imgf000067_0002
2OA
To a solution of the compound 19A (0.10g; 0.25 mmol) in MeOH (20 ml_) was added NaBH4 (0.029 g, 0.75 mmol). The mixture was stirred for 2 h at room temperature, acidified with 4 N HCI in dioxane, filtered and concentrated in vacuo. The residue was redissolved in 10% MeOH/DCM with 0.5% aqueous NH4OH. The solution was filtered and concentrated, and the residue was treated with 4 N HCI in dioxane to produce, after concentration, 0.12 g of HCI salt of the title compound as an off-white solid. MH+ 403 Example 21
Preparation of Compound 21 A
Figure imgf000067_0003
21A Step 1 :
Figure imgf000068_0001
LiAIH4 (10.0 g, 0.264 mol, 1.24 eq) was portionwise added to a solution of methyl-2-chloro-6-methylpyridine-4-carboxylate 54 (39.62 g, 0.213 mol) in dry THF (800 mL) at room temperature, with stirring, over a period of 1.4 h. The resulting mixture was stirred for 1 h and quenched with water. Then 15% aqueous NaOH (100 mL) was added, followed by aqueous sodium-potassium tartrate (1 I). The resulting mixture was stirred for a further 1.25 h and extracted with DCM (2 x 1 I) to give, after concentration, (2-chloro-6-methylpyridin-4-yl)-methanol 55 (31.06 g, 93%) as a yellow solid. Step 2:
Figure imgf000068_0002
A bomb was charged with 55 (30.0 g, 0.190 mol) and aqueous cone NH3 (225 mL) and the resulting mixture was heated at 210 0C for 20 h. The system was cooled to room temperature, the volatiles removed under vacuo and the residue purified using column chromatography (DCM: MeOH/NH3 0.4N 9:1) to give (2- amino-6-methyl pyridine-4-yl)-methanol as a mixture of free base and hydrochloride salt, which was redisolved in DCM: i-PrOH 1 :1 (1 I) and treated with 20% aqueous NaOH (500 mL). The layers were: separated and the organic phase extracted with DCM: i-PrOH 1:1 (1 x 1 I). The combined organic phase was dried and the solvent evaporated to give (2-amino-6-methyl pyridine-4-yl)-methanol 56 (15.51 g, 59%) as pale orange crystals. Step 3:
Figure imgf000068_0003
Di-te/ϊ-butyl dicarbonate (105.75 g, 0.485 mol, 4.33 eq) was added to a stirred solution of 56 (15.51 g, 0.112 mol) in tert-butyl alcohol (500 mL) at room temperature. The resulting mixture was heated at 95 0C for 19 h under a N2 atmosphere, then was cooled to room temperature and the solvent evaporated under vacuo. The resulting brown oil was purified using column chromatography (EtOAc: hexanes 1 :1) to give the diprotected aminoalcohol (38.25 g) as a yellow solid. Then, 25% aqueous NaOH (150 ml_) was added to a solution of the above material in MeOH (500 ml_) over a period of 10 min. The resulting mixture was stirred for 1 h, diluted with water (200 ml_) and extracted with DCM (2 x 750 mL) to give 57 (21.0 g, 79% over two steps) as an orange foam.
Step 4:
Figure imgf000069_0001
Dess-Martin periodinane (50.0 g, 0.118 mol, 1.34 eq) was portionwise added to a solution of 57 (21.0 g, 0.088 mol) in DCMrpyridine 10:1 (1.1 I). The resulting solution was stirred at room temperature for 2 h and then, water (700 mL) was added. The mixture was stirred for a further 5 min, then the layers were separated. The aqueous layer was extracted with DCM (1 x 11), the combined organic phase dried and the solvent evaporated to give a brown solid which was purified using column chromatography (EtOAc: hexane 1:2) to afford 58 (20.5 g, 99%) as a pale orange solid. Step 5:
Figure imgf000069_0002
Compound 59 was prepared using the procedure of Example 10, step 5. Compound 59 was converted into the title compound using the procedure of Example 10, step 6. MH+ 492
Example 22 Preparation of Compound 22A
Figure imgf000070_0001
22A
Step i:
Figure imgf000070_0002
To a stirred solution of 4-bromophenol (8.52 g, 0.049 mol), 18 (8.25g, 0.041 mol), PPh3 (12.9g, 0.049 mol) in dry THF (100 ml_) was added DEAD (8.57g, 0.049 mol) slowly. The mixture was allowed to stir in a sealed flask at 5O0C for 12h. The mixture was diluted with ether, washed with 1N NaOH (2X), brine, dried and concentrated in vacuo. Flash chromatography (EtOAc: Hexanes/1:9) afforded 60 (8.50 g, 48% yield). Step 2:
Figure imgf000070_0003
The mixture of 69 (800 mg, 2.25 mmol), Pd2(dba)3 (206 mg, 0.225 mmol), P(tBu)3 (10 wt % in hexanes, 730 rng, 0.36 mmol), NaOtBu (324 mg, 3.37 mmol) and N-methylpiperazϊne (337 mg, 3.37 mmol) was stirred at room temperature in toluene (6 mL) for 48 h. The mixture was diluted with DCM and filtered. Flash chromatography (MeOH:DCM 1:20) afforded a brown oil. The oil was dissolved in DCM (5 mL) and TFA (5 mL). The solution was stirred at room temperature for 1h and concentrated in vacuo. The resulting residue was stirred in DCM and 1 N NaOH for 10 min. The DCM layer was washed with brine and concentrated in vacuo to give the amine 61 (550 mg, 89%). Step 3:
Compound 61 was converted into the title compound using the procedure of Example 10, steps 5 and 6. MH+ 382
Using the method described above, compounds 23A-69A were prepared:
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0002
Example 23 Preparation of Compound 7OA
Figure imgf000078_0001
7OA
Step 1 :
Figure imgf000079_0001
To a stirred mixture of potassium tert-butoxide (12.8 g, 115 mmol) and compound 8 (22.0 g, 110 mmol) in tø/t-butanol (150 ml_), maintained at 50 0C, was added 2-chloro-5-nitropyridine (19.0 g, 120 mmol) in one portion. After being heated at 50 0C for 16 h, the mixture was cooled to room temperature, diluted with Et2O
(300 ml_) and treated with water (200 ml_). The aqueous phase was extracted with a second portion (200 m) of Et2O. Combined extracts were washed with brine (200 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. The residue was purified using flash chromatography, eluting with DCM- EtOAc (-4.5:1 ) to provide 31.6 g of compound 62 as a light yellow solid. Step 2:
Figure imgf000079_0002
Raney nickel (10 g (W. R. Gra.ce; 2800; slurry in water)) was added to a solution of compound 62 (31.5 g, 97.5 mmol) in THF (450 ml_)-EtOH (150 mL), and the resultant mixture was hydrogenated at an initial pressure of 30 psi for 16 h. The spent catalyst was filtered off and washed with EtOH. Combined filtrate and washings were concentrated under vacuum to produce crude product 63 as a light cream-colored solid which was used without further treatment in the next step. Step 3:
Figure imgf000079_0003
To a stirred, ice-cooled mixture of 4,6-dichloro-5-nitropyrimidine (4.00 g, 20.6 mmol) and K2CO3 (5.40 g, 39.2 mmol) in THF (30 mL) was added slowly a solution of 63 (5.75 g, 19.6 mmol) in THF (30. mL) over 20 min. The resultant mixture was stirred at 00C for 1 h. The reaction mixture was then treated with water (100 mL) and extracted with EtOAc (2 x 200 mL). Combined extracts were washed with brine (150 mL), dried over anhydrous MgSO4, filtered and concentrated under vacuum. The residue was purified using flash chromatography, eluting with EtOAc-hexanes (1 :3) to provide 5.82 g of compound 64 as a lemon-colored solid. Step 4;
Figure imgf000080_0001
To a mixture of 65 (5.80 g, 12.9 mmol) in EtOH (100 ml_)-THF (100 ml_) was added 20% palladium hydroxide-on -carbon catalyst (0.60 g), and the resultant mixture was hydrogenated for 16 h on a Parr shaker apparatus at an initial pressure of 40 psi. Catalyst was removed by filtration, and the filtrate was concentrated under vacuum to provide a black residue, which was purified using flash chromatography, eluting with DCM-2N methanolic ammonia (12:1 ) to provide 4.61 g of compound 65 as a gray solid. Step 5:
Figure imgf000080_0002
To a stirred solution of 66 (2.3g, 5.80 mmol) and Et3N (1.61 ml, 11.6 mmol) in
DCM (50 ml_), maintained at 0 0C in an ice-water bath, was added slowly via dropping funnel 3,4-difluorobenzoyl chloride (0.877 ml, 6.97 mmol). The resultant mixture was stirred at 0 0C for 1 h, then at room temperature for 16 h. The reaction mixture was washed successively with 1N NaOH solution (25 ml_) and brine (25 mL), and was then dried over anhydrous MgSO4. The drying agent was filtered and the filtrate was concentrated under vacuum. The residue was flash chromatographed on silica gel, eluting with DCM-2N methanolic ammonia (20:1 ), to provide 2.21 g of compound 66 as a yellow solid. Step 6:
Compound 66 was converted into the title compound using the methods set forth in Example 10, Steps 4-6. MH+ 515
Example 24 Preparation of Compound 71 A
Figure imgf000081_0001
71 A
Step i:
Figure imgf000081_0002
A stirred mixture of 2-chloro-3-nitropyridine (4.75 g, 30 mmol), K2CO3 (8.28 g, 60 mmol), Kl (150 mg) and 67 (8.8φg, 30 mmol) was heated at 1 10 0C for 16 h. The reaction mixture was then cooled, treated with water (100 m) and extracted with EtOAc (1 x 200; 1 x 100 ml_). Combined extracts were washed with brine (100 ml_), dried over anhydrous MgSO-1, filtered and concentrated under vacuum. The residue was purified using flash chromatography, eluting with DCM-acetone (20:1 ) to provide 7.1 g of 67 as a bright orange solid.. Step 2:
Figure imgf000081_0003
To a solution of nitro compound 67 (7.1Og, 17.1 mmol) in EtOH (50 ml_)-THF
(150 mL) was added Raney nickel catalyst (2.4 g (W.R. Grace; 2800; slurry in water)), and the resultant mixture was hydrogenated for 16 h on a Parr shaker apparatus at an initial pressure of 40 psi. Catalyst was removed by filtration, and the filtrate was concentrated under vacuum to provide 6.16 g of 68 as a light brown solid. Step 3:
Compound 68 was converted into the title compound using the methods set forth in Example 10, Steps 3-6. MH+ 520
Example 25 Preparation of Compound 72A
Figure imgf000082_0001
72A
Step 1 ;
Figure imgf000082_0002
A solution of 68 (1.65 g, 4.28 mmol) and thiocarbonyldiimidazole (90%; 1.91 g, 9.63 mmol) in anhydrous THF (22.5 ml_) was heated at ~720C in a sealed tube for 22 h. Solvent was removed under vacuum. The residue was triturated with EtOAc (-100 mL). Insoluble solid was filtered and purified using flash chromatography on silica gel, elutiπg with DCM-MeOH -ammonia (97:3:0.25), to provide 832 mg of 69 as a light gray solid. Step 2:
Figure imgf000082_0003
To a stirred mixture of 69 (500 mg, 1.17 mmol) and powdered K2CO3 (193 mg, 1.40 mmol) in DMF (14 mL) was added CH3I (76.8 μl; 175 mg, 1.23 mmol). The resultant mixture was stirred at room temperature in a sealed tube until the starting thione was consumed, as judged by TLC (<16 h). The reaction mixture was filtered, and the filtrate was concentrated uinder vacuum. The residue was purified using flash chromatography on silica gel,, eluting with DCM-MeOH-ammonia (98:2:0.25), to provide 489 mg of 70 as a foamy white solid. Step 3:
Figure imgf000083_0001
A solution of 71 (485 mg, 1.10 mmol) and TFA (813 μl; 1.25 g, 10.9 mmo!) in DCM (8 ml_) was stirred at room temperature for 23 h. The reaction mixture was concentrated under vacuum. The residue was partitioned between DCM (25 ml_) and water (2 mI_)-2M aqueous Na2Cθ3 (2 ml_)-6N NaOH (2 ml_). The aqueous layer was extracted with DCM (3 x 5 mL). Combined extracts were washed with brine (2 mL) and filtered through anhydrous MgSO4. The filtrate was stripped of solvent under vacuum to provide 344 mg of 71 as an amorphous white solid, which was sufficiently pure for use in the next step. Step 4:
Compound 71 was converted into the title compound using the methods set forth in Example 10, Steps 5-6. MH+ 448
Example 26 Preparation of Compound 73A
Figure imgf000083_0002
73A
Step i:
Figure imgf000083_0003
To a solution of 2-bromo-5-fl!uoropyridine (500 mg, 2.84 mmol) and f-butyl-
1 ,4-diazepine-i-carboxylate 72 (1.7 g, 8.52 mmol) in DMF (5 mL) was added anhydrous K2CO3 powder (3 g). The mixture was stirred at 1200C for 12 h under N2. The mixture was filtered and concentrated to remove DMF. Flash chromatography (EtOAc/Hexanes, 1 :4) afforded a yellow oil as the coupled product. The oil was stirred in TFA (5 ml_) and DCM (5 rriL) for 30 min, then concentrated in vacuo. The residue was dissolved in DCM. 1 N, NaOH was added and the mixture was stirred for 10 min. The DCM layer was separated, dried over MgSO4, filtered and concentrated to give the amine 73 (260 mg). Step 2:
Figure imgf000084_0001
To a solution of 73 (250 mg, 1.28 mmol) and 46 (586 mg, 1.92 mmol) in DCM (5 ml_) was added HOAc (0.1 mL). The mixture was stirred for 10 min, then NaBH(OAc)3 (426 mg, 1.92 mmol) was added. The mixture was stirred at room temperature for 12 h. The mixture was diluted with DCM, washed with 1 N NaOH1 brine, dried over MgSO4, filtered and concentrated in vacuo. Flash chromatography (MeOH/DCM, 1 :10) afforded a yellow oil. The oil was stirred in TFA (5 mL) and DCM (5 mL) for 30 min, then concentrated in vacuo. The residue was dissolved in DCM, 1N NaOH was added and the mixture was stirred for 10 min. The DCM layer was separated, dried over MgSO4, filtered and concentrated to give the amine 74 (170 mg). Step 3:
Figure imgf000084_0002
Compound 75 was prepared from commercially available 2-aminothiazole-5- carbaldehyde by a standard procedure ((BOC)2O, DCM, room temperature).
Using the procedure of Example 10, Step 5, 76 was prepared from 74 and 75. Step 4:
Compound 76 was converted into the title compound using the procedure of Example 10, Step 6. MH+ 497
Example 27 Preparation of Compound 74A
Figure imgf000085_0001
74A
Step 1
Figure imgf000085_0002
NaH (64mg, 1.6mmol) was added to a mixture of compound 14 (465mg, O.δmmol, was prepared using the method described in steps 1-6 of example 4) in anhydrous DMF (5 ml_). The resulting reaction was allowed to stir at 45°C for 30 min, then iodoethaπe (78μl, 0.96mrnol) was added, and the reaction was heated to 60 0C and allowed to stir at this temperature for 16 h. The reaction mixture was cooled to room temperature, then E-tOAc (30 ml_) and water (30 ml_) were added, and the aqueous phase was extracted again with EtOAc (20 mL). The combined organic phases were washed with brine (20 mL), dried over anhydrous MgSO4, and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, elutiπg with CHaCb-MeOH (25:1) to provide compound 77 as a beige solid (266 mg).
Step 2 Compound 77 was converted into the title compound using the method set forth in Example 4, step 8. MH+ 506.
Example 28 Preparation of Compound 75 A
Figure imgf000086_0001
75A
Step 1
Figure imgf000086_0002
A mixture of 4-nitro benzaldehyde (20.Og, 129mmol) and 1-Boc piperazine (20.Og, 107mmol) in DCM (500 ml_)ιwas allowed to stir at room temperature for 1.5h, then Na(OAc)3BH (45.3g, 214mmol) was added and the resultant reaction was allowed to stir stirring at room temperature for an additional 3h. The reaction mixture was then sequentially washed with I N NaOH (250 ml_) and brine (250 ml_), dried over anhydrous MgSO4, and concentrated in vacuo to provide compound 78 as a light orange solid (35.1g).
Step 2
Figure imgf000086_0003
To a solution of compound 78 (35g, 110mmol) in a mixture of THF (300 ml_) - EtOH (100 mL) was added 50% Raney Nickel (12 g, aqueous slurry), and the mixture was placed on a Parr Shaker and hydrogenated at P0 = 40Psi for 16h. The spent catalyst was filtered off, and the filtrate was concentrated in vacuo. The resultant residue was purified using flash column chromatography on silica gel, eluting with CH2CI2-MeOH (25:1 ) to provide compound 79 as a light yellow solid (24.1g).
Step 3
Figure imgf000087_0001
80
To a mixture of 2-chloro-3-nitropyridine (6.3g, 40mmol) in toluene (100 ml_) was added compound 79 (11.6g, 4Gmmol), followed by solid K2CO3(Hg, 80mmol), and the resulting reaction was heated to 1100C and allowed to stir at this temperature for 16h. BINAP (500mg, 2% mol) and Pd(OAc)2 (180mg, 2%mol) were then added to the reaction mixture gnd the reaction was allowed to stir for an additional 4 h at 1100C. The reaction mixture was cooled to room temperature, then EtOAc (250 mL) and water (200 ml_) were added, and the resulting solution was filtered through Celite to remove any insoluble material. The filtrate was separated and the aqueous phase was extracted with EtOAc (200 mL). The combined organic phases were washed with brine (300 mL), dried over anhydrous MgSO4, and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, eluting with EtOAc-Hexane (1 :1 ) to provide compound 80 as a red solid (24.1 g).
Step 4
Figure imgf000087_0002
Compound 80 (15.8g, 38mmol) was converted to compound 81 using the method set forth in step 2. Compound 81 was a light grey solid (11.8g). Step 5
Figure imgf000088_0001
A solution of compound 81 (3.83g, lOmmol) in DCM (60 ml_) and Et3N (4mL) was cooled to 0 0C, then 2-picolinoyl chloride (2.14g, 12mmol) was added, and the resulting reaction was allowed to stir at O0C for 1h, then at room temperature for 16h. The reaction mixture was washed sequentially with 1 N NaOH (40 ml_), and brine (40 mL), dried over anhydrous MgSO4, and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, eluting with CH2CI2- MeOH (50:1 ) to provide compound 82 as yellow foam (4.41 g).
Step 6
Figure imgf000088_0002
83
A mixture of compound 82 (2.2Og, 4.5mmol) in ethylene glycol (15mL) was heated to 1700C and allowed to stir at this temperature for 16h. EtOAc (60 mL) and water (30 mL) were added to the cooled mixture and the aqueous layer was extracted once more with EtOAc (60 mL). The combined organic phases were washed with brine (30 mL), dried over anhydrous MgSO4, and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, eluting with CH2CI2-MeOH (13:1 ) to provide compound 83 as a light yellow solid (0.41 g). Step 7
Compound 83 was converted into the title compound using the methods set forth in Example 4, steps 6-7. MH+ 477
Example 29 Preparation of Compound 76A
Figure imgf000089_0001
76A
Step j
Figure imgf000089_0002
84
A solution of 4-hydroxy-N-Boκ piperidine (2.01 g, lOmmol) in DCM (30 ml_) and Et3N (2.8OmL, 20mmol) was cooled to 0 0C, and methanesulfonyl chloride was slowly added. The reaction was allowed to stir at O0C for 2h and was then concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, eluting with EtOAc-Hexane (1 :1 ) to provide compound 84 as a white solid (2.76g).
Step 2
Figure imgf000090_0001
NaH (9.2g, 230mmol) was added portionwise over a period of 30 min to a solution of compound 84 (43g, 153rnmol) in DMF (400 ml_). The reaction was allowed to stir at room temperature for 2h, then 4-amino benzene thiol (23g, 184mmol) was added. The resulting reaction was allowed to stir at room temperature for 16h and was then poured into water (400 mL), extracted with EtOAc (50OmL x 2), and the combined organics were washed with brine (500 mL), dried over anhydrous MgSO4, and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, eluting with EtOAc-Hexane (3:4) to provide compound 85 as a light yellow solid (38.8g).
Step 3
Compound 85 was converted to the title compound using the procedures from steps 3-6 of Example 1337450, folbwed by steps 6-7 of Example 4. MH+ 494
Example 30 Preparation of Compound 77A
Figure imgf000090_0002
77A
Step j
Figure imgf000090_0003
86 A solution of N-Boc piperazine (14.4g, 77.4mmol) in DCM (300 ml_) and Et3N (21.6mL, 155mmol) was cooled to G 0C and p-Nitrobenzene sulfonyl chloride (20.5g, 93mmol) was added portionwise to the cooled solution. The resulting reaction, was allowed to stir at 00C for 1 h, then at room temperature for 16h. The reaction mixture was washed sequentially with 1 N NaOH (50 ml_) and brine (50 ml_), and the organic phase was dried over anhydrous MgSO4, and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, eluting with EtOAc-Hexane (1:1 ) to provide compound 86 as a light yellow solid (28.Og).
Step 2
Compound 86 was converted to the title compound using the methods set forth in steps 2-6 of Example 75, followed by steps 6-7 of Example 4. MH+ 527
Example 31 Preparation of Compound 78A
Figure imgf000091_0001
78A
Step 1
Figure imgf000091_0002
A solution of compound 12 (2.4Og, 6.2mmol, prepared as described in steps 1-4 of Example 4) in DCM (60 ml_) and Et3N (1.3mL, 9.3mmol) was cooled to 00C and, 1 ,3-thiazole-2-carbonyl chlorid;e (1.0Og, 6.8mmol) was added to the cooled solution. The resulting reaction was allowed to stir at O0C for 1h, then at room temperature for 16h. The reaction mixture was washed sequentially with 1N NaOH (30 mL), and brine (30 mL), then the organic phase was dried over anhydrous MgSθ4, and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, eluting with DCM-Acetone (12:1) to provide compound 87 as a tan solid (2.95g).
Step 2
Figure imgf000092_0001
A mixture of compound 87 (1g, 2.08mmol) in ethylene glycol (6mL) was heated to 1500C and allowed to stir at this temperature for 16h, wherein mass spectra confirmed the disappearance of the starting material. The reaction mixture was cooled to room temperature, then diluted with EtOAc (60 mL) and water (60 mL). The aqueous layer was separated, and the extracted once more with EtOAc (30 mL). The combined organic layers were dried over anhydrous MgSO,*, concentrated in vacuo, and the residue was purified using flash column chromatography on silica gel, eluting with DCM-acetone (15:1) to provide compound 88 as a tan solid (0.362g).
Step 3
88
Figure imgf000092_0002
Trifluoroacetic acid (1mL) was added to a solution of compound 88 (360mg, 0.755mmol) in DCM (4ml_), and the reaction was allowed to stir at room temperature for 16h. The reaction mixture was then diluted with DCM (10 ml_), basified using 50% NH4OH (v/v, 6 ml_), then the aqueous was extracted once more with DCM (10 ml_). The combined organics were dried over anhydrous MgSO4, and concentrated in vacuo to provide compound 89 as a light pink solid (0.265g).
Step 4 Compound 89 was converted to the title compound using the methods set forth in steps 6-7 of Example 4. MH+ 484
Example 32 Preparation of Compound 79A
Figure imgf000093_0001
79A
Step 1
Figure imgf000093_0002
To a solution of compound 90 (25g, 117mmol) in a mixture of THF (300 ml_) - EtOH (100 ml_) was added 50% Raney Nickel (5 g, aqueous slurry), and the mixture was placed on a Parr Shaker and hydrogenated at P0 = 40Psϊ for 16h. The spent catalyst was filtered off, and the filtrate was passed through Celite, then concentrated in vacuo to provide compound 91 as a light yellow solid (22.3g). Step 2
∞ + F3C
Figure imgf000094_0001
A solution of compound 91 (22g, 120mmol) in DCM (500 ml_) and Et3N
(10.5mL, 143mmol) was cooled to 0 0C, then trifluoroacetic anhydride was added to the cooled solution via an addition funnel over a period of 20 min. The resultant reaction was allowed to stir at 0 0C for 1 h, then at room temperature for 2h. The reaction mixture was then concentrated in vacuo and the resulting residue was purified using flash column chromatography on silica gel, eluting with DCM-acetone (9:1) to provide compound 92 as a yellow solid (25.8g).
Step 3
Figure imgf000094_0002
93
To a mixture of compound 92 (25g, 89.2mmol) in acetic acid (180 ml_) was added PtO2 (3g), and the reaction vessel was place on a Parr shaker and hydrogenated at P0 = 40 Psi for 16h. The reaction mixture was then filtered to remove catalyst and the filtrate was washed with MeOH (100 ml_), then passed through a pad of Celite and concentrated in vacuo. The resulting residue was dissolved in MeOH (100 ml_), and the resulting solution was poured into Et2O (600 mL). The white precipitate formed and was filtered, washed with Et2θ, and dried to provide compound 93 as a white solid (30.Og).
Step 4
Figure imgf000095_0001
A mixture of compound 93 (30.Og1 86.7mmol) in DCM (500 ml_) was cooled to 0 0C, then Et3N (18ml_, 130mmol) was added slowly. To the resulting solution was added a solution of Boc2O (20.Og, 95.4mmol) in DCM (100 ml_) via a dropping funnel over a period of 10 min. The resulting reaction was allowed to stir at O0C for 2h, then NaOH (2N, 50 mL) was added to the reaction, and the resulting reaction was allowed to stir at room temperature for 1h. The reaction mixture was separated and the organic layer was washed with brine (100 mL), dried over anhydrous MgSO4, and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, eluting with EtOAc-Hexane (1 :4) to provide compound 94 as a white solid (30.1g).
Step 5
Figure imgf000095_0002
K2CO3 (2N aqueous solution, 150 mL) was added to a solution of compound
94 (30.Og, 78mmol) in MeOH (300 mL), and the reaction was allowed to stir at room temperature for 16h. The reaction mixture was concentrated in vacuo and the resulting residue was extracted with DCM (300 mL x 2). The combined organics were dried over anhydrous MgSO4, and concentrated in vacuo to provide compound
95 as light brown syrup which solidified into a tan solid upon standing (24.6g).
Step 6
Figure imgf000096_0001
Compound 96 was prepared from compound 95 and 2-chloro-3-nitropyridine using the method set forth in Example 75, step 3.
Step 7
Compound 96 was converted to the title compound using the methods set forth in steps 1-3 of Example 78, followed by steps 6-7 of Example 4. MH+ 476
Example 33 Preparation of Compound 8OA
Figure imgf000096_0002
8OA
Step i
Figure imgf000096_0003
A solution of compound 97 (250mg, 0.513mmol, prepared using the method set forth in Example 75) in DCM was chilled in an isopropanol-dry ice bath, and to the cooled solution was added m-cfoloroperbenzoic Acid (114mg, 0.513mmol). The reaction was allowed to stir in the cooling bath for 3h and the reaction mixture was then washed sequentially with 1 N IMaOH (6mL) and brine (6ml_), dried over anhydrous MgSO4, and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, eluting with DCM-MeOH (1 :45) to provide compound 98 as a white foam (236mg).
Step 2
Compound 98 was converted to the title compound using the methods set forth in step 7 of Example 78, followed by steps 6-7 of Example 4. MH+ 510
Example 34 Preparation of Compound 81 A and 81 B
Figure imgf000097_0001
Step i
Figure imgf000097_0002
A solution of compound 97 (250mg, 0.513mmol, prepared using the method set forth in Example 1337450) in DCM was chilled in an isopropanol-dry ice bath, and to the cooled solution was added m-chloroperbenzoic Acid (114mg, 0.513mmol). The reaction was allowed to stir in the cooling bath for 3h and the reaction mixture was then washed sequentially with 1 N NaOH (6mL) and brine (6mL), dried over anhydrous MgSQ4, and concentrated in vacuo. The resulting residue was purified using flash column chromatography on silica gel, eluting with DCM-MeOH (1 :45) to provide compound 98 as a light yellow solid (85mg) and 99 as a light yellow foam (131mg).
Step 2
Compounds 98 and 99 were converted to the title compounds 81 A and 81 B, respectively, using the methods set forth in steps 6-7 of Example 4.
Example 35
Preparation of Compound 82A
Figure imgf000098_0001
82A
Figure imgf000098_0002
To a solution of 2-chloro-3-nitropyridine (4.75g, 30mmol) and compound 100
(4.95g, 30 mmol) in toluene (150 ml_) was added K2CO3 (8.28g, 60mmol)f NaI (0.15g, 1mmol), BINAP (0.37g, 0.6mmol), and Pd(OAc)2 (0.14g, O.βmmol). The resulting reaction was heated to 1100C and allowed to stir at this temperature for 2Oh. The reaction mixture was then cooled to room temperature, extracted with EtOAc and the organics were washed with water, dried over Na2SO4, concentrated in vacuo. The resulting residue was purified using flash chromatography using 10% of EtOAc/hexane to provide compound 101 as orange solid. Yield: 6.5g, 75%.
Step 2
Figure imgf000099_0001
101 102
To a solution of compound 101 (5.5g, 19.1 mmol) in EtOH (100 mL) (in a 500 mL hydrogenation bottle) was added Ra-Ni (1.9g). The mixture was hydrogenated at room temperature at 50 psi under H2 for 2Oh. The reaction mixture was then filtered through celite, and the filtrate concentrated in vacuo to provide compound 102.
Yield: 4.7 g, 95%.
Step 3
Figure imgf000099_0002
To a solution of compound 102 (2.2g, 8.6mmol) and Et3N (3.6ml_, 25.8mmol) in CH2CI2 (40 mL) was slowly added picolinoyl chloride hydrochloride (2.Og, 10.3mmol). The reaction was allowed to stir at room temperature for 1.5h, after which time the reaction mixture was extracted with CH2CI2 and water. The combined organic layers were dried over Na2SO4, concentrated in vacuo, and purified using flash chromatography to provide compound 103. Yield: 2.6g, 84%.
Step 4
Figure imgf000100_0001
A solution of compound 103 (2.6g, 7.2mmol) in acetic acid (20 mL) was heated to 120 0C under N2 and allowed to remain at this temperature for 2Oh. The reaction mixture was then cooled to room temperature and concentrated in vacuo to provide compound 104. Yield: 2.5 g, 99%.
Step 5
Figure imgf000100_0002
To a suspension of compound 104 (1.Og, 2.9mmol) in a 1 :1 mixture of MeOH/water (20 mL) was added LiOH-H2O (1.9g, 4.4mmol). The reaction mixture was heated to 600C and allowed to stir at this temperature for 1.5h, after which time the reaction was concentrated in vacuo to provide compound 105. Yield: 1.0g, 100%.
Step 6
Figure imgf000100_0003
To a solution of compound 1|05 (1.0g, 3.1mmol) and 1-Boc-piperazine (0.58g, 3.1mmol) in DMF (10 mL) at 250C, was added DEC (0.89g, 4.7mmol) and HOBT (0.63g, 4.7mmol). The reaction was heated to 600C and allowed to stir at this temperature for 2Oh, after which tirriie 5% of NaOH aqueous solution was added. The resulting solution was extracted with CH2CI2, washed sequentially with water (3x) and brine, dried over Na2SO4, then filtered. The filtrate was concentrated in vacuo and purified using flash chromatography to provide compound 106. Yield: 1.3 g, 87%.
Step 7
Figure imgf000101_0001
To a solution of compound 1'06 (1-3g, 2.7mmol) in CH2Cl2 (20 mL) was added
CF3COOH (6 mL). The resulting reaction was allowed to stir at room temperature for 2Oh, after which time concentrated NH 4OH was added until the solution was at pH 11-12. The resulting mixture was extracted with CH2CI2, washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to provide compound 107. Yield: 1.0g, 96%.
Step 8
Figure imgf000102_0001
To a solution of compound 107 (0.2g, 0.52mmol) and N-Boc-2-aminopyridine- 4-carbaldehyde (see WO2002032893) (0.14g, 0.62mmol) in CH2CI2(IO mL) was added Na(OAc)3BH (0.44g, 2.08mmol). The resulting reaction was allowed to stir at room temperature for 2Oh. The reaction mixture was then extracted with CH2CI2 and the organics were washed with saturated NaHCO3 aqueous solution then brine, dried over Na2SO4, and concentrated in vacuo. The resulting residue was purified using flash chromatography to provide compound 108. Yield: 0.11 g, 36%.
Step 9
Compound 108 was converted to Compound 82A using the method described in step 7 of this example. MH+ 491
Using the methods set forth above, compounds 83A-112A were prepared:
Figure imgf000102_0002
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0003
Example 36 Preparation of Compound 113A
Figure imgf000107_0001
113A
Step 1
Figure imgf000107_0002
109 To a 0 C solution of 4-bromobenzoyI chloride (11.0 g; 50 mmol) in 200 mL of
CH2CI2 was added 1 -Boc-piperazine (9.3 g; 50 mmol), followed by Et3N (20.9 mL; 150 mmol). The reaction was allowed to stir at 00C for about 1 hour, then at room temperature for 3 hours. The reaction mixture was concentrated in vacuo and the resulting residue was partitioned between ethyl acetate and water. The organic phase was washed with water, then brine, dried over MgSO4 and concentrated in vacuo. The crude product obtained was purified using flash chromatography to provide intermediate compound 109 (15.8 g).
Step 2
Figure imgf000108_0001
109 110
To a 0 0C solution of compound 109 (10.0 g; 27.2 mmol) in 60 mL Of CH2CI2 was added dropwise TFA (15 mL). The reaction was allowed to stir at 00C for about 1 hour, then at room temperature for 3 hours. The reaction mixture was concentrated in vacuo and the resulting residue was partitioned between ethyl acetate and aqueous NaHCO3. The organic phase was washed with saturated aqueous NaHCOe and brine, then was dried and concentrated in vacuo to provide intermediate compound 110 (4.6 g), which was used without purification.
Step 3
Figure imgf000108_0002
Compound 110 was convert:ed to 111 by using the method described in
Example 35, step 8.
Step 4
Figure imgf000108_0003
Compound 111 was converted to 112 by using the method described in step 2 of the present example. Step 5
Figure imgf000109_0001
A solution of compound 112 (150 mg; 0.4 mmol), 3-fluorσ-4-pyridineboronic acid (169 mg; 1.2 mmol), [1 ,1'-bis(djphenylphosphino) ferrocene]dichloropalladium(ll) (82 mg; 0.1 mmol) and Na2CO3 (254 mg; 2.4 mmol) in 2 mL DME/water (4:1) was placed in a microwave vial, degassed and heated to 1200C for 12 minutes in an EMRY microwave apparatus. The reaction mixture was cooled to room temperature, then partitioned between ethyl acetate(20 mL) and 10 mL of water (10 mL). The organic layer was separated, dried and concentrated in vacuo and the resulting residue was purified using flash chromatography to provide Compound 113A. MH+ 392
Using the method set forth above, compounds 114A-116A were prepared:
Figure imgf000109_0002
Example 37
General Procedure for H3-Receptor Binding Assay The source of the H3 receptors in this experiment was guinea pig brain. Alternatively, the source of H3 receptors was recombinant human receptor, expressed in HEK-293 (human embryonic kidney) cells.
The animals weighed 400-600 g. The brain tissue was homogenized with a solution of 50 mM Tris, pH 7.5. The final concentration of tissue in the homogenization buffer was 10% w/v. The homogenates were centrifuged at 1 ,000 x g for 10 min. in order to remove clumps of tissue and debris. The resulting supernatants were then centrifuged at 50,000 x g for 20 min. in order to sediment the membranes, which were next washed three times in homogenization buffer (50,000 x g for 20 min. each). The membranes were frozen and stored at -700C until needed. All compounds to be tested were dissolved in DMSO and then diluted into the binding buffer (50 mM Tris, pH 7.5) such that the final concentration was 2 μg/ml with 0.1% DMSO. Membranes were then added (400 μg of protein, 5 μg in the case of recombinant human receptor) to the reaction tubes. The reaction was started by the addition of 3 nM [3H]R-α-methyl histamine (8.8 Ci/mmol) or 3 nM [3H]Nα-methyl histamine (80 Ci/mmol) and continued under incubation at 300C for 30 min. Bound ligand was separated from unbound ligand by filtration, and the amount of radioactive ligand bound to the membranes was quantitated by liquid scintillation spectrometry. All incubations were performed in duplicate and the standard error was always less than 10%. Compounds that inhibited more than 70% of the specific binding of radioactive ligand to the receptor were serially diluted to determine a Kj (nM).
Compounds of formula (I) have a Ki within the range of about 0.6 to about 600 nM at the recombinant human H3 receptor and from about 18 nM to about 400 nM at the guinea pig brain receptor. Compound 69A has a Kj of 0.6 nM the recombinant human receptor assay and a K1 of 18 nM in the guinea pig receptor assay. Example 38 Effects of the Compounds of the Invention on Diet-Induced Obesity in Mice
Lean mice (male, approx. 5 weeks of age, purchased from The Jackson Laboratory, Bar Harbor, ME) were maintained in individual cages at 22 0C on a 12:12 hr light/dark cycle. The "treated" mice (N= 12) were administered a Thiazole Derivative (10 mg/kg) by gavage once daily for four consecutive days. Control mice (N=12) were administered vehicle only, once daily for four days. Both control and treated mice were fed a high-fat diet from days 0 to 4 and body weight and food intake was monitored daily. The percent inhibition for weight gain and food intake was calculated by comparing the increase in weight gain and food intake in the treated mice to the increase in weight gain and food intake in the control mice.
Table 1 shows the effects of illustrative compounds of the invention on diet- induced obesity in mice. Compound numbers correspond to the compound numbering set forth in the specification.
Table 1
Figure imgf000111_0001
The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the relevant art and are intended to fall within the scope of the appended claims.
A number of references have been cited, the entire disclosures of which have been incorporated herein in their entirety.

Claims

WHAT IS CLAIMED IS:
1. A compound having the formula:
Figure imgf000112_0001
(I) or a pharmaceutically acceptable salt or solvate thereof, wherein: a is O, 1 , 2, 3 or 4; b is O, 1 , 2 or 3;
M is CH, n is 1 or 2, and p is 0, 1 or 2; or M is N, n is 2, and p is 1 or 2; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, -C(O)-, -C(N-OR5)-, -C(N-OR5)-CH(R6)-, -CH(R6)-C(N-OR5)-, -O-, -OCH2-, -CH2O-, -CH(OH)-, -S-, -S(O)- or -S(O)2-;
Y is -O-, -CH2-, -(CH2)2-, -C(=0)-, -C(=NOR7)-, -S-, -S(O)- Or -SO2-, provided that when M is N, Y is -CH2-, -(CH2)2-, -C(=O)-, -S-, -S(O)- or -SO2-; Z is a bond, -CH(R9)-(R10-C1»C5 alkylene), -CH(R9)-CH(R9)-O-, -CH(R9)-CH(R9)-N-, -CH(R9)-C(R9a).=C(R9a)-, -CH(R9)-C(R9a)=C(R9aHR10-Ci-C3 alkylene) or R8-alkylene interrupted by a cycloalkylene or heterocycloalkylene group, provided that when Z is R8-alkylene interrupted by a heterocycloalkylene group bonded through a ring nitrogen, the alkylene portion of the Z group has 2-4 carbon atoms between the ring to which it is attached and said nitrogen;
R1 is R11-alkyl, R11-cycloalkyl, R11-aryl, R11-arylalkyl, R11-(6-membered heteroaryl), R11-(6-membered heteroaryl)alkyl, R11-(5-membered heteroaryl), R11-(5- membered heteroaryl)alkyl, R11-heterocycloalkyl,
Figure imgf000112_0002
provided that when R1 is attached to X by a nitrogen atom, X is a bond or alkylene; k is O, 1 , 2, 3 or 4; k1 is 0, 1 , 2 or 3; k2 is 0, 1 or 2;
Q is O or S; R2 is R13-alkyl, R13-alkenyl, R13-aryl, R13-arylalkyl, R13-heteroaryl, R13- heteroarylalkyl, R13-cycloalkyl or R1 J-heterocycloalkyl; each R3 is independently selected from the group consisting of H, alkyl, halo, -OH, alkoxy, -CF3, -OCF3, -OCHF2, -NO2, -CO2R14, -N(R14)2, -CON(R14J2, - NHC(O)R14, -NHSO2R14, -SO2N(R14J2 and -CN; each R4 is independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OH, alkoxy, -CF3 and -CN;
R5 is H, alkyl, haloalkyl, R15-£iryl, R15-heteroaryl, R15-cycloalkyl, R15- heterocycloalkyl, R15-arylalkyl, -CF3 or -CH2CF3; R6 is H or alkyl;
R7 is H, alkyl, haloalkyl, R15-aryl or R15-heteroaryl;
R8 is 1, 2 or 3 substituents independently selected from the group consisting of H, R15-cycloalkyl, R15-heterocycloalkyl, R15-aryl, R15-heteroaryl and haloalkyl, provided that when the R8 substituent is on the carbon joined to the nitrogen atom of the M-containing ring, R8 is joined through a ring carbon atom;
R9 is independently selected from the group consisting of H, alkyl and haloalkyl;
R9a is independently selected from the group consisting of H, fluoro, alkyl and haloalkyl; R10 is 1 , 2 or 3 substituents independently selected from the group consisting of H, R15-cycloaikyl, R15-heterocyclc»alkyl, R15-aryl, R15-heteroaryl, halo, haloalkyl, - CN, -OH, alkoxy, -OCF3, -NO2, and -N(R6)2;
R11 is 1 , 2, 3 or 4 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OH, alkoxy, alkylthio, R15-cycloalkyl, R15- heterocycloalkyl, R15-aryl, R15-arylalkyl, R15-heteroaryl, R15-heteroarylalkyl, aryloxy, -OCF3, -OCHF2, -NO2, -CO2R12, -N(R12J2, -CON(R12J2, -NHC(O)R12, -NHSO2R12, -SO2N(R12)2 and -CN; R11a is H, alkyl, haloalkyl, alkoxy, alkylthio, R15-cycloalkyl, R15-heterocycloalkyl, R15-aryl, R15-arylalkyl, R15-cycloalky,l, R15-heterocycloalkyl, R15-heteroaryl, R15- heteroarylalkyl, R15-aryloxy, -OCF3, -OCHF2, -N(R12)2 Or-SCF3;
R12 is independently selected from the group consisting of H, alkyl, haloalkyl, R15-aryl, R15-heteroaryl, R15-arylalkyl, R15-cycloalkyl and R15-heterocycloalkyl;
R13 is 1 , 2 or 3 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl, -OH, alkoxy, R15-aryl, R15-aryloxy, -OCF3, -OCHF2, -NO2, -CO2R14, -N(R14J2, -CON(R14)2> -NHC(O)R14, -NHSO2R14, -SO2N(R14)2 and -CN;
R14 is independently selected from the group consisting of H, alkyl, haloalkyl, R15-aryl, R15-heteroaryl, R15-cycloalkyl and R15-heterocycloalkyl;
R15 is 1 , 2 or 3 substituents independently selected from the group consisting of H, alkyl, halo, haloalkyl, alkoxy, -N(R18)2, -alkylene-N(R18)2> -CN, -OCF3 and - OCHF2;
R16 is independently selected from the group consisting of alkyl, halogen, haloalkyl, alkenyl, OH, alkoxy, -SO0-2-alkyl and -OCF3;
R17 is H, alkyl, hydroxyl-substituted(C2-C6)alkyl-, haloalkyl-, haloalkoxyalkyl-, alkoxyalkyh R15-aryl, R15-arylalkyl-,. R15-heteroaryl, R15-heteroarylalkyl-, R15- cycloalkyl or R15-cycloalkylalkyl; and
R18 is independently selected from the group consisting of H and alkyl.
2. The compound of claim 1 wherein M is CH, n is 2 and p is 1.
3. The compound of claim 1 wherein both U and W are CH.
4. The compound of claim 1 wherein X is a single bond or -C(N-OR5)- and wherein R5 is H or alkyl.
5. The compound of claim 1 wherein Y is -O- or -C(=O)-.
6. The compound of claim 1 wherein Z is C1-C3 alkylene, -CH(R9)-(R10-Ci-C5 alkylene)-, -CH(R9)-C(R9a)=C(R9a)-, -(CH2)2-O- or C1-C3 alkylene interrupted by a cycloalkylene group, wherein R9 and R9a are each H, and R10 is halo.
7. The compound of claim 6 wherein Z is -CH2-, -(CH2)3-, -CH2-CH=CH-, -(CH2J2-
CH(F)-, -CH2-CH(F)-CH2-, -(CH2J2-O- or
Figure imgf000115_0001
8. The compound of claim 1 wherein M is CH, n is 2, p is 1 , a and b are each 0, X is a single bond or -C(N-OR5)-, Y is -O-, and Z is -CH2-.
9. The compound of claim 1 wherein R2 is a 5- or 6-membered R13-heteroary! or a 4, 5 or 6-membered R13-heterocycloalkyl.
10. The compound of claim 9 wherein R2 is selected from the group consisting of R13-pyridyl, R13-pyrimidyl, R13-pyradazinyl, R13-tetrahydropyranyl, R13-azetidinyl, R13- oxazolyl and R13-thiazolyl, wherein R13 is 1 or 2 substituents independently selected from the group consisting of H, -CH3, -IMH2 and -NHCH3.
11. The compound of claim 10 wherein R2 is 2-amino pyridyl, 2-amino oxazolyl, 2- amino thiazolyl, 1-methyl-azetidinyl or tetrahydropyranyL
12. The compound of claim 1 wherein R1 is R11-aryl, R11-(6-membered heteroaryl),
Figure imgf000115_0002
13. The compound of claim 12 wherein R1 is R11-phenyl or R11-pyridyl, and R11 is 1 to 4 substituents independently selected from the group consisting of H, halo, alkyl, haloalkyl and -CN.
14. The compound of claim 1 wherein R1 is
Figure imgf000116_0001
wherein R11a is C1-C3 alkyl, halo(CrC3)alkyl, C1-C3 alkoxy, C1-C3 alkylthio, R15- phenyl or R15-pyridyl; R15 is 1-3 substituents independently selected from H, halo, alkyl, haloalkyl, -OCF3, -CHF2 and k, k1 and k2 are each 0, 1 or 2.
15. The compound of claim 14 wherein R1 is
Figure imgf000116_0002
wherein R11a is (Ci-C3)alkyl, C1-C3 alkoxy, Ci-C3 alkylthio, R15-phenyl or R15-pyridyl; R15 is 1 or 2 substituents independently selected from H, halo, alkyl and haloalkyl; and k1 is 0 or 1.
16. The compound of claim 15 wherein R1 is
Figure imgf000116_0003
wherein R11a is -C2F5, -CF3, C2H5-O-, CH3-O-, C2H5-S-, CH3-S-, R15-phenyl or R15- pyridyl; R15 is 1 or 2 substituents independently selected from H, F, Cl, -CH3, and -CF3; and k1 is 0, or k1 is 1 and R15 is H, F, Cl Or -CF3.
17. A compound having the structure:
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000118_0002
Figure imgf000119_0001
or a pharmaceutically acceptable salt or solvate thereof.
18. A pharmaceutical composition comprising an effective amount of at least one compound of claim 1 and a pharmaceutically acceptable carrier.
19. The composition of claim 18 further comprising an effective amount of at least one Hi receptor antagonist.
20. The composition of claim 18 further comprising an effective amount of at least one other compound useful for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder.
21. The composition of claim 20 wherein the at least one other compound useful for treating obesity, an obesity-related disorder or metabolic syndrome is selected from the group consisting of appetite suppressants, anti-diabetic agents, metabolic rate enhancers, nutrient absorption inhibitors, HMG-CoA reductase inhibitors, substituted azetidinones and substituted β-lactam sterol absorption inhibitors, and the other compound useful for treating a cognition deficit disorder is selected from the group consisting of atomoxetine, dexmethylphenidate, olanzapine, risperidone, aripiprazole, donepezil, heptylphysqstigmine, tacrine, rivastigmine and galantamine.
22. The composition of claim 21 , wherein the at least one other compound is an appetite suppressant.
23. The composition of claim 20, wherein the at least one other compound useful for treating obesity, an obesity-related disorder or metabolic syndrome is rimonabant.
24. The composition of claim 18, wherein the at least one compound of claim 1 is a compound of claim 17.
25. The composition of claim 22, further comprising at least one HMG-CoA reductase inhibitor.
26. The composition of claim 25, wherein the at least one HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, atorvastatin, fluvastatin, resuvastatin, cerivastatin, rivastatin and pitavastatin.
27. The composition of claim 26, wherein the at least one HMG-CoA reductase inhibitor comprises simvastatin.
28. A method for treating allergy, an allergy-induced airway response, congestion, hypotension, a cardiovascular disease, a disease of the gastrointestinal tract, hypermotility of the gastrointestinal tract, hypomotility of the gastrointestinal tract, acidic secretion of the gastrointestinal tract, metabolic syndrome, obesity, an obesity-related disorder, a sleeping disorder, hypo or hyperactivity of the central nervous system, a cognition deficit disorder, or migraine in a patient, the method comprising administering to the patient an effective amount of at least one compound of claim 1.
29. The method of claim 28 wherein the treating is for an allergy-induced airway response, nasal congestion, metabolic syndrome, obesity, an obesity-related disorder or a cognition deficit disorder.
30. A method for treating allergy, an allergy-induced airway response or congestion in a patient, comprising administering to the patient an effective amount of at least one compound of claim 1 and an effective amount of an Hi receptor antagonist.
31. A method for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder in a patient, comprising administering to the patient an effective amount of at legist one compound of claim 1 and an effective amount of at least one other compound useful for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder.
32. The method of claim 31 , wherein the at least one compound useful for treating obesity, an obesity-related disorder or metabolic syndrome is selected from the group consisting of appetite suppressants, metabolic rate enhancers and nutrient absorption inhibitors.
33. The method of claim 32, wherein the appetite suppressants are selected form the group consisting of cannabinoid receptor 1 antagonists or inverse agonists, Neuropeptide Y antagonists, metabotropic glutamate subtype 5 receptor antagonists, melanin-concentrating hormone receptor antagonists, melanocortin receptor agonists, serotonin uptake, inhibitors, serotonin transport inhibitors, norepinephrine transporter inhibitors, ghrelin antagonists, leptin or derivatives thereof, opioid antagonists, orexin antagonists, bombesin receptor subtype 3 agonists, Cholecystokinin-A agonists, ciliary neurotrophic factor or derivatives thereof, monoamine reuptake inhibitors, glucagons-like peptide 1 agonists, topiramate, and phytopharm compound 57; the Metabolic rate enhancers are selected from the group consisting of acetyl-CoA carboxylase-2 inhibitors, beta adrenergic receptor 3 agonists, diaeylglycerol acyltransferase inhibitors, fatty acid synthase inhibitors, phosphodiesterase inhibitors, thyroid hormone β agonists; uncoupling protein activators, acyl-estrogens; glucocorticoid antagonists; 11 -beta hydroxyl steroid dehydrogenase type 1 inhibitors, melanocortin-3 receptor agonists and stearoyl-CoA desaturase-1 compounds; and the nutrient absorption inhibitors are selected from the group consisting of lipase inhibitors, fatty acid transporter inhibitors, dicarboxylate transporter inhibitors, glucose transporter inhibitors and phosphate transporter inhibitors.
34. The method of claim 31 , wherein the compound useful for treating obesity or metabolic syndrome is selected from the group consisting of rimonabant, 2-methyl-6- (phenylethynyl)-pyridine, 3[(2-methyl-1 ,4-thiazol-4-yl)ethyπyl]pyridine, Melanotan-ll, Mc4r agonists, dexfenfluramine, fluoxetine, paroxetine, fenfluramine, fluvoxamine, sertaline, imipramine, desipramine, talsupram, nomifensine, leptin or derivatives thereof; nalmefene, 3-methoxy-naltrexone, naloxone, nalterxone, butabindide, axokine, sibutramine, topiramate, phytopharm compound 57, Cerulenin, theophylline, pentoxifylline, zaprinast, sildenafil, amrinone, milrinone, cilostamide, rolipram, cilomilast, phytanic acid, 4:-[(E)-2-(5,6,7,8-tetramethyl-2-naphthalenyl)-1- propenyljbenzoic acid, retinoic acid, oleoyl-estrone, orlistat, lipstatin, tetrahydrolipstatin, teasaponin and diethylumbelliferyl phosphate.
35. The method of claim 34, wherein the compound useful for treating obesity or metabolic syndrome is rimonabant.
36. The method of claim 31 , wherein the compound useful for treating a cognition deficit disorder is selected from the group consisting of atomoxetine, dexmethylphenidate, olanzapine, risperidone, aripiprazole, donepezil, heptylphysostigmine, tacrine, rivastigmine and galantamine.
37. The method of claim 31 , further comprising administering an effective amount of at least one additional compound selected from: an HMG-CoA reductase inhibitor, a substituted azetidinone or a substituted β-lactam sterol absorption inhibitor.
38. The method of claim 37, wherein the at least one additional compounds being administered comprise an HMG-CoA reductase inhibitor.
39. The method of claim 38, wherein the at least one HMG-CoA reductase inhibitors are selected from the group consisting of lovastatin, simvastatin, pravastatin, atorvastatin, fluvastatiπ, resuvastatin, cerivastatin, rivastatin and pitavastatin.
40. The method of claim 39, wherein the at least one HMG-CoA reductase inhibitors comprise simvastatin.
41. The composition of claim 18 further comprising an effective amount of at least one anti-diabetic agent.
42. The composition of claim 41 wherein the at least one antidiabetic agent is selected from: a sulfonylurea, an insulin sensitizer, an α-glucosidase inhibitor, an insulin secretagogue, an anti-obesity agent, a meglitinide, insulin or an insulin- containing composition.
43. A method for treating diabetes in a patient, comprising administering to the patient an effective amount of at least one compound of claim 1.
44. The method of claim 43, further comprising administering to the patient an effective amount of at least one anti-diabetic agent.
45. The method of claim 44, wherein the at least one antidiabetic agent is selected from: a sulfonylurea, an insulin sensitizer, an α-glucosidase inhibitor, an insulin secretagogue, an anti-obesity agent, a meglitinide, insulin or an insulin- containing composition.
46. The method of claim 45, wherein the at least one anti-diabetic agent comprises an insulin sensitizer or a sulfonylurea.
47. The method of claim 46, wherein the insulin sensitizer is a PPAR activator.
48. The method of claim 47, wherein the PPAR activator is a thiazolidinedione.
49. A method for treating obesity or metabolic syndrome in a patient, comprising administering to the patient an effective amount of at least one compound of claim 1 and an effective amount of at least one anti-diabetic agent.
50. The method of claim 49, wherein the at least one antidiabetic agent is selected from: a sulfonylurea, an insulin sensitizer, an α-glucosidase inhibitor, an insulin secretagogue, an anti-obesity agent, a meglitinide, insulin or an insulin- containing composition.
51. The method of claim 50, wherein the at least one anti-diabetic agent comprises an insulin sensitizer or a sulfonylurea.
52. The method of claim 51 , wherein the insulin sensitizer is a PPAR activator.
53. The method of claim 52, wherein the PPAR activator is a thiazolidinedione.
54. The method of claim 43, wherein the diabetes is type I diabetes.
55. The method of claim 43, wherein the diabetes is type Il diabetes.
56. The method of claim 31 , wherein the treating is for obesity.
57. The method of claim 28, wherein the at least one compound administered is a compound of claim 17.
58. The method of claim 30, wherein the at least one compound administered is a compound of claim 17.
59. The method of claim 31 , wherein the at least one compound administered is a compound of claim 17.
60. The method of claim 43, wherein the at least one compound administered is a compound of claim 17.
61. The method of claim 49, wherein the at least one compound administered is a compound of claim 17.
62. A pharmaceutical composition comprising an effective amount of at least one compound of claim 17 and a pharmaceutically acceptable carrier.
63. The composition of claim 62 further comprising an effective amount of at least one H-i receptor antagonist.
64. The composition of claim 62 further comprising an effective amount of at least one other compound useful for treating obesity, an obesity-related disorder, metabolic syndrome or a cognition deficit disorder.
65. A compound having the formula:
Figure imgf000125_0001
(IA) and pharmaceutically acceptable salts or solvates thereof, wherein
M is CH or N; W is CH or N;
X is a single bond, -CH2-, -C(O)-, -C(=NOR)-, -CH(OH)-; Y is -O-, -S-, -SO2-, -C(O)- Qr-CH2-, such that when M is N, Y is -S-, -SO2-, - C(O)- Or -CH2-;
Z is a single bond; R1 is -aryl, -heteroaryl, -heterocycloalkyl,
Figure imgf000126_0001
wherein an aryl group can be substituted with up to 2 groups chosen from alkyl, halo or -CN; a heterocycloalkyl can be substituted with up to groups chosen from alkyl and heteroaryl; and a heteroaryl group can be substituted with up to 2 groups chosen from -halo, alkyl and alkoxy;
R2 is -heterocycloalkyl, heteroaryl, -CH(G)-aryl, -CH(G)-heteroaryl,
Figure imgf000126_0002
each occurrence of R3 is independently -halo; R11a is -H, -S-alkyl, heteroaryl, aryl, -CF2(CF3) or -CF3;
R16 is -H, -halo, Ci-C6 alkyl;: or alkenyl; R19 is -H or alkyl; R20 is -H or -alkyl; G is -H or -alkyj; Q is O or S; V is CH or N; a is 0, 1 or 2; and k is 0 or 1.
PCT/US2006/048349 2005-12-21 2006-12-19 Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists WO2007075629A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2006331882A AU2006331882A1 (en) 2005-12-21 2006-12-19 Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
JP2008547422A JP2009521448A (en) 2005-12-21 2006-12-19 Phenoxypiperidine and analogs useful as histamine H3 antagonists
MX2008008337A MX2008008337A (en) 2005-12-21 2006-12-19 Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists.
EP06839411A EP1976848A2 (en) 2005-12-21 2006-12-19 Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
CA002634250A CA2634250A1 (en) 2005-12-21 2006-12-19 Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
IL192309A IL192309A0 (en) 2005-12-21 2008-06-19 Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75263605P 2005-12-21 2005-12-21
US60/752,636 2005-12-21

Publications (2)

Publication Number Publication Date
WO2007075629A2 true WO2007075629A2 (en) 2007-07-05
WO2007075629A3 WO2007075629A3 (en) 2007-10-18

Family

ID=38180952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048349 WO2007075629A2 (en) 2005-12-21 2006-12-19 Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists

Country Status (12)

Country Link
US (1) US7638531B2 (en)
EP (1) EP1976848A2 (en)
JP (1) JP2009521448A (en)
KR (1) KR20080087833A (en)
CN (1) CN101426777A (en)
AU (1) AU2006331882A1 (en)
CA (1) CA2634250A1 (en)
IL (1) IL192309A0 (en)
MX (1) MX2008008337A (en)
PE (1) PE20071009A1 (en)
TW (1) TW200734337A (en)
WO (1) WO2007075629A2 (en)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008072703A1 (en) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. Biphenylamide derivative
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009041567A1 (en) * 2007-09-27 2009-04-02 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative having antagonistic activity on melanin-concentrating hormone receptor
WO2009067406A1 (en) * 2007-11-20 2009-05-28 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
JP2009538928A (en) * 2006-05-30 2009-11-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Substituted pyridylamide compounds as modulators of histamine H3 receptors
WO2009153182A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamide derivatives
WO2010011653A1 (en) * 2008-07-23 2010-01-28 Schering Corporation Tricyclic heterocycle derivatives as histamine h3 antagonists
JP2011503233A (en) * 2007-11-20 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of histamine H3 receptors
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2013100054A1 (en) * 2011-12-27 2013-07-04 大正製薬株式会社 Phenyltriazole derivative
WO2013098373A1 (en) * 2011-12-29 2013-07-04 Boehringer Ingelheim International Gmbh New azetidine derivatives, pharmaceutical compositions and uses thereof
US8530460B2 (en) 2011-12-19 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014056771A1 (en) * 2012-10-08 2014-04-17 Boehringer Ingelheim International Gmbh New pyrrolidine derivatives and their use as acetyl-coa carboxylase inhibitors
US8952166B2 (en) 2012-07-26 2015-02-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999990B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999991B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9062070B2 (en) 2011-08-19 2015-06-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9073882B2 (en) 2010-10-27 2015-07-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9108947B2 (en) 2011-10-31 2015-08-18 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
US9206199B2 (en) 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9527830B2 (en) 2011-09-16 2016-12-27 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9604998B2 (en) 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2017079641A1 (en) * 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9765074B2 (en) 2013-03-15 2017-09-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9777002B2 (en) 2012-11-29 2017-10-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
EP2986604B1 (en) * 2013-04-17 2017-12-20 Boehringer Ingelheim International GmbH Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
US9902696B2 (en) 2015-06-18 2018-02-27 Cephalon, Inc. 1,4-substituted piperidine derivatives
US10160751B2 (en) 2015-02-12 2018-12-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10556013B2 (en) 2017-06-20 2020-02-11 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
WO2020073011A1 (en) 2018-10-05 2020-04-09 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US10800757B2 (en) 2017-10-27 2020-10-13 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US10919875B2 (en) 2015-06-18 2021-02-16 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivatives
EA039638B1 (en) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Muscarinic receptor 4 antagonists and methods of using same
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531753A (en) * 2004-03-31 2007-11-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Non-imidazole heterocyclic compounds
PA8713501A1 (en) * 2006-02-07 2009-09-17 Wyeth Corp 11-BETA HYDROXIESTEROID DEHYDROGENASA INHIBITORS - 11ßHSD1
MX2008013237A (en) * 2006-04-14 2009-03-06 Merck & Co Inc Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators.
CN101511807A (en) * 2006-06-29 2009-08-19 詹森药业有限公司 Substituted benzamide modulators of the histamine H3 receptor
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CA2684059C (en) * 2007-04-11 2016-07-12 Omeros Corporation Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions
MX2009010296A (en) * 2007-04-18 2009-12-14 Kissei Pharmaceutical Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes.
EP2222650A1 (en) * 2007-11-20 2010-09-01 Janssen Pharmaceutica, N.V. Substituted pyrazinyl amide compounds as modulators of the histamine h3 receptor
US8188131B2 (en) * 2008-02-07 2012-05-29 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
KR20100137561A (en) * 2008-04-07 2010-12-30 아이알엠 엘엘씨 Compounds and compositions as modulators of gpr119 activity
MX2012004078A (en) * 2009-10-09 2012-07-25 Irm Llc Compounds and compositions as modulators of gpr119 activity.
SG186885A1 (en) 2010-06-04 2013-02-28 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012108478A1 (en) * 2011-02-09 2012-08-16 武田薬品工業株式会社 Monocyclic compound
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
TWI654978B (en) * 2017-01-27 2019-04-01 美商美國禮來大藥廠 5-methyl-1,2,4-oxadiazol-3-yl compounds
CN106995476B (en) * 2017-05-16 2018-03-13 河北美荷药业有限公司 A kind of preparation method of emamectin benzoate B2 benzoates
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR20220017917A (en) * 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 THR-beta modulators and methods of use thereof
CN114126593B (en) * 2019-07-26 2024-07-26 埃斯佩尔维塔治疗股份有限公司 Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0157145A1 (en) * 1984-03-09 1985-10-09 Robert Bosch Gmbh Antenna plug socket
US5424924A (en) * 1994-03-02 1995-06-13 Ewing; Johnny W. G. Illuminated vehicle bra
WO2003088967A1 (en) * 2002-04-18 2003-10-30 Schering Corporation (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists
US20040019039A1 (en) * 2001-07-02 2004-01-29 Dorwald Florencio Zaragoza Substituted piperazines and diazepanes
WO2006124748A2 (en) * 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Multicyclic compounds and methods of their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242924A (en) * 1992-07-02 1993-09-07 Sterling Winthrop Inc. Tetrazolyl-(phenoxy and phenoxyalkyl)-piperidinylpyridazines as antiviral agents
US5364865A (en) * 1992-12-30 1994-11-15 Sterling Winthrop Inc. Phenoxy- and phenoxyalkyl-piperidines as antiviral agents
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
PE20020507A1 (en) 2000-10-17 2002-06-25 Schering Corp NON-IMIDAZOLE COMPOUNDS AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR
CN1298715C (en) 2001-03-13 2007-02-07 先灵公司 Non-imidazole compounds as histamine H3 antagonists
ATE529112T1 (en) 2002-04-18 2011-11-15 Schering Corp 1-(4-PIPERIDINYL)BENZIMIDAZOLONE AS A HISTAMINE H3 ANTAGONIST
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
CN100497334C (en) 2002-06-24 2009-06-10 先灵公司 Indole derivatives useful as histamine h3 antagonists
WO2004069816A1 (en) * 2003-02-07 2004-08-19 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
GB0308333D0 (en) 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
TW200503713A (en) 2003-04-23 2005-02-01 Glaxo Group Ltd Novel compounds
US20040224952A1 (en) 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
AU2004260758B2 (en) * 2003-08-01 2007-06-07 Nippon Soda Co., Ltd. Phenylazole compounds, production process, and antioxidants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0157145A1 (en) * 1984-03-09 1985-10-09 Robert Bosch Gmbh Antenna plug socket
US5424924A (en) * 1994-03-02 1995-06-13 Ewing; Johnny W. G. Illuminated vehicle bra
US20040019039A1 (en) * 2001-07-02 2004-01-29 Dorwald Florencio Zaragoza Substituted piperazines and diazepanes
WO2003088967A1 (en) * 2002-04-18 2003-10-30 Schering Corporation (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists
WO2006124748A2 (en) * 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Multicyclic compounds and methods of their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEY S. ET AL: "A Rapid Approach for Optimisation of Polymer Supported Reagents in Synthesis" SYNLETT, GEORG THIEME VERLAG, STUTTGART, DE, no. 11, 2000, pages 1603-1607, XP002441215 ISSN: 0936-5214 *
MORGAN T K JR ET AL: "SYNTHESIS AND CARDIAC ELECTROPHYSIOLOGICAL ACTIVITY OF N SUBSTITUTED 4-1H IMIDAZOL-1-YLBENZAMIDES NEW SELECTIVE CLASS III AGENTS" JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 4, 1990, pages 1091-1097, XP002441214 ISSN: 0022-2623 *

Cited By (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538928A (en) * 2006-05-30 2009-11-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Substituted pyridylamide compounds as modulators of histamine H3 receptors
US8637520B2 (en) 2006-05-30 2014-01-28 Janssen Pharmaceutica Nv Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
US8940731B2 (en) 2006-05-30 2015-01-27 Janssen Pharmaceutica Nv Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
US9321729B2 (en) 2006-05-30 2016-04-26 Janssen Pharmaceutica Nv Substituted pyridyl amide compounds as modulators of the histamine H3 receptor
WO2008072703A1 (en) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. Biphenylamide derivative
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009041567A1 (en) * 2007-09-27 2009-04-02 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative having antagonistic activity on melanin-concentrating hormone receptor
CN105712977A (en) * 2007-11-20 2016-06-29 詹森药业有限公司 Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
WO2009067406A1 (en) * 2007-11-20 2009-05-28 Janssen Pharmaceutica N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
US8883776B2 (en) 2007-11-20 2014-11-11 Janssen Pharmaceutica N.V. Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor
JP2011503233A (en) * 2007-11-20 2011-01-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of histamine H3 receptors
KR101546712B1 (en) 2007-11-20 2015-08-24 얀센 파마슈티카 엔.브이. Cycloalkyloxy- and heterocycloalky-loxypyridine compounds as modulators of the histamine h3 receptor
US8227613B2 (en) 2008-06-18 2012-07-24 Hoffmann-La Roche Inc. Heteroaryl carboxamide derivatives
JP2011524400A (en) * 2008-06-18 2011-09-01 エフ．ホフマン−ラ ロシュ アーゲー Novel heteroarylcarboxamide derivatives
CN102066359A (en) * 2008-06-18 2011-05-18 弗·哈夫曼-拉罗切有限公司 Novel heteroaryl carboxamide derivatives
CN102066359B (en) * 2008-06-18 2013-08-21 弗·哈夫曼-拉罗切有限公司 Novel heteroaryl carboxamide derivatives
WO2009153182A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamide derivatives
WO2010011653A1 (en) * 2008-07-23 2010-01-28 Schering Corporation Tricyclic heterocycle derivatives as histamine h3 antagonists
US9018211B2 (en) 2009-05-06 2015-04-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9073882B2 (en) 2010-10-27 2015-07-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US9062070B2 (en) 2011-08-19 2015-06-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9527830B2 (en) 2011-09-16 2016-12-27 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999991B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999990B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9108947B2 (en) 2011-10-31 2015-08-18 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9206199B2 (en) 2011-12-16 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8530460B2 (en) 2011-12-19 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
WO2013100054A1 (en) * 2011-12-27 2013-07-04 大正製薬株式会社 Phenyltriazole derivative
WO2013098373A1 (en) * 2011-12-29 2013-07-04 Boehringer Ingelheim International Gmbh New azetidine derivatives, pharmaceutical compositions and uses thereof
US8530461B2 (en) 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US8952166B2 (en) 2012-07-26 2015-02-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9206198B2 (en) 2012-07-26 2015-12-08 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9169205B2 (en) 2012-10-08 2015-10-27 Boehringer Ingelheim International Gmbh Pyrrolidine derivatives, pharmaceutical compositions and uses thereof
WO2014056771A1 (en) * 2012-10-08 2014-04-17 Boehringer Ingelheim International Gmbh New pyrrolidine derivatives and their use as acetyl-coa carboxylase inhibitors
US9777002B2 (en) 2012-11-29 2017-10-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9604998B2 (en) 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10995078B2 (en) 2013-03-13 2021-05-04 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10800750B2 (en) 2013-03-13 2020-10-13 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10472342B2 (en) 2013-03-13 2019-11-12 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10457655B2 (en) 2013-03-13 2019-10-29 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10450286B2 (en) 2013-03-13 2019-10-22 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US9765074B2 (en) 2013-03-15 2017-09-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2986604B1 (en) * 2013-04-17 2017-12-20 Boehringer Ingelheim International GmbH Pyrimidine-substituted pyrrolidine derivatives, pharmaceutical compositions and uses thereof
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9975858B2 (en) 2013-11-08 2018-05-22 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US10160751B2 (en) 2015-02-12 2018-12-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US10851057B2 (en) 2015-06-18 2020-12-01 89Bio Ltd 1,4-substituted piperidine derivatives
US10221135B2 (en) 2015-06-18 2019-03-05 89Bio Ltd 1,4-substituted piperidine derivatives
US12098130B2 (en) 2015-06-18 2024-09-24 89Bio Ltd 1,4-substituted piperidine derivatives
US11878966B2 (en) 2015-06-18 2024-01-23 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivates
US9902696B2 (en) 2015-06-18 2018-02-27 Cephalon, Inc. 1,4-substituted piperidine derivatives
US11702388B2 (en) 2015-06-18 2023-07-18 89Bio Ltd 1,4-substituted piperidine derivatives
US10919875B2 (en) 2015-06-18 2021-02-16 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivatives
CN108349936B (en) * 2015-11-06 2021-10-01 纽罗克里生物科学有限公司 Compounds as muscarinic receptor 4 antagonists
CN108349936A (en) * 2015-11-06 2018-07-31 纽罗克里生物科学有限公司 It is used to treat N- [2- (1- benzyl piepridine -4- bases) ethyl] -4- (pyrazine -2- bases)-piperazine -1- carboxamides derivatives and related compound of neurological disorder as muscarinic receptor 4 (M4) antagonist
WO2017079641A1 (en) * 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
US11033539B2 (en) 2015-11-06 2021-06-15 Neurocrine Biosciences, Inc. Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases
EA039638B1 (en) * 2016-01-06 2022-02-21 Нейрокрин Байосайенсиз, Инк. Muscarinic receptor 4 antagonists and methods of using same
US10556013B2 (en) 2017-06-20 2020-02-11 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US10953102B2 (en) 2017-06-20 2021-03-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US10918728B2 (en) 2017-06-20 2021-02-16 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US11844840B2 (en) 2017-06-20 2023-12-19 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US11376330B2 (en) 2017-06-20 2022-07-05 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US10889568B2 (en) 2017-10-27 2021-01-12 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
USRE49699E1 (en) 2017-10-27 2023-10-17 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
US10800757B2 (en) 2017-10-27 2020-10-13 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
EP4364798A2 (en) 2018-10-05 2024-05-08 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US11944622B2 (en) 2018-10-05 2024-04-02 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
WO2020073011A1 (en) 2018-10-05 2020-04-09 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US11299484B2 (en) 2018-10-10 2022-04-12 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US11267805B2 (en) 2018-10-29 2022-03-08 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US12065410B2 (en) 2020-06-30 2024-08-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11746090B2 (en) 2020-06-30 2023-09-05 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US12110275B2 (en) 2020-06-30 2024-10-08 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl] piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Also Published As

Publication number Publication date
US7638531B2 (en) 2009-12-29
IL192309A0 (en) 2009-02-11
MX2008008337A (en) 2008-09-03
TW200734337A (en) 2007-09-16
CN101426777A (en) 2009-05-06
WO2007075629A3 (en) 2007-10-18
US20070167435A1 (en) 2007-07-19
JP2009521448A (en) 2009-06-04
AU2006331882A1 (en) 2007-07-05
CA2634250A1 (en) 2007-07-05
KR20080087833A (en) 2008-10-01
PE20071009A1 (en) 2007-10-24
EP1976848A2 (en) 2008-10-08

Similar Documents

Publication Publication Date Title
WO2007075629A2 (en) Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
US7879880B2 (en) Substituted aniline derivatives useful as histamine H3 antagonists
EP1902046B1 (en) Piperidine derivatives useful as histamine h3 antagonists
US7408066B2 (en) Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
EP2493307B1 (en) Bridged bicyclic piperidine derivatives and methods of use thereof
EP2382204B1 (en) Pyrimidine derivatives as gpcr modulators for use in the treatment of obesity and diabetes
CA2595157A1 (en) Imidazole and benzimidazole derivatives useful as histamine h3 antagonists
AU2009330208A1 (en) Bicyclic heterocycle derivatives and methods of use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006839411

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2634250

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008547422

Country of ref document: JP

Ref document number: 12008501496

Country of ref document: PH

Ref document number: 2006331882

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/008337

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 569447

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2006331882

Country of ref document: AU

Date of ref document: 20061219

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087017595

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200680051714.9

Country of ref document: CN